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de l’Hôpital-Maisonneuve Rosemont (CRHMR), under the direction of Dr L’Hocine Yahia and 
co-direction of Dr Jean-Pierre Hallé. Some of this work was also completed at the University 
Medical Centre Groningen (UMCG) under the supervision of Dr Paul de Vos, during a 6-month 
internship. 
The majority of the results presented in this thesis are the basis of three original articles that 
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separate chapters. During my doctoral studies, I also contributed to a number of other published 
works that have either been included as an Appendix or have not been included at all. These 
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vii 
Table P.1 (continued). List of publications written during my doctoral studies (2005-2010) 
Original articles (first author) 
 Based on 
master’s 
research 
Contributed 
40% 
Tam SK, Dusseault J, Polizu S, Ménard M, Hallé JP, Yahia L. 
Impact of residual contamination on the biofunctional properties of 
purified alginates used for cell encapsulation. Biomaterials (Mar 
2006) 27(8): 1296-1305. 
 Based on 
master’s 
research 
Contributed 
80% 
Tam SK, Dusseault J, Polizu S, Ménard M, Hallé JP, Yahia L. 
Physicochemical model of alginate-poly-l-lysine microcapsules 
defined at the micrometric/nanometric scale using ATR-FTIR, XPS, 
and ToF-SIMS. Biomaterials (Dec 2005) 26(34): 6950-6961. 
Original articles (not first author) 
 Not main 
contributor 
Contributed   
4% 
Langlois G, Dusseault J, Bilodeau S, Tam SK, Hallé JP. Effects of 
the co-encapsulation of duct cells with islets on the viability and 
function of islets. PLoS ONE [submitted for publication] 
 Not main 
contributor 
Contributed 
15% 
Bilodeau S, Tam SK, Langlois G,  Hallé JP. Improved ability of rat 
islet cell aggregates to resist hypoxia. Transplant Proc [submitted 
for publication] 
 Not main 
contributor 
Contributed 
2.5% 
Ménard M, Dusseault J, Langlois G, Baille WE, Tam SK, Yahia 
L’H, Zhu XX, Hallé JP. Role of protein contaminants in the 
immunogenicity of alginates. J Biomed Mater Res B Appl Biomater 
(May 2010) 93(2): 333-40. 
 Not main 
contributor 
contributed 
5% 
Langlois G, Dusseault J, Bilodeau S, Tam SK, Magassouba D, Hallé 
JP. Direct effect of alginate purification on the survival of islets 
immobilised in alginate-based microcapsules. Acta Biomater (Nov 
2009) 5(9): 3433-40. 
 Based on 
master’s 
research 
contributed 
30% 
Dusseault J, Tam SK, Ménard M, Polizu S, Jourdan G, Yahia L’H, 
Hallé JP. Evaluation of alginate purification methods: effect on 
polyphenol, endotoxin and protein contamination. J Biomed Mater 
Res A (Feb 2006) 76(2): 243-51. 
Review articles 
 Not original 
works 
contributed 
20% 
Orive G, Tam SK, Pedraz JL, Hallé JP. Biocompatibility of 
Biomaterials for Cell Encapsulation. Biomaterials (Jul 2006) 27(20): 
3691-3700. 
 Not original 
works 
contributed 
5% 
de Vos P, Andersson A, Tam SK, Faas MM, Hallé JP. Advances and 
barriers in mammalian cell encapsulation for treatment of diabetes. 
Curr Med Chem (Apr 2006) 6(2): 139-153. 
   included in thesis ;  not included in thesis 
 
 
viii 
Table P.1 (continued). List of publications written during my doctoral studies (2005-2010) 
Book Chapters 
 Appendix II contributed 
90% 
Tam SK, Hallé JP, Yahia L’H. Ch 11 La microencapsulation pour la 
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technologies (2007) Coord. Vandamme TF, Poncelet D and Subra-
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RÉSUMÉ 
 
La microencapsulation représente une stratégie visant à protéger les cellules ou les tissus 
thérapeutiques du rejet de greffe à l’aide d’une barrière physique. Cette approche est 
avantageuse puisqu’elle ne nécessite pas l’administration d’immunosuppresseurs à long terme et 
qu’elle permet l’option d’exploiter des sources de cellules non-cadavériques (ex. les cellules 
d’animaux). Les microcapsules que nous étudions sont conçues pour l’immunoprotection des 
îlots de Langerhans (qui sont responsables de sécréter l’insuline) dans le but de traiter le diabète 
insulino-dépendant. 
La transplantation d’îlots microencapsulés n’est pas encore utilisée régulièrement en 
clinique parce que la survie et le fonctionnement des cellules greffées restent limités. Un facteur 
qui contribue à l’échec de la greffe est la biocompatibilité inadéquate des microcapsules elles-
mêmes. Dans ce cas, les cellules immunitaires adhèrent à la surface du dispositif et sécrètent des 
substances cytotoxiques pouvant pénétrer la barrière protectrice et endommager les cellules à 
l’intérieur. Ensuite, du tissu fibrotique se développe autour de l’implant, ce qui peut obstruer ou 
limiter la diffusion des nutriments, de l’oxygène, du glucose et de l’insuline à travers la 
membrane et ultimement mener au dysfonctionnement et/ou la mort des cellules encapsulées. 
Au moins deux groupes de recherche ont démontré la faisabilité, sous conditions 
optimales, de fabriquer des microcapsules d’alginate-polycation biocompatibles. Cependant, la 
plupart des laboratoires ont de la difficulté à reproduire de tels résultats. Ceci souligne notre 
manque de connaissances à propos des paramètres importants qui déterminent la 
biocompatibilité de la microcapsule. Cette situation est fortement reliée au fait qu’aucun 
standard n’existe pouvant nous guider dans la fabrication des microcapsules afin d’atteindre une 
biocompatibilité et une bioperformance optimales.  
A l’aide des techniques d’analyses physicochimiques, cette recherche cherchait à 
comprendre quelles propriétés de la microcapsule sont importantes pour déterminer sa 
biocompatibilité. L’objectif de ce travail était d’élucider les corrélations entre la structure 
chimique, les propriétés physicochimiques, et la biocompatibilité in vivo des microcapsules à 
base d’alginate. Ces informations aideront la communauté scientifique à comprendre les facteurs 
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qui doivent être contrôlés afin d’optimiser la biocompatibilité. Notre approche est basée sur 
l’hypothèse que la réponse immunitaire est déterminée par, et donc peut être contrôlée par, des 
propriétés physicochimiques spécifiques de la microcapsule et de ses composantes matérielles. 
Le travail expérimental a été divisé en cinq phases, chacune ayant un but spécifique: (1) 
Prouver que les immunoglobulines s’adsorbent sur la surface des microcapsules d’alginate-
polycation, et corréler cette adsorption avec la chimie de la microcapsule. (2) Tester la 
reproductibilité interlaboratoire de la fabrication des microcapsules biocompatibles, et 
déterminer si nos matériaux et protocoles de fabrication sont appropriés pour des études 
subséquentes. (3) Déterminer quelles propriétés physicochimiques des alginates influencent la 
biocompatibilité in vivo de leur gel. (4) Déterminer quelles propriétés physicochimiques des 
microcapsules d’alginate-polycation sont les plus importantes pour leur biocompatibilité in vivo. 
(5) Déterminer si une membrane légèrement immunogénique augmente ou diminue la capacité 
d’une microcapsule d’immunoprotéger des xénogreffes d’îlots dans des souris diabétiques. Afin 
d’atteindre ces buts, une gamme d’analyses physicochimiques a été employée pour la 
caractérisation des alginates et des microcapsules. Les propriétés des alginates qui ont été 
étudiées incluent la pureté (essai LAL, essai microBCA), la composition chimique (la résonance 
magnétique nucléaire, NMR), la composition élémentaire (la spectroscopie de photoélectrons 
avec rayons X, XPS), et l’hydrophilicité (l’angle de contact). Quant aux microcapsules, la 
composition chimique de leur surface (XPS) et l’hydrophilicité, ainsi que les interactions entre 
l’alginate et le polycation (la spectroscopie infrarouge à transformée de Fourier, FTIR) et la 
résistance de la membrane (le gonflement osmotique) ont aussi été évaluées. 
Les résultats de cette recherche ont mené à plusieurs conclusions importantes à propos 
de la biocompatibilité des alginates et des microcapsules à base d’alginate. D’abord, la 
purification de l’alginate ne garantit pas qu’elle sera biocompatible. Effectivement, nous avons 
démontré que la composition chimique de l’alginate (i.e. le contenu relatif de mannuronate et 
guluronate) et sa viscosité intrinsèque influencent le degré d’adhésion des cellules immunitaires 
à surface des billes d’alginate. En employant un alginate biocompatible, nous avons démontré 
que la membrane polycationique des microcapsules compromet la biocompatibilité de la 
microcapsule. Cette membrane était responsable de l’adsorption des protéines opsonisantes in 
vitro ainsi que l’adhésion des cellules immunitaires in vivo. Cela dit, la sévérité de la réponse 
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inflammatoire contre la membrane peut se varier, et celle-ci dépendait de la structure de la 
microcapsule, incluant le choix de l’alginate et du polycation. Les résultats de nos analyses 
physicochimiques ont suggéré que le facteur le plus important pour la biocompatibilité est la 
capacité du polycation de diffuser dans le gel d’alginate et de le lier. De plus, le fait d’ajouter 
une couche d’alginate à la microcapsule n’a pas contrecarré les effets de la membrane 
polycationique sur des différentes propriétés des microcapsules (la composition de sa surface, 
son hydrophobicité, sa stabilité), ni réduit son immunogénicité. 
Même si nous avons fourni de nombreuses preuves que la membrane de la microcapsule 
est le problème principal du manque de biocompatibilité, nous avons aussi démontré que la 
gravité de ce problème peut varier selon les procédés de fabrication. Ce résultat est important à 
noter puisqu’il confirme la possibilité d’atteindre une biocompatibilité optimale si les 
interactions entre alginate et polycation sont idéales. Néanmoins, les résultats de notre étude sur 
la survie et le fonctionnement des îlots encapsulés, qui ont démontré un échec presque total des 
microcapsules contrairement aux billes d’alginate sans membrane, soulèvent la question 
suivante : Vaut-il la peine d’essayer d’optimiser la biocompatibilité de la membrane si celle-ci 
n’est peut-être pas nécessaire à l’immunoprotection des cellules thérapeutiques transplantées? 
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ABSTRACT 
 
Microencapsulation represents a method for immunoprotecting transplanted therapeutic 
cells or tissues from graft rejection using a physical barrier. This approach is advantageous in 
that it eliminates the need to induce long-term immunosuppression and allows the option of 
transplanting non-cadaveric cell sources, such as animal cells and stem cell-derived tissues. The 
microcapsules that we have investigated are designed to immunoprotect islets of Langerhans 
(i.e. clusters of insulin-secreting cells), with the goal of treating insulin-dependent diabetes. 
Microencapsulated islet transplantation has not yet reached regular clinical application 
because graft survival and function remains limited and variable. One of the main factors that 
contribute to graft failure is an inadequate biocompatibility of the microcapsule itself. Upon 
recognition of the microcapsule, host immune cells adhere to the device and secrete cytotoxic 
substances that are small enough to penetrate the protective barrier and potentially harm the 
cells within. As the inflammatory response persists, fibrotic tissue develops around the implant 
and can hinder the diffusion of cell nutrients, oxygen, glucose and insulin into and out of the 
microcapsule, thereby leading to encapsulated cell dysfunction and death. 
At least two research groups have demonstrated the feasibility of producing alginate-
polycation microcapsules that are biocompatible. However, most labs have had difficulty 
reproducing such results. This underlines our lack of understanding about the parameters that 
are important for determining the biocompatibility of the microcapsule. This situation is 
intimately related to the fact that no standards currently exist to guide the fabrication process of 
microcapsules in order to achieve optimal biocompatibility and bioperformance. 
With the aid of techniques for physicochemical analysis, this research focused on 
understanding which properties of the microcapsule are the most important for determining its 
biocompatibility. The objective of this work was to elucidate correlations between the chemical 
make-up, physicochemical properties, and in vivo biocompatibility of alginate-based 
microcapsules. This information is expected to help the research community understand what 
factors must be controlled and standardized in order to achieve optimal biocompatibility. Our 
approach was based on the hypothesis that the immune response to the microcapsules is 
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governed by, and can therefore be controlled by, specific physicochemical properties of the 
microcapsule and its material components.  
The experimental work was divided into five phases, each associated with a specific aim 
: (1) To prove that immunoglobulins adsorb to the surface of alginate-polycation microcapsules, 
and to correlate this adsorption with the microcapsule chemistry. (2)  To test interlaboratory 
reproducibility in making biocompatible microcapsules, and evaluate the suitability of our 
materials and fabrication protocols for subsequent studies. (3) To determine which 
physicochemical properties of alginates affect the in vivo biocompatibility of their gels. (4) To 
determine which physiochemical properties of alginate-polycation microcapsules are most 
important for determining their in vivo biocompatibility (5) To determine whether a modestly 
immunogenic membrane hinders or helps the ability of the microcapsule to immunoprotect islet 
xenografts in diabetic mice. To achieve these aims, extensive physicochemical analyses of the 
alginates and microcapsules were carried out. Among the properties of the alginates that were 
investigated include their purity (LAL assay, microBCA), chemical composition (nuclear 
magnetic resonance, NMR), elemental composition (x-ray photoelectron spectroscopy, XPS), 
and hydrophilicity (contact angle technique). As for the microcapsules, we also examined their 
surface chemical composition (XPS), hydrophilicity, as well as alginate-polycation interactions 
(Fourier transform infrared spectroscopy, FTIR), and membrane strength (osmotic swelling). 
The results of this research led to a number of important conclusions about the 
biocompatibility of alginates and alginate-based microcapsules. First of all, purifying an alginate 
does not guarantee its biocompatibility. Indeed, we provided evidence that both the alginate 
chemical composition (i.e. relative content of mannuronate and guluronate) and its intrinsic 
viscosity influence the extent of host cell adhesion to alginate gel beads. Using a biocompatible 
alginate, we then provided evidence that microcapsule biocompatibility is greatly compromised 
by its polycationic membrane. We showed that this membrane is responsible for the adsorption 
of opsonizing proteins in vitro and the adhesion of immune cells in vivo. That said, the severity 
of inflammatory response to the membrane can vary, and this depended on the microcapsule 
design, including the choice of alginate and polycation type. Results of our physicochemical 
analyses suggested that the most important factor determining biocompatibility is the ability of 
the polycation to diffuse into, and subsequently bind to, the alginate gel core. Moreover, adding 
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a final coating of alginate had no significant effect on reversing the effects of the membrane on 
various microcapsule properties (surface composition, hydrophobicity, stability), nor did this 
coating reduce its immunogenicity. 
Although we repeatedly provided evidence that the microcapsule membrane is the main 
problem for biocompatibility, we also demonstrated that the severity of this problem can vary 
according to the fabrication details. This is an important note, as it confirms the possibility of 
achieving optimal microcapsule biocompatibility if the interactions between the alginate and 
polycation are ideal. Nevertheless, the results of our study on the survival and function of 
encapsulated islets, which demonstrated an almost complete failure of the microcapsules in 
contrast to alginate beads without a membrane, forces us to raise the following question : Is it 
worth trying to optimize the biocompatibility of the membrane when this membrane may not 
even be necessary for the immunoprotection of transplanted therapeutic cells? 
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CONDENSÉ EN FRANÇAIS 
 
INTRODUCTION 
La microencapsulation pour l’immunoprotection 
La microencapsulation représente une stratégie pour protéger des cellules et des tissus 
thérapeutiques contre le rejet de greffe à l’aide d’une barrière physique. La majorité des 
microcapsules conçues pour l’immunoprotection des cellules sont à base d’alginate, avec une 
membrane polycationique semi-perméable. En principe, les composantes de haut poids 
moléculaire du système immunitaire (les cellules et les anticorps) sont bloquées par la 
membrane, tandis que les nutriments, l’oxygène, et le produit thérapeutique (que les cellules 
encapsulées sécrètent) peuvent diffuser librement à travers la membrane afin d’assurer le bon 
fonctionnement et la survie des cellules encapsulées. 
Les principaux avantages de l’immunoprotection par la microencapsulation sont que le 
patient n’a pas besoin de prendre des immunosuppresseurs à long terme et que la microcapsule 
permet l’utilisation de source de cellules non-cadavériques, telles que les cellules d’animaux, les 
cellules souches ou les cellules modifiées génétiquement. Dans notre laboratoire, nous 
travaillons avec des microcapsules à base d’alginate conçues pour l’immunoprotection des îlots 
de Langerhans (des groupements de cellules qui sécrètent l’insuline) dans le but de traiter le 
diabète insulino-dépendant. Autour du monde, des premiers essais cliniques de transplantation 
d’îlots encapsulés sont en cours. 
La problématique 
La période de survie et de fonctionnement des îlots encapsulés in vivo reste toujours 
limitée et variable (de quelques jours à quelques années). Un des facteurs qui contribuent au 
rejet de la greffe est une biocompatibilité inadéquate des microcapsules. En effet, si une 
microcapsule n’est pas suffisamment biocompatible, des cellules immunitaires adhèrent à sa 
surface et sécrètent des agents cytotoxiques de faibles poids moléculaire qui peuvent diffuser 
dans la membrane de la microcapsule et endommager les cellules à l’intérieur. Si la réponse 
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inflammatoire persiste, un tissu fibrotique se développe autour de l’implant, ce qui peut obstruer 
la diffusion des nutriments, de l’oxygène, de glucose, et de l’insuline à travers la membrane et 
donc mener au dysfonctionnement et/ou la mort des cellules encapsulées. 
Même si quelques groupes de recherche ont démontré la faisabilité, sous conditions 
optimales, de fabriquer une microcapsule d’alginate-polycation biocompatible, d’autres 
laboratoires ont eu de la difficulté à reproduire ces résultats. Ceci souligne notre manque de 
connaissances concernant les facteurs déterminant la biocompatibilité des microcapsules. Cette 
situation est fortement liée au fait qu’aucun standard n’existe pouvant nous guider dans la 
fabrication des microcapsules afin d’atteindre une biocompatibilité et une bioperformance 
optimales. 
Notre objectif général 
 Le but de tous les chercheurs dans ce domaine est d’optimiser le système d’îlots 
encapsulés afin que la greffe survive et reste fonctionnelle tout au long de la vie du patient 
diabétique. 
Le but de cette recherche est de contribuer à l’optimisation d’un aspect de ce système : la 
biocompatibilité des microcapsules. La question que nous visons à répondre est pourquoi une 
microcapsule est biocompatible tandis qu’une autre ne l’est pas, malgré leurs structures 
similaires. Notre objectif est donc d’élucider les corrélations entre la structure chimique, les 
propriétés physicochimiques, et la biocompatibilité in vivo des microcapsules. 
Notre hypothèse 
Ce travail est basé sur l’hypothèse que la réponse immunitaire contre les microcapsules, 
incluant l’adsorption des protéines et la réponse cellulaire, est gouvernée par, et donc peut être 
contrôlée par, les propriétés physicochimiques spécifiques de la microcapsule et ses 
composantes matérielles. 
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Nos buts spécifiques 
La section expérimentale de cette thèse a été divisée en cinq phases qui suivent le 
processus de notre recherche. Chacune de ces phases a été dirigée par un but de recherche 
spécifique :  
1) Prouver que les immunoglobulines s'adsorbent à la surface des microcapsules 
d’alginate-polycation, et corréler cette adsorption à la chimie des 
microcapsules. 
2) Évaluer la reproductibilité interlaboratoire de la fabrication des 
microcapsules alginate-poly-L-lysine biocompatibles, et déterminer si nos 
matériaux et notre protocole pour fabrication sont appropriés pour des études 
subséquentes. 
3) Déterminer quelles propriétés physicochimiques des alginates influencent la 
biocompatibilité in vivo de leur gel. 
4) Déterminer quelles propriétés physicochimiques des microcapsules 
d’alginate-polycation sont les plus importantes pour leur biocompatibilité in 
vivo. 
5) Déterminer si la membrane légèrement immunogénique des microcapsules 
d’alginate-poly-L-ornithine augmente ou diminue la capacité de la 
microcapsule à prolonger la survie et le fonctionnement des xénogreffes 
d’îlots dans des souris diabétiques. 
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RÉSUMÉS DES RÉSULTATS 
Partie I 
L’adsorption de l’immunoglobuline humaine sur les microcapsules implantables à base 
d’alginate-poly-L-lysine : L’effet de la composition de la microcapsule 
PUBLIÉ : Tam SK, de Haan BJ, Faas MM, Hallé JP, Yahia L, de Vos P. Adsorption of human 
immunoglobulin to implantable alginate-poly-L-lysine microcapsules: Effect of microcapsule 
composition. J Biomed Mater Res A 2009 Jun; 89(3): 609-15. 
Les microcapsules d’alginate-poly-L-lysine-alginate (APA) continuent d’être les 
dispositifs les plus communément étudiés pour l’immunoprotection des cellules thérapeutiques 
transplantées. La fabrication des microcapsules APA qui ont une biocompatibilité de haut 
niveau et reproductible demande une connaissance des mécanismes de la réponse immunitaire 
contre les implants. Ici, nous investiguons l’adsorption des immunoglobulines (IgG, IgM et IgA) 
sur la surface des microcapsules APA in vitro après que celles-ci aient été exposées au sérum et 
au liquide péritonéal humain. Les immunoglobulines (Ig) sont des protéines opsonisantes, donc 
ils ont une tendance à faciliter l’inflammation quand ils s’adsorbent aux surfaces étrangères. 
L’adsorption d’Ig a été évaluée avec la technique d’immunofluorescence directe. La quantité 
d’Ig qui a adhéré à la surface de la microcapsule n’a pas été influencée significativement par le 
contenu d’acide guluronique (G), ni par la pureté de l’alginate. Pourtant, les microcapsules à 
base d’alginate pure et ayant un contenu intermédiaire de G ont corrélé avec le niveau le plus 
faible d’adsorption. L’adsorption d’Ig était négligeable quand la poly-L-lysine était omise, ce 
qui suggère que les charges positives à la surface de la microcapsule sont responsables de la 
liaison d’Ig. 
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Partie II 
Une comparaison interlaboratoire des alginates et des microcapsules APA (Groningen vs 
Montréal) 
PAS SOUMIS POUR PUBLICATION 
Le laboratoire de Groningen est connu pour sa capacité de fabriquer des microcapsules 
alginate-poly-L-lysine-alginate (APA) qui sont biocompatibles. Nous avons essayé de 
reproduire leurs résultats en suivant leur protocole de fabrication des microcapsules, mais en 
utilisant les matériaux et les équipements qui sont disponibles au laboratoire de Montréal. 
L’alginate que nous avons acheté et purifié nous-mêmes était légèrement contaminé, mais 
similaire en composition à l’alginate fourni par le labo de Groningen. Néanmoins, les deux 
alginates étaient biocompatibles in vivo. Les microcapsules APA produites avec les deux 
alginates avaient des immunogénicités comparables. En utilisant l’alginate de Montréal, nous 
avons réussit à fabriquer des billes de gel parfaitement biocompatibles, indépendamment du 
protocole de fabrication de billes employé. Cependant, notre version du protocole de Groningen 
pour la fabrication des microcapsules APA a mené à des microcapsules plus immunogéniques (p 
< 0,01) que celles qui étaient fabriquées en suivant le protocole de Montréal. Cette discordance 
a été attribuée aux modifications apportées au protocole original de Groningen, comme la 
méthode de génération des gouttelettes et le choix de modèle animal. Les résultats de cette étude 
démontrent la difficulté d’atteindre la reproductibilité interlaboratoire. Finalement, les 
protocoles de Montréal de purification de l’alginate et de la fabrication des billes et des 
microcapsules APA peuvent être considérés comme étant satisfaisants pour les études 
subséquentes d’implantation.  
 
 
 
 
xx 
Partie III 
Les facteurs qui influencent la biocompatibilité des gels d’alginate 
SOUMIS POUR PUBLICATION APRÈS 2e RÉVISION (J Biomed Mater Res A): Tam SK, 
Dusseault J, Bilodeau S, Langlois G, Hallé JP, Yahia L. Factors influencing alginate gel 
biocompatibility. 
L’alginate reste toujours le polymère le plus populaire pour l’encapsulation des cellules, 
pourtant sa biocompatibilité est inconsistante. Deux alginates commerciaux ont été comparés, 
l’un avec 71% guluronate (HiG), et l’autre avec 44% (IntG). Les deux alginates ont été purifiés, 
et leur pureté a été vérifiée. Après deux jours dans la cavité péritonéale des souris C57BL/6J, les 
billes d’alginate IntG (gélifiées avec du baryum (Ba) et du calcium (Ca)) étaient propres, tandis 
que les cellules de l’hôte ont adhéré aux billes d’alginate HiG. Les billes de gel IntG, cependant, 
ont démontré de la fragmentation in vivo, tandis que les billes de gel HiG sont restées fermes. 
Les propriétés physicochimiques des alginates de sodium et de leurs gels ont été caractérisées 
extensivement. La viscosité intrinsèque de l’alginate IntG était 2,5 fois plus grande que celle de 
l’alginate HiG, ce qui suggère une masse molaire plus élevée. La spectroscopie de 
photoélectrons avec rayons X a indiqué que les deux alginates étaient similaires en termes de 
composition élémentaire, incluant la présence de faibles niveaux de contre-ions dans tous les 
gels. La mouillabilité des deux alginates et des gels était aussi identique, selon des mesures de 
l’angle de contact de l’eau sur des films secs. Les billes de Ba de l’alginate HiG résistaient 
beaucoup plus au gonflement et à la dégradation quand elles étaient immergées dans l’eau que 
les autres types de billes. Ces résultats suggèrent que les facteurs principaux qui contribuent à la 
biocompatibilité des gels d’alginate purifié sont le contenu de mannuronate/guluronate et/ou la 
viscosité intrinsèque. 
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Partie IV 
La biocompatibilité et les caractéristiques physico-chimiques des microcapsules 
d’alginate-polycation 
SOUS PRESSE : Tam SK, Bilodeau S, Dusseault J, Langlois G, Hallé JP, Yahia L. 
Biocompatibility and physicochemical characteristics of alginate-polycation microcapsules. 
Acta Biomaterialia 2010. 
Il y a une nécessité de mieux comprendre la biocompatibilité des microcapsules 
d’alginate-polycation basé sur leurs caractéristiques physicochimiques. Des microcapsules 
composées d’alginate avec 44% (IntG) ou 71% (HiG) guluronate, gélifiées avec le calcium (Ca) 
ou le baryum (Ba), et entourées avec le poly-L-lysine (PLL) ou la poly-L-ornithine (PLO), suivi 
par une couche d’alginate IntG ont été comparées. Pour les microcapsules avec un cœur de gel 
IntG(Ca), l’utilisation de PLO au lieu de PLL a mené à moins d’adhésion de cellules 
immunitaires après deux jours dans les souris C57BL/6J. En plus, les microcapsules de PLO 
étaient caractérisées par une plus forte hydrophilicité et une résistance supérieure au gonflement 
et au dommage sous le stress osmotique. Pour les microcapsules avec une membrane de PLL, la 
substitution de cœur de gel IntG(Ca) par IntG(Ba) ou HiG(Ca) a mené à des réponses 
immunitaires plus fortes (p < 0,05). Ceci a été expliqué par une faible pénétration du PLL dans 
le gel, tel que démontré par des analyses de FTIR et par une rupture plus importantes des 
membranes pendant le gonflement osmotique. Les analyses de XPS ont démontré que toutes les 
microcapsules avaient la même quantité de polycation à leur surface. De plus, les revêtements 
d’alginate n’avaient pas des effets significatifs sur la biocompatibilité et les propriétés 
physicochimiques des microcapsules. Donc, les interactions alginate-polycation lors de la 
création de la membrane sont plus importantes pour la biocompatibilité que la quantité de 
polycation à la surface et le revêtement d’alginate. 
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Partie V 
Induire la normoglycémie dans les souris diabétiques avec les îlots microencapsulés : Avec 
ou sans la membrane 
PAS SOUMIS POUR PUBLICATION 
La membrane polycationique est supposée résulter en des microcapsules d’alginate-
polycation ayant une perméabilité contrôlée et une plus grande stabilité, mais sa 
biocompatibilité n’est pas optimale. Cette étude cherche à déterminer si une membrane 
légèrement immunogénique sert à diminuer ou à augmenter la capacité des microcapsules 
d’immunoprotéger. Nous avons évalué la capacité de 300 îlots de rats, encapsulés, soit dans les 
microcapsules alginate-PLO ou dans les billes d’alginate de baryum, de normaliser les taux de 
glucose sanguin des souris diabétiques immunocompétentes. Une des quatre souris qui a été 
transplantée avec des îlots dans les microcapsules PLO est devenue normoglycémique (pour 14 
jours), tandis que les trois autres sont restées diabétiques. Toutes les souris qui ont reçu des îlots 
immobilisés dans des billes de gel sont devenues normoglycémiques pour des périodes entre 16 
et 50+ jours. Une fois que l’hyperglycémie était rétablie, les échantillons étaient explantés et 
examinés sous microscope afin de comprendre pourquoi les greffes ont échouées. Dans le cas 
des microcapsules PLO, l’échec de la greffe semblait d’être à cause de la fragmentation et la 
dégradation des échantillons in vivo. Dans le cas des billes de gel, la cause de l’échec de la 
greffe était moins claire. Plusieurs des billes explantées étaient endommagées et/ou adhérées 
avec des cellules de l’hôte. Environ 10% des îlots pouvaient être récupérés, mais certains d’entre 
eux étaient en mauvais état ou dégradés. La durée de survie des greffes n’a pas corrélé avec la 
proportion de îlots récupérés ni avec la sévérité d’adhésion de cellules de l’hôte. En conclusion, 
la membrane PLO n’était clairement pas bénéfique pour la fonction et la survie des îlots in vivo, 
mais il reste incertain qu’une membrane d’un autre type est nécessaire pour l’immunoprotection. 
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CONCLUSIONS GÉNÉRALES 
La biocompatibilité des microcapsules d’alginate-polycation n’a pas pu être optimisée 
dans notre laboratoire. Elles étaient régulièrement immunogéniques en termes de l’adhésion des 
cellules immunitaires à leur surface in vivo. Ces réactions inflammatoires étaient clairement 
induites par la présence du polycation qui forme la membrane de la microcapsule. De plus, un 
revêtement d’alginate, qui est ajouté dans le but d’améliorer la biocompatibilité des 
microcapsules en masquant les charges du polycation, n’a eu aucun effet significatif sur les 
propriétés physicochimiques, ni sur l’immunogénicité des microcapsules. Pourtant, la sévérité 
de la réponse immunitaire a varié dépendamment des interactions entre le polycation et le gel 
d’alginate, ce qui est relié à la composition chimique de la microcapsule. Cette observation 
démontre qu’il y toujours une possibilité d’améliorer la biocompatibilité des microcapsules en 
choisissant une combinaison de matériaux (l’alginate, le cation pour gélification, le polycation) 
qui optimise la diffusion et la liaison du polycation dans le gel d’alginate. Quand nous avons 
évalué l’efficacité des microcapsules à protéger les îlots transplantés, ce n’était pas la réponse 
immunitaire aux microcapsules qui était le plus problématique pour la survie de la greffe, mais 
plutôt la tendance de ces microcapsules de se dégrader in vivo. 
Par contre, il a été démontré que l’alginate était parfaitement biocompatible dans des 
conditions spécifiques. Dans notre cas, ceci demandait un contenu intermédiaire de guluronate, 
une masse molaire plus grande, et un niveau de pureté adéquat. La biocompatibilité de ces gels, 
cependant, était contrariée par leur fragilité, ce qui présente un problème pour l’immobilisation 
et la protection des cellules transplantées. Néanmoins, la survie et  le fonctionnement des îlots 
transplantés étaient améliorés avec l’utilisation des billes de gel d’alginate sans membrane. 
 
RECOMMANDATIONS 
Pour améliorer la biocompatibilité des microcapsules d’alginate-polycation, il est 
recommandé d’optimiser la diffusion et la liaison du polycation avec le gel d’alginate. Afin de 
trouver la meilleure combinaison de paramètres pour optimiser les interactions alginate-
polycation (choix de matériaux, dynamiques de gélification, etc.), il est d’abord suggéré 
d’évaluer une gamme de formules en utilisant le FTIR pour surveiller les interactions 
xxiv 
intermoléculaires. Après avoir passé cette étape de base, il est recommandé de vérifier les autres 
propriétés physicochimiques qui ont été corrélées avec la biocompatibilité, telles que 
l’hydrophilicité (angle de contact), la charge de surface (potentiel de zêta), et la morphologie de 
la surface (la microscopie à force atomique). Il est fortement suggéré de cesser d’essayer 
d’optimiser la biocompatibilité en manipulant le revêtement d’alginate. 
Même si la biocompatibilité de la microcapsule est optimisée, ceci ne veut pas dire 
qu’une réponse immunitaire peut nécessairement être complètement éliminée. La chirurgie 
nécessaire à l’implantation et des défauts physiques sur des microcapsules individuelles sont 
deux facteurs qui sont essentiellement inévitables et qui risque de déclencher l’inflammation. Il 
est donc recommandé d’incorporer des anti-inflammatoires dans les microcapsules qui agissent 
à courte terme et localement. 
Finalement, une fois que la biocompatibilité de la microcapsule d’alginate-polycation 
sera établie, il est nécessaire de vérifier l’effet des modifications sur la stabilité et la 
perméabilité des microcapsules, puisqu’une microcapsule biocompatible n’est pas utile si elle 
n’est pas appropriée pour l’immunoprotection des cellules transplantées. 
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INTRODUCTION 
A NEED TO OPTIMIZE THE BIOCOMPATIBILITY OF 
IMMUNOPROTECTIVE MICROCAPSULES 
 
The purpose 
The purpose of microencapsulation is to physically protect transplanted therapeutic cells 
and tissues from graft rejection with the aid of a semipermeable membrane. This approach to 
graft immunoprotection has the advantage of not requiring general immunosuppression of the 
patient. Moreover, the use of microcapsules allows the option of using non-cadaveric sources of 
cells, including genetically engineered cells and xenografts, for cell therapy. For these two 
reasons alone, the use of microcapsules has the potential of making cell therapy more widely 
accessible than ever. 
In practice, immunoprotective microcapsules can potentially be used to treat range of 
disorders by allowing the transplantation of cells that secrete a specific protein or hormone that 
the patient is lacking. One of the most popular applications for these microcapsules is to protect 
and transplant islets of Langerhans (i.e. clusters of insulin secreting cells that are found in the 
pancreas) in order to “cure” type 1 diabetes. Since encapsulated islet transplantation is also the 
main research axe of my co-director, Dr Hallé, this thesis focuses principally on the 
characterization, performance, and optimization of microcapsules designed for islet 
transplantation. 
Researchers have proven on numerous occasions that encapsulated islets can 
successfully induce normoglycemia (normal blood sugar levels) in a range of animal models, 
and a handful of phase I/II clinical trials have begun. Proof-of-concept has been demonstrated, 
and hopes remain high for this approach to treat diabetes. 
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The problem 
The greatest challenge that we are facing is that encapsulated islet graft survival is both 
limited and variable. That is, in vivo viability and function of encapsulated islets can still range 
from days to years. Many different biological factors have been associated with the failure of 
encapsulated islets, but also material factors. In particular, an inadequate biocompatibility of the 
microcapsules contributes to graft failure. 
When a microcapsule is not sufficiently biocompatible, there is a non-specific foreign 
body reaction to the device. Activated immune cells adhere to the microcapsule surface and 
secrete cytokines and nitric oxide that can penetrate the microcapsule membrane and harm the 
islet cells within. As inflammation progresses, fibrotic tissue surrounds the microcapsules and 
can hinder the diffusion of oxygen and cell nutrients towards the enclosed islets. The diffusion 
of insulin and glucose is also hindered, which can lead to slower response times of the 
encapsulated islets. Increasing the lifetime and efficiency of encapsulated islets therefore 
requires that we minimize the immunogenicity of the microcapsules. Adequate biocompatibility 
of the microcapsule is also necessary in order to focus, without interference, on other aspects of 
the encapsulated islet system that must be optimized. 
Although a couple of researchers have demonstrated their ability to produce alginate-
polycation microcapsules that are impressively biocompatible, other labs have had difficulty 
reproducing such results. This underlines our lack of understanding about which factors are the 
most important for determining the biocompatibility of the microcapsules. This situation is 
intimately related to the fact that there currently exist no standards that can guide us in the 
fabrication of the microcapsules in order to achieve optimal biocompatibility and performance 
of the devices. 
  
Our goal 
The ultimate goal of all the researchers in this field is to optimize the performance of 
encapsulated islets to the point that the transplant can survive and properly function for the 
lifetime of the diabetic patient. 
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The goal of this research is to contribute to the optimization of one aspect of the 
encapsulated islet system : the biocompatibility of the microcapsule. The main question that we 
seek to answer is why one microcapsule is biocompatible while another is not, despite their 
similar designs. Our objective is thus to elucidate the correlations between the chemical make-
up, physicochemical properties, and in vivo biocompatibility of the microcapsules. 
 
Our hypothesis 
This research is based on the hypothesis that the host response to microcapsule, 
including protein adsorption and cellular response, is governed by, and can therefore be 
controlled by, the physicochemical properties of the device and its material components. 
 
Specific research aims 
This experimental section of this thesis has been divided into five chapters, each 
representing a phase in my doctoral studies, and each driven by specific research aims : 
1) To prove that immunoglobulins adsorb to the surface of alginate-polycation 
microcapsules, and to correlate this adsorption with the microcapsule 
chemistry 
2) To test interlaboratory reproducibility in making biocompatible 
microcapsules, and to evaluate the suitability of our materials and fabrication 
protocols for subsequent studies 
3) To determine which physicochemical properties of alginates affect the in 
vivo biocompatibility of their gels 
4) To determine which physiochemical properties of alginate-polycation 
microcapsules are most important for determining their in vivo 
biocompatibility 
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5) To determine whether a modestly immunogenic membrane hinders or helps 
the ability of the microcapsule to immunoprotect islet xenografts in diabetic 
mice 
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CHAPTER 1 
BACKGROUND AND CRITICAL REVIEW OF THE LITERATURE 
 
1.1 Microencapsulation for immunoprotection 
1.1.1 The benefits of immunoprotection by encapsulation 
immune cells
antibodies
glucose, 
insulin
nutrients, O2, 
metabolic waste
islet
 
Figure 1.1 Schematic representation of immunoprotection by encapsulation using the example of an 
insulin-secreting islet enclosed within a microcapsule. 
Immunoprotection refers to a strategy to protect cells and tissues from graft rejection by 
encapsulating them within a semi-permeable membrane. As a general rule, the encapsulated 
cells secrete some type of molecule (a hormone, enzyme, or another type of protein) and are 
transplanted into a patient that is unable to adequately produce this molecule. The semi-
permeable membrane is intended to physically block out larger components of the host immune 
system (antibodies ∼ 150 kDa and immune cells) while simultaneously allowing the free 
diffusion of smaller molecules (cell nutrients, oxygen, metabolic waste, and the therapeutic 
substance (e.g. insulin 5.8 kDa) into and out of the device. Ideally, the membrane is also capable 
of immunoisolating the therapeutic cells by preventing the host immune cells from both 
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detecting and reacting to the enclosed cells by blocking cell-to-cell contact [1, 2]. The concept 
of immunoprotection by encapsulation is illustrated in Figure 1.1, using the example of an islet 
(a cluster of insulin-secreting cells) enclosed within a microcapsule.  
The main advantage of immunoprotection by encapsulation is that long-term general 
immunosuppression of the patient is not required in order to avoid graft rejection of the 
transplanted therapeutic cells. Since the development of the “Edmonton protocol” for isolating 
islets from a cadaveric donor pancreas, first published by Shapiro et al in 2000 [3, 4], 
immunosuppression has been used to successfully protect non-encapsulated islet transplants in 
hundreds of patients, with graft function sometimes extending as long as several years [5, 6]. 
However, because of the risks (vulnerability to infections, tumours and cancer) and undesirable 
side effects (mouth ulcers, diarrhea, acne) associated with immunosuppression [7], non-
encapsulated islet transplantation is currently reserved for patients with severe hyperglycemia or 
who also require kidney transplants that demand immunosuppression. 
Another benefit of using encapsulation devices is the possibility that the membrane can 
also potentially protect the host from the cells, a concept that was demonstrated in our lab [8]. 
This implies the option of transplanting non-cadaveric sources of cells in a safe manner, 
including animal cells (xenografts) [9, 10] and genetically engineered cells [11, 12]. This feature 
of encapsulation may help alleviate the current problem of insufficient sources of human islets 
available for widespread clinical transplantation [13]. 
Another potential advantage to encapsulated cell transplantation is the possibility of 
incorporating bioactive substances that enhance graft performance into the device. Such 
substances, for example, can improve oxygenation of the cells [14] or suppress acute 
inflammation upon transplantation of the grafts [15, 16]. Similarly, co-encapsulation with 
different cell types has also been explored as a strategy to improve the viability and function of 
the therapeutic cells [17, 18]. 
Finally, the encapsulation devices can also protect the transplanted cells from 
mechanical stress [19], thereby increasing their chance for proper function and survival. 
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1.1.2 The advantages of microcapsules 
A range of devices for immunoprotection purposes have been developed, including 
intravascular devices, and extravascular macrocapsules (generally planar or tubular diffusion 
chambers), and extravascular microcapsules [20-22]. Intravascular devices have the advantage 
of placing the enclosed cells close to the bloodstream, but the surgery can be complicated and 
thrombosis (blood clotting) can block blood flow or necessitate the use of anti-coagulants [20, 
22]. Extravascular macrocapsules, which are used to encapsulate a large number of cells or 
many islets at once, are easy to retrieve in the case of graft failure, but their geometry makes 
them generally unfavourable for oxygen and nutrient diffusion, as well as diffusion of the 
therapeutic agent [20, 22]. 
Extravascular microcapsules are generally < 1.5 mm in diameter. In the case of islet 
transplantation, each microcapsule is intended to enclose a single islet (human islets can 
measure 50 to 300 µm in diameter [23]). The advantages and disadvantages associated with 
microcapsules vs. macrocapsules have been compared in ‘Tableau 1’ of our book chapter 
(APPENDIX II). The greater surface-to-volume ratio is probably the greatest advantage of 
using microcapsules, since this geometry should theoretically allow an increased diffusion 
efficiency of the devices [22, 24]. In the case of islet transplantation, this can lead to a greater 
viability and quicker response time of the islet cells due to an increased diffusion of oxygen, 
nutrients, and glucose towards the enclosed islets, and of insulin out of the microcapsule [25]. 
Other important advantages of using microcapsules in place of macrodevices include the 
accessibility to a greater range of transplantation sites [26, 27] and the possibility of maintaining 
graft survival even if a small percentage of the microcapsules break. 
Similar to microcapsules are also conformal coatings or nanoencapsulation, which 
involves directly coating a cellular aggregate (such as an islet) with a thin polymer layer (as thin 
as 10 µm), with idea of minimizing transplant volume and maximizing diffusion properties. This 
has been investigated by directly applying the first polycationic layer to the negatively charged 
islet surface [28, 29], by interfacial precipitation using poly(hydroxyethyl methacrylate-co-
methyl methacrylate) HEMA-MMA [30], or a variety of techniques to graft polyethylene glycol 
(PEG) to the cell surface (i.e. PEGylation) [31-33], a polymer known to discourage protein and 
cell adhesion [34]. With the exception of PEGylation, however, conformal coating and 
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nanoencapsulation have not yet shown the same level of promise as microcapsules for cell 
immunoprotection. 
1.1.3 Alginate-based microcapsules 
The vast majority of microcapsules that have been developed for cell immunoprotection 
purposes have used a hydrogel as the main component [35]. Hydrogels have several favourable 
properties for encapsulation purposes (section 3.1 of our book chapter, APPENDIX II), the 
most important of these being their pliability, which minimally irritates surrounding biological 
tissues by friction, and their high water content, which minimizes the interfacial tension between 
the capsule surface and surrounding tissues/fluids, making protein and cell adhesion 
energetically unfavourable [36, 37]. A detailed description of hydrogels that have been used for 
cell encapsulation is presented in section 3.1 of our book chapter (APPENDIX II).  
The most popular hydrogel in the cell encapsulation field remains alginate. Molecularly 
speaking, alginate is an unbranched copolymer with blocks of (1-4)-linked β-D-mannuronate 
(M) and α-G-guluronate (G) residues. These two residues are identical in atomic composition 
but take on different chair conformations. A schematic of a -GGMM- segment of alginate is 
illustrated in Figure 5.1. In addition to possessing the favourable qualities of other hydrogels, 
this natural polysaccharide has the added advantage of quickly gelling under conditions that are 
compatible with living cells [38]. To immobilize a cell within a microbead of alginate gel, one 
has only to suspend the cell in a viscous, aqueous solution of alginate and then immerse droplets 
of this suspension in a solution containing divalent cations (generally Ca2+ or Ba2+). 
Most research groups have opted to include some type of membrane in the design of 
their microcapsules in order to reduce the permeability and increase the stability of the devices. 
In most cases, these membranes are formed by polyelectrolyte complexation, which requires an 
electrostatic interaction between the negatively charged alginate gel and some type of polycation 
(i.e. a positively charged polymer). Membrane formation using this approach is simple to 
perform in the lab, as it generally requires successive incubations of the bead or capsule into 
polymer and buffer solutions. The general protocol for this technique, as well as alternative 
techniques for microcapsule fabrication, is described in detail in our book chapters in 
APPENDIX II and APPENDIX III. 
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Historically, Alginate-Poly(L-lysine)-Alginate (APA) microcapsules have been 
investigated more than any other microcapsule design. In 1980, Lim and Sun were the first to 
propose the APA microcapsule as a device for immunoprotecting islets in a paper that published 
in Science [39]. Since, APA microcapsules (or slight variations of) have continued to dominate 
the cell encapsulation field [40, 41], most likely because of the proven ability of these devices to 
function short-term in vivo, the apparent simplicity of the fabrication protocol, and the low cost 
of the materials required. Despite thirty years of research dedicated to developing the APA 
microcapsule, however, the design persistently shows limitations (including inconsistent 
biocompatibility [42]) that have made it difficult to advance towards regular clinical 
applications. For this reason, several researchers have decided to investigate alternative alginate-
based microcapsule designs. These have recently been reviewed by others [41, 43] and are also 
listed in ‘Tableau 2’ of our book chapter (APPENDIX II). Overall, the best candidates for 
replacing the PLL as the polycation in for alginate-based microcapsules seem to be PLO [44, 
45], PMCG [46, 47], and chitosan [48, 49]. 
Finally, a handful of research groups have opted to use alginate gel beads without adding 
a membrane [50-53]. Despite the risk of inadequate immunoprotection due to the high porosity 
of the alginate gel, the main motivation behind omitting the membrane is based on the challenge 
of overcoming the immunogenicity of the polycation (see section 1.4.2). 
 
1.2 Recent progress of microencapsulated islet transplantation 
The goal of encapsulated cell and tissue transplantation is to provide a specific molecule 
(hormone, enzyme, or other protein) to a patient that is unable to produce this molecule on their 
own. Encapsulated cell therapy has been investigated for the treatment of a variety of health 
problems, including hemophilia [54], cancer [55], renal failure [56], hyperparathyroidism [57], 
and dwarfism [58]. In our lab, we are investigating the encapsulation of the islets of Langerhans 
as a method to supply insulin to type 1 (insulin-dependent) diabetics. An overview of the history 
and recent progress of encapsulated islet transplantation is illustrated in Figure 1.2 and are 
further discussed in this section. 
 
10 
1980
Lim and Sun (Canada/US)
5 rats
A
LL
O
TR
A
N
SP
L
A
N
T
S
X
EN
O
TR
A
N
SP
LA
N
TS
1992
Sun et al (Toronto)
1 monkey
1992
VivoRx (California)
7 dogs (immunosuppressed)
1994
VivoRx (California)
1 patient (immunosuppressed)
2005
Amcyte (California/Toronto)
1 patient
2006
Calafiore et al (Italy)
2 patients
1980 1990 2000 2010
2006
Tuch et al (Australia)
4 patients
1996
LCT (New Zealand)
1 patient (immunosuppressed)
2009
LCT (New Zealand)
8 patients
2007
LCT (Russia)
8 patients
2005
Novocell (California)
2 patients
A
LL
O
TR
A
N
SP
L
A
N
T
S
X
EN
O
TR
A
N
SP
LA
N
TS
 
Figure 1.2 Timeline of key moments in allotransplantations (between same species) and 
xenotransplantations (between different species) of islet encapsulation. In this graph, xenotransplantation 
implies the transplantation of porcine islets. Animal model studies are represented by blue lines, while 
clinical trials are represented by red lines. LCT = Living Cell Technologies. 
1.2.1 Key moments using animal models 
1980: Lim and Sun (Canada/US) published the hallmark study for islet encapsulation, i.e. the 
first known publication to demonstrate the efficiency of encapsulated islets for treating diabetes 
in vivo [39]. These researchers implanted batches of 2000-3000 rat islets, encapsulated within 
alginate-PLL microcapsules, into five STZ-induced diabetic Wistar rats. In all five recipients, 
normoglycemia was induced and maintained for two to three weeks. 
1992: This year marked the first experiments in large animal models. Sun et al (Toronto) 
demonstrated that porcine islets encapsulated within alginate-PLL could normalize the blood 
sugars of a spontaneously diabetic monkey for more than 150 days [59]. Four years later, they 
extended their study to nine diabetic monkeys. Without the use of immunosuppression, all nine 
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recipients became normoglycemic and then remained insulin independent for 120 to 804 days 
[60]. In the same year, Soon-Shiong et al (VivoRx, California) transplanted islet allografts into 
seven spontaneous diabetic dogs, also using alginate-PLL microcapsules, but in combination 
with a low dose of immunosuppressants [61, 62]. They reported successful reversal of diabetes 
in all seven dogs, which remained insulin-free for a period of 63 to 172 days. 
1992 to present: Several studies use large animal models to demonstrate the efficiency of 
encapsulated islet transplantation. Here we name a few. Lanza et al reversed diabetes in dogs for 
60 to >175 days in diabetic dogs using islet allografts encapsulated in uncoated alginate beads in 
combination with low doses of immunosuppressants [63]. Kendall et al announced that long-
term normoglycemia (nine months) was induced in a diabetic baboon using porcine islets 
enclosed within alginate-PLO microcapsules [64]. Kin et al used a microcapsule composed of 
agarose and polystyrene sulfonic acid mixed gel to immunoprotect pig islets when transplanted 
in diabetic dogs, achieving moderate success [65]. Living Cell Technologies transplanted 
neonatal porcine islets immobilized in alginate–PLO microcapsules into eight diabetic monkeys, 
which resulted in lower insulin requirements and, in one monkey, insulin independence [66]. 
Novocell tested PEG-coated islets in combination with low doses of immunosuppressants in two 
sets of experiments involving diabetic baboons, with about half of the recipients achieving 
insulin independence several months post-transplantation [67]. Wang et al allotransplanted islets 
encapsulated within multi-layered alginate-based microcapsules into diabetic dogs without the 
use of immunosuppression, and all nine dogs were normoglycemic and insulin-free for 64 to 
214 days [68] 
1.2.2 Clinical trials of allotransplantation (human islets) 
1994: Soon-Shiong et al (VivoRx, California) were granted approval for Phase I/II trials of 
encapsulated islets using patients that are candidates for whole organ pancreas transplantations 
[69]. The first patient received two intraperitoneal injections of 10 000 then 5 900 human ieq/kg 
enclosed in alginate-PLL microcapsules, and was insulin independent by nine months post-
transplantation. According to a follow-up report two years later, the patient continued to show a 
reduction in exogeneous insulin [69]. However, it has been pointed out that this patient was 
already under immunosuppression due to a kidney graft, so the effectiveness of the 
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microcapsule remains questionable [70]. Results concerning other patients have been difficult to 
find, likely due to legal problems associated with the company in the late 90’s [71, 72].  
Feb 2005: As part of a phase I/II clinical trial AmCyte (now ReNeuron Group, California) 
transplanted islets encapsulated within alginate-PLL microcapsules into the abdominal cavity of 
a man at the Toronto General Hospital with no long-term immunosuppression. [73-75]. No 
follow-up reports have been found. 
Nov 2005: Novocell (now ViaCyte, California) started Phase I/II clinical trials of the safety 
and efficacy of PEG-encapsulated primary islet allografts implanted subcutaneously in type I 
diabetic patients [76]. Preliminary evidence of safety and function in two patients was 
demonstrated. At 12 months post-transplantation, there were no significant side effects and 
evidence of islet function [77, 78]. However, in May 2010, ViaCyte announced that they have 
discontinued their work on PEG-encapsulated islets in order to focus on stem cell derived 
treatments for diabetes (Pro-IsletTM) [79].  
Feb 2006: Tuch et al (Prince of Wales Hospital, Australia) started pilot clinical trials for the 
transplantation of human islets encapsulated within in barium alginate beads in the absence of 
anti-rejection drugs [80, 81]. In a 2009 publication, they describe that over a period of 19 
months, four patients received one to four intraperitoneal infusions of (on average) 178 200 
encapsulated ieq [82]. Any effect of the transplant on blood glucose or insulin requirements 
didn’t last more than a day. In one patient, they examined the transplants by laparoscopy 16 
months after the first infusion and noted that the microcapsules were attached to internal organs, 
surrounded by fibrous tissue, and the islets were necrotic. A few months later, the same 
researchers published a study that implied a need to go back to small animal models to 
understand what went wrong [83]. 
2006: Calafiore et al (University of Perugia, Italy)  received approval for a phase 1 pilot 
clinical trial of microencapsulated human islet allografts into ten non-immunosuppressed 
patients with type 1 diabetes [84]. A total of 400 000 or 600 000 ieq enclosed within alginate-
PLO microcapsules were transplanted into two patients by injection in the abdomen. After 
several weeks, the patient show improved blood glucose levels and less need for insulin [85]. In 
a 2010 publication, Calafiore reported that two more patients have since been transplanted, and 
they also showed a reduction in insulin requirements [70]. 
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1.2.3 Clinical trials of xenotransplantation (porcine islets) 
Clinical trials of encapsulate xenotransplantation has been dominated by one New Zealand-
based company called Living Cell Technologies (LCT). This company’s currently leading 
product, described under the brand name DIABECELL®, consists of neo-natal porcine islets 
encapsulated within alginate-polyornithine microcapsules [86]. LCT uses an ultra-pure alginate 
that was developed by Calafiore et al (University of Perugia) and holds an exclusive license and 
rights to the Perugia alginate [87]. 
1996: LCT (New Zealand) initiated the first Phase I/II clinical trials of encapsulated animal 
islets (neo-natal porcine islets) in Type 1 diabetic patients that have kidney transplants (thus are 
already immunosuppressed). A follow-up report in 2007 describes that a total of 1 305 000 ieq 
enclosed in alginate-PLL microcapsules, and then re-encapsulated within larger microcapsules, 
were transplanted intraperitoneally into one patient [88]. At 12 weeks post-transplantation, 
insulin requirements were reduced, but by 49 weeks, the patient was back to original insulin 
dosages. At 9.5 years post-transplantation, the microcapsules were embedded in the omentum, 
opaque and rigid, but some of the islets appeared to have survived but were not well-functioning 
[88].  
2000: LCT explains that trials with encapsulated porcine islets have begun in Type 1 diabetic 
patients without immunosuppression. However, due to worldwide concerns on 
xenotransplantation, the New Zealand Ministry of Health placed a hold on further clinical trials 
until new viral tests, etc. can be developed [89].  
2007: LCT circumvents approval issues by starting a Phase I/IIa clinical trial for 
DIABECELL® in Moscow, Russia. Up to ten patients are to receive implants of varying dose 
strength, and some patients will receive multiple doses [90]. By June 2009, eight patients have 
been transplanted, and two were still off insulin injections, while all patients showed better 
blood glucose control an reduced insulin dosages [91]. 
Jul 2009: LCT started a Phase I/II Clinical trial in New Zealand that investigates the safety and 
effectiveness of DIABECELL® in non-immunosuppressed patients with type I diabetes [92]. 
Three study groups are to receive dosages of 10, 15 and 20 thousand ieq/kg injected into the 
abdominal cavity via laparoscopy. The first implant was in Oct 2009. In Apr 2010, study 
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received a major grant from the JDRF to support the project [93]. On 4 Aug 2010, the company 
announced that the Minister of Health has approved an addition to the New Zealand Phase II 
clinical trial of DIABECELL® to include four more patients. To date, eight patients have 
already received the transplants. So far, none show adverse side effect and all have experienced 
less frequent hypoglycemia [94]. 
Apart from LCT, other companies are trying to enter the marked of encapsulated porcine islet 
transplantation. For instance, MicroIslet (California) plans to pilot xenotransplantation human 
clinical studies employing the MicroIslet-PTM in a yet to be determined foreign country. This 
company employs an alginate-based capsules for the transplantation of porcine islets into the 
abdominal cavity [95, 96]. 
1.2.4 Main obstacles to regular clinical applications 
Despite the promise expressed in the recent progress of pilot clinical trials of 
encapsulated islet transplantation, we are still a number of years away from regular clinical 
applications. The main obstacles that are being faced are : 
Lack of human donor organs: As much as allotransplantations are easier to deal with from an 
immunological point of view than xenotransplantations, suitable human pancreases and islets 
are not easy to come by (not all donated organs are suitable for transplantation) [97, 98]. 
Safety and regulatory approval: As a strategy to overcome the obstacle of limited human islets 
available, xenotransplantation has become an interesting alternative, particularly the use of 
porcine islets. However, the risks of transmitting animal viruses and/or inducing a strong 
immune response have made it difficult to get approval for xenotransplantations [99, 100]. No 
clinical trials involving xenotransplantation have been approved by Health Canada to date [101]. 
Researchers have tried to overcome approval issues by setting up clinical trials in foreign 
countries that impose less strict regulations. The situation is similar for the use of genetically 
engineered cells that secrete insulin.  
Limited graft survival: Of course, if the graft does not work efficiently, hopes for clinical 
applications will remain dim. There are a number of factors that contribute to death or 
dysfunction of encapsulated cells. These have been reviewed in a number of recent publications 
[22, 41, 102-107] and won’t be explained in detail here. However, it is important to understand 
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that, from a biological point of view, the life of an encapsulated islet is very stressful. If one can 
imagine, the islet must first endure the stress of being isolated from its native pancreas [108]. 
After being isolated, the islet must then be able to survive the encapsulation procedure [109]. 
Once inside the microcapsule and transplanted, the islet must try to survive inside this artificial 
environment. This encapsulated islet cannot count on blood vessels to bring it necessary 
nutrients and oxygen since the microcapsule prevents revascularization of the tissues. Instead, 
the islet relies solely on diffusion for nutrient and oxygen transport [110, 111]. If this diffusion 
is not efficient, islet cells (particularly those in the middle of the cluster) risk dying from 
hypoxia [112, 113]. In addition to all these factors involving the islet, it is believed that an 
inadequate biocompatibility of the microcapsules contributes to graft failure. This topic is 
discussed in more detail in section 1.3.4. 
Uncertainty of long-term performance: Associated with the fact that we are still struggling to 
maintain long-term survival of the transplanted islets, there is an uncertainty about how the 
transplant will perform, or should perform, over the course of several years. This uncertainty 
also applies to the performance of the microcapsules themselves. In particular, are the capsules 
expected to eventually biodegrade, thus requiring regular injections of fresh encapsulated islets, 
or should we be aiming to develop a ‘permanent’ capsule that will remain stable for the lifetime 
of the patient ? 
 
1.3 Microcapsule biocompatibility : Biological considerations 
What do we mean when we say that a microcapsule is “biocompatible” ? In the case of 
encapsulated cell transplantation, a “biocompatible” system is interpreted as inducing minimal 
host cell adhesion, cellular overgrowth or fibrotic overgrowth. There is accumulated evidence 
that the host response to the microcapsules is a non-specific foreign body response (as opposed 
to an adaptive immune response). This response, which is similar for all biomaterial types, is 
briefly reviewed here. 
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1.3.1 Relevant aspects of the host response to implants 
James Anderson elegantly described the host response to implants in his article 
“Biological Responses to Biomaterials”, published in the Annual Review of Materials Research 
[114]. Extracts of this paper that are considered to be relevant to understanding the host 
response to microcapsules have been summarized here. 
Anderson [114] has described the host response to implanted medical devices as a 
sequence of eight events. These are : 
(1) Injury: This refers to injury to vascularised connective tissue involved with the 
transplantation procedure. The inflammatory response is initiated by injury. 
(2) Blood-material interactions: Immediately following injury, fluid, proteins, and blood 
cells flow towards to the injured tissue. This is accompanied by changes in blood 
composition and a range of cellular events. Chemicals are released from plasma, cells, 
and injured tissue that mediate, and therefore characterize, the inflammatory response. 
Classes of chemical mediators include complement components, oxygen-derived free 
radicals, cytokines, and growth factors. 
(3) Provisional matrix formation: Development of a provisional matrix at the implant site 
occurs within minutes to hours following implantation. This matrix consists of cross-
linked fibrin and various inflammatory products. Components within or released from 
this matrix initiate processes such as inflammatory cell and fibroblast recruitment. The 
fibrin network also provides a substrate for cell adhesion and migration. 
(4) Acute inflammation: Acute inflammation lasts from minutes to days, depending on the 
extent of injury. It is characterized by the exudation of fluid and plasma proteins and the 
emigration of leukocytes (predominantly short-lived neutrophils) towards the 
implantation site. The major role of neutrophils is to phagocytose microorganisms and 
foreign materials. Recognition of the implant by the neutrophils and other phagocytes is 
facilitated when the implant surface is coated by opsonins (see section 1.3.2). Although 
biomaterials are not generally phagocytosed because they are much larger than cells, 
certain events in phagocytosis may occur, including frustrated phagocytosis. This 
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process does not involve engulfment of the biomaterial but does cause the extracellular 
release of leukocyte products in an attempt to degrade the biomaterial.  
(5) Chronic inflammation: Persistent inflammatory stimuli lead to chronic inflammation. 
The chemical and physical properties of the biomaterial, as well as motion of the 
implant, may lead to chronic inflammation. This phase is characterized by the presence 
of macrophages and monocytes (which differentiate into macrophages), as well as 
plasma cells and lymphocytes. Macrophages, however, are the predominant cell type 
during chronic inflammation and these can survive several weeks. Macrophages may be 
activated upon adherence to the biomaterial surface. Like neutrophils, macrophages are 
phagocytes, and when activated, will attempt phagocytosis of the biomaterial. 
Macrophages are also principally responsible for normal wound healing in the foreign 
body reaction. By processing and presenting antigens to immunocompetent cells, 
macrophages also play a role in the development of immune reactions. 
(6) Granulation tissue: Granulation tissue is associated with healing inflammation. 
Depending on the extent of injury, granulation tissue may be seen as early as three to 
five days following implantation of a biomaterial. Characteristic histological features of 
granulation tissue include the formation of new small blood vessels from pre-existing 
ones (i.e. neovascularization) and the proliferation of fibroblasts, which are active in 
synthesizing collagen and proteoglycans. Collagen, especially type I collagen, forms the 
fibrous capsule.  
(7) Foreign body reaction: The foreign body reaction is composed of foreign body giant 
cells, macrophages, fibroblasts, and capillaries. Foreign body giant cells are formed by 
the fusion of monocytes/macrophages in an attempt to phagocytose larger foreign 
bodies. The specific composition of the foreign body reaction, however, is determined 
by the form and surface topography of the biomaterial. On relatively flat and smooth 
surfaces, this can consist of one or two layers of macrophages, while on rough surfaces, 
foreign body reaction may consist of foreign body giant cells as well as macrophages. 
High surface-to-volume implants also lead to higher ratios of macrophages and foreign 
body giant cells. 
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(8) Fibrosis/Fibrous capsule development: The end-stage healing response to biomaterials 
is generally fibrosis or fibrous encapsulation. Essentially, connective tissue (collagen) 
surrounds the implant and its interfacial foreign body reaction, thus isolating the implant 
from the local tissue environment. 
The predominant cell type that is present during inflammation varies with the age of the 
injury. The size, shape, topography and chemical and physical properties of the biomaterial may 
be responsible for variations in the intensity and time duration of the inflammatory and wound 
healing processes. Thus intensity and/or time duration of inflammatory reaction may 
characterize the “biocompatibility” of a biomaterial. Implant biocompatibility with tissue has 
usually been described in terms of the acute and chronic inflammatory responses, and of the 
fibrous capsule formation that is observed at various post-implantation time points. Evaluation 
of implant biocompatibility commonly involves histological evaluation of tissue adjacent to 
implanted materials as a function of implant time.  
1.3.2 Protein adsorption to biomaterials 
As mentioned in the previous section, blood-material interactions occur immediately 
after injury. Amongst these interactions is the flow of proteins towards the site of injury. It is 
now generally accepted that protein adsorption is the host tissue’s first interaction with the 
biomaterial [115]. Within one second upon implantation, proteins can already be observed on 
biomaterial surfaces, and within minutes a monolayer of protein adsorbs to most surfaces [116, 
117]. Proteins are present in all biological fluids (including blood and peritoneal fluid), and are a 
primary source of information for biological recognition [37]. Simply put, the cellular response 
to implanted biomaterials is actually determined by the nature of the adsorbed protein layer 
rather than to the biomaterial itself [118]. 
In turn, the type of proteins that adsorb to a biomaterial, as well as the manner in which 
they adsorb (quantity, conformation) is thought to be influenced by the surface properties of the 
biomaterial. Thermodynamically speaking, the major interactions which drive the interfacial 
activity and adsorption of proteins are the electrostatic and hydrophobic interactions [37]. 
Accordingly, neutral, highly hydrophilic polymers are known to have minimal or weak 
interactions with most aqueous proteins [119]. In addition to surface charge and wettability, 
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topography and chemistry are also material properties that govern protein adsorption [120]. This 
observation, however, does not necessarily imply that all neutral, hydrophilic polymers will be 
biocompatible when implanted, or that protein-attracting surfaces will necessarily be 
immunogenic, as some proteins can be beneficial for biocompatibility when adsorbed to the 
surface [121]. 
Certain protein types, when adsorbed to a biomaterial surface, may be more potent than 
others in terms of their role in facilitating an unwanted inflammatory response. In particular, 
opsonizing proteins, or opsonins, adsorb readily to foreign surfaces so that phagocytic cells 
(macrophages, neutrophils) having cell receptors for these proteins, can recognize, adhere to, 
and attempt to phagocytose the foreign body. The two major opsonins are the complement 
factor C3b that participates in complement activation and the antibody IgG that plays a role in 
the immune response [114, 120, 122, 123]. Other proteins that can mediate cell adhesion include 
fibronectin and vitronectin [120]. 
1.3.3 Observed responses to microcapsules 
In general, problems with microcapsule biocompatibility have been described in terms of 
‘cellular overgrowth’, ‘fibrotic overgrowth’, or ‘fibrosis’ that is observed to surround the 
microcapsules after a certain transplantation periods in vivo. In many cases, similar 
inflammatory responses to both empty and cell-containing microcapsules imply that it is the 
microcapsule, rather than recognition of the enclosed islets, that induces the inflammatory 
response [124-126]. The most common immune and inflammatory responses that have been 
described against microcapsules designed for cell transplantation are described here : 
Protein adsorption: As early as 1992, Sawhney and Hubbell [127] observed protein adhesion 
and complement binding to different versions of APA microcapsules. De Vos et al [128, 129] 
measured the nitrogen levels on explanted APA microcapsules to demonstrate that rat proteins 
adsorb to their microcapsules when implanted into the peritoneal cavity. In our own lab, 
Dusseault et al [130] used an elution technique combined with mass spectrometry to identify a 
few dozen kinds of mouse serum/plasma proteins are capable of adsorbing to APA 
microcapsules in vitro. Xie et al recently demonstrated that bovine serum fibrinogen and 
immunoglobulin (IgG) bind to alginate-chitosan microcapsules in vitro [131, 132]. 
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Infiltration of immune cells to the implantation site: In our own lab, Robitaille et al [133] 
demonstrated that, within the first few hours after implanting APA microcapsules in the 
peritoneal cavity of rats, there is increase in free-floating neutrophils towards the implantation 
site. By 48 hours, macrophages, lymphocytes, and eosinophils take over. 
Cellular adhesion, overgrowth, and fibrosis: As implied in section 1.3.1, the specific 
composition of the cellular overgrowth or foreign body reaction surrounding microcapsules 
appears to vary with time. The majority of the studies mentioned here employed standard 
histological or immunohistochemical staining in order to determine the composition of the 
overgrowth. De Vos et al [128] noted that at 24 hours post-transplantation of APA 
microcapsules, the overgrowth appears to be mainly macrophages and some granulocytes, with 
small numbers of other cell types (mainly erythrocytes associated with trauma, but some 
basophiles). By five days post-transplantation, the overgrowth was still dominated by 
macrophages and the appearance of some fibroblasts and multinucleated giant cells [128]. By 
one week post-transplantation, macrophage population slightly decreased and fibroblasts 
became more important (about 30% of the cellular composition) [128]. King et al [134] 
observed that, in their case, cellular overgrowth on APA microcapsules became significant only 
at one week post-transplantation, and this reaction did not increase in severity by day 28. 
Fritschy et al [125] noted, at two weeks post-transplantation, the presence of macrophages, 
fibroblasts, fibrocytes, foreign body giant cells, granulocytes, and collagen deposition, but not B 
lymphocytes, T lymphocytes, dendritic cells, nor natural killer (NK) cells. The lack of B- and T- 
lymphocytes suggest a non-specific foreign body response to the microcapsules as opposed to 
an adaptive immune response [135]. Observations by Clayton et al [40] of monocytes, 
macrophages, fibroblasts, and collagen fibres, but not T cells nor B lymphocytes, at three weeks 
post-transplantation confirmed the results of Fritschy et al [125]. Also supporting these 
observations, Gotfredsen et al [126] saw, at various post-transplantation periods of two weeks 
and later, no evidence of lymphocytic invasion, but rather an overgrown layer of histiocytes and 
numerous layers of fibroblasts. By two months post-transplantation, de Vos et al [136] observed 
that macrophages had totally disappeared from the overgrowth, as they only found several layers 
of fibroblasts and connective tissue. 
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Activation of immune cells: In 1993, Pueyo et al [137] demonstrated that APA microcapsules 
are capable of stimulating IL-1β release and intracellular IL-1β and IL-1α production by human 
macrophages in vitro. Similarly, Orive et al demonstrated that APA microcapsules can activate 
the proliferation of murine splenocytes, as well as stimulate the release of TNF-α from mouse 
peritoneal macrophages in vitro [138]. Moreover, King et al [134] demonstrated activation of 
macrophages by APA microcapsules in vivo by collecting peritoneal exudates of mice that 
received microcapsule implantations and then measuring the expression of IL-1β and TNF-α 
using real time PCR. We later confirmed the ability of implanted APA microcapsules to 
stimulate the expression of TNF-α, IL-1β and TGF-β1 in vivo [133]. 
Antibody response: After injecting microcapsules into Balb/c mice, serum samples from the 
recipients have been positive for immunoglobulins that have been developed against the 
material components of APA microcapsules [139, 140]. 
A schematic that visually summarizes the inflammatory response to alginate-polycation 
microcapsules, as based on the evidence just described, is presented in Figure 1.3 below. 
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Figure 1.3 Schematic describing the probable time-course of the host response to alginate-polycation 
microcapsules upon implantation. 
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1.3.4 Contribution of non-biocompatibility to graft failure 
There has been evidence that an inflammatory response to the microcapsules is 
hazardous for the function and survival of the enclosed islets, and thereby contributes to graft 
failure. Indeed, in the early 90’s, graft failure was almost synonymous with “cellular 
overgrowth” or “fibrotic overgrowth” that develops around the alginate-polycation microcapsule 
within a few days of their implantation in vivo [124, 141, 142]. Graft failure has also been seen 
to be associated with lower recovery rates and greater proportion of capsules with pericapsular 
infiltrate [125]. The main concern for graft survival is that the fibrotic tissue can block or hinder 
the free diffusion of oxygen and nutrients across the capsule membrane, resulting in cell 
dysfunction or death, particularly hypoxia-induced islet necrosis [104, 143]. Similarly, hindered 
diffusion of insulin and glucose can slow the response time of the transplanted islets, making 
them less efficient. In addition to creating a physical barrier, cellular overgrowth may form a 
metabolic barrier to nutrient diffusion since cells within the overgrowth compete with the 
enclosed islets for glucose at the implantation site [134, 144]. More recently, there are additional 
concerns that activated macrophages and other immune cells are stimulated by the 
microcapsules to secrete a range of products that are small enough to penetrate the capsule 
membrane and damage the cells within, including the cytokines IL-1β (17.5 kDa), TNF-α (25-
51 kDa) [145, 146], as well as nitric oxide [147-149]. 
Also, the non-biocompatibility of the microcapsule hinders progress of the cell 
encapsulation approach by interfering with the process of understanding other aspects of graft 
failure.  
 
1.4 Microcapsule biocompatibility : Material considerations 
The best approach towards optimizing the biocompatibility of microcapsules intended 
for cell encapsulation is to consider what we already know. Here we review studies that have 
investigated the biocompatibility of alginates and alginate-based microcapsules and critically 
discuss what the study conclusions suggest as far as recommendations for producing a 
biocompatible microcapsule. 
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1.4.1 Alginate considerations 
There currently exists an international standard for the characterization and testing of 
alginates as starting materials intended for use in biomedical and tissue-engineering applications 
[150]. While this standard provides an excellent overview of recommended techniques for 
alginate characterization, it does not specifically concern alginates intended for cell 
encapsulation, nor does it explicitly state what combination of properties leads to the most 
biocompatible alginate. In this section, we present the current status of research in relation to 
selecting the best alginate for biocompatibility, although, as you will see, which alginate to 
choose ultimately depends on whether the alginate is soluble, gelled, or used as a microcapsule 
component. 
Purity 
Alginates that are used for cell encapsulation are derived from marine algae, and can 
therefore contain many kinds of natural contaminants, particularly proteins, endotoxins, and 
polyphenolic compounds [151, 152]. Logically, purifying the alginates to rid of such 
contaminants is the first step to improving their biocompatibility. 
In 1992, the Würzburg group [153] demonstrated that commercial alginates contained 
fractions of impurities that showed mitogenic activity. Upon removing these fractions using 
free-flow electrophoresis, the purified alginates did not induce mitogenic activity in vitro. When 
barium alginate beads were implanted intraperitoneally in rodents for three weeks, purified 
samples showed no fibrosis, in contrast to non-purified samples. Shortly after, they developed a 
chemical extraction method for purification that resulted in alginates that showed no mitogenic 
activity in vitro and induced significantly less fibrosis in vivo than non-purified alginates [154, 
155]. Also in the 90’s, de Vos et al [136] demonstrated that, by purifying their alginates in the 
lab, they could dramatically reduce the extent of cellular overgrowth on APA microcapsules 
implanted in the peritoneal cavity of AO rats. More recently, Leinfelder et al [156] developed a 
highly sensitive cell assay based on the apoptosis of Jurkat cells to validate their alginate 
purification methods. As well, the Spanish group has demonstrated that the use of pure alginates 
vs. non-pure alginates leads to less serum antibody response in mice implanted with APA 
microcapsules [139], as well as less secretion of TNF-α from murine macrophages and reduced 
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proliferation of splenocytes in vitro [138]. Mallet and Korbutt [157] also demonstrated that 
using purified alginate increases graft survival and function of islets encapsulated in simple 
alginate microcapsules, as well as dramatically reduced capsular overgrowth. 
We have seen similar benefits of purifying alginates in our own lab, including the 
production of gel beads that induce significantly less mRNA expression of TNF-α and IL-1β 
from a rat macrophage cell line in vitro [158]. More recently, we demonstrated that, while 
purifying commercial alginates significantly reduces the extent of cell adhesion, thickness of 
fibrotic layer, and amount collagen deposition surrounding alginate gel beads in vivo, the 
severity of foreign body response varied with the efficacy of purification protocol applied [159]. 
In particular, we provided evidence that proteins in the commercial alginate were particularly 
problematic for biocompatibility, as removal of these proteins by dialysing the alginates against 
saline correlated with less host cell adhesion to gel beads implanted in C57BL/6 mice [160]. 
Relative proportion of mannuronate to guluronate (M/G content) 
Researchers agree that, due to the conformational differences between the M and G 
residues, the alginate’s physical properties (including its gels) is strongly dependent on the 
composition and distribution of each of these residues along the polymeric chain. In contrast, the 
effect of the alginate’s M/G content on its biocompatibility is a subject of continual debate. To 
complicate this affair, the effect of M/G content on biocompatibility seems to depend on the 
whether the alginate is in solution form, gelled, or crosslinking with a polycation. 
In the early 1990’s, the Norwegian group demonstrated that, when in solution form, high 
M alginates are more potent stimulators than high G alginates of monocytes to produce 
cytokines such as TNF-α, IL-6 and IL-1 [161-163]. To emphasize their point, they later 
implanted APA microcapsules into rats, and observed that the microcapsules based on high M 
alginates induced an antibody response while the high G microcapsules did not [140]. It has 
been suggested that the immunogenicity of the high M microcapsules is associated with the fact 
that the mannuronic-rich fragments, which do not take part in the gelling process, can leach out 
the capsules and trigger an immune response [164]. In the same era, Clayton et al [40] observed 
the opposite result. That is, when implanted in rats, APA microcapsules coated with high M 
alginate provoked a weaker immune response than those coated high G alginate (both 
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microcapsule types had a high M alginate gel core). However, in this study, they did not 
mention purifying their alginates, nor did they test the biocompatibility of their alginates in the 
absence of PLL, so one can not definitely conclude that their high M alginate was actually more 
biocompatible. 
In response to the claimed immunogenicity of high M alginates by the Norwegian group, 
the German group published a study to demonstrate that all alginates can be rendered non-
mitogenic and biocompatible if they are properly purified, including those with a high M 
content [154, 155]. A study from the Groningen group suggested the same point of view, having 
demonstrated that (in the absence of a polycation), purified alginate with a high G content is just 
as biocompatible as an alginate with intermediate G content, as evaluated by the extent of 
cellular overgrowth on gel beads in vivo [165]. 
The Boston group showed that (uncoated) barium alginate beads of high G alginate 
induced slightly more fibrotic overgrowth when implanted in mice than high M gel beads 
(which were biocompatible) [52]. In a more recent study of theirs, however, they compared the 
in vivo biocompatibility of two high M alginate and one high G alginate in Lewis rats, and while 
all beads showed minimal overgrowth, only one of the two high M alginates performed better 
than the high G alginate, indicating that some factor other than M/G content influenced the 
biocompatibility of their alginate gels [53]. 
When a polycationic membrane is added to form alginate-polycation microcapsules, the 
story becomes even more complex. Some have claimed that using high M alginate results in 
APA microcapsules of greater biocompatibility  [140, 165], others have claimed that APA 
microcapsules based on high G alginate are more biocompatible [40], and others have observed 
no significant difference between the two in terms of inducing fibrotic overgrowth [52]. This 
situation implies that the alginate is not alone in influencing the biocompatibility of the 
complete alginate-polycation microcapsule (see section 1.4.2 for more details on this topic). 
Molecular weight (Mw) and solution viscosity 
These two properties of alginate are intimately related, since the viscosity of an alginate 
solution depends on (among other factors such as concentration), the average molecular weight 
of the sample [166].  
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In 1993, Otterlei et al [167] reported that TNF-α production of human monocytes in 
vitro by alginate solutions depended strongly on the molecular weights of poly M and high M 
alginate, with maximal TNF-α production occurring at Mw’s above 50,000 and 200,000, 
respectively. The implications of these results for the biocompatibility of microcapsules, 
however, is unclear since the alginate is normally crosslinked or complexed when it is 
incorporated into the microcapsule. 
More recently, Schneider et al [168] reported that gel beads and multilayer 
microcapsules made from alginates with a lower Mw average alginate elicited a much stronger 
fibrotic response compared to samples based on higher Mw average alginate when implanted in 
rats. However, this study has (with reason) been criticized by Wandrey for its scientific value 
[169], including the authors’ incorrect calculations of molar mass and their neglect to mention 
that the alginates were purified. 
That said, the German group has been strongly promoting the use of ultra-high viscosity 
(UHV) alginates [14, 170, 171], stating that both viscosity and biocompatibility increase with 
molecular mass. 
Other considerations 
Although not an intrinsic property of the alginate per se, how the alginate is crosslinked 
to form a gel may have an influence on the gel biocompatibility. For instance, Duvivier-Kali et 
al [52] observed that, for gel beads of high M alginate, barium cross-linked alginate induced 
slightly less fibrosis in vivo than calcium cross-linked alginates. 
1.4.2 Membrane considerations 
Many of the published works investigating the relationship between the membrane and 
the biocompatibility of alginate-based microcapsules have been based on simple comparisons of 
different microcapsule formulations. Here, we review and discuss a number of such studies. 
Let’s, for the moment, ignore the benefits of adding a membrane for optimizing the 
permeability and stability of the microcapsule, and concentrate on what influence this 
membrane has on biocompatibility. Unfortunately, more than one study has provided evidence 
that the microcapsule membrane is immunogenic. This is demonstrated by observations that the 
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in vivo and in vitro biocompatibility of alginate gel beads is significantly worsened once it is 
coated with a polycation to form a membrane [52, 134, 158, 172, 173]. In contrast, not a single 
study that we know of has suggested that adding a membrane can actually enhance the 
biocompatibility of the microcapsule. 
Despite the results of the above-mentioned studies, a few groups have managed to 
develop microcapsules (with membranes) that are not significantly immunogenic. These include 
the Groningen group, who uses APA microcapsules [136, 174], and the Perugia group, who 
prefers alginate-PLO microcapsules [44, 175]. The success of these groups demonstrates the 
feasibility of developing biocompatible alginate-polycation microcapsules with the appropriate 
combination of materials and techniques. 
If one should decide to add a membrane to form the microcapsule, it is advised to take 
care that there are no unbound, positively charged functional groups of the polycation exposed. 
This precaution is supported by a study by Strand et al [176], which demonstrated that unbound 
PLL is capable of inducing massive cell death (necrosis) and stimulating monocytes to produce 
TNF in vitro, and moreover, that this effect can be reduced by combining the polycation with 
alginate. In accordance with this view, the most common strategy to improving the 
biocompatibility of the microcapsule membrane is to add a final coating of dilute polyanion 
(usually alginate), with the intention of binding any uncomplexed portions of the polycation 
which, as we just stated, is considered to be immunogenic [104]. As far as we know, only one 
group has clearly observed that adding this alginate coating had an effect of reducing (but not 
eliminating) the immunogenicity of the PLL membrane of alginate-based microcapsules [172]. 
This study, and at least one other, suggested that the extent of the alginate coating’s effect 
depends on the chemical composition of the alginate [172, 177]. Strangely enough, there is a 
notable lack of published studies that have demonstrated the efficiency of the alginate coating 
for enhancing biocompatibility by directly comparing the performance of alginate-polycation 
microcapsules before and after the final alginate coating. 
Of course, the choice of polycation is also expected to influence the overall 
biocompatibility of the microcapsule membrane. A few groups have directly compared the 
biocompatibility of alginate-based microcapsules made with different polycations, including 
Ponce et al [129], who concluded that PLL is a better choice than each PDL and PLO, as well as 
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Calafiore et al [44], who observed that PLO microcapsules resulted in the attraction of fewer 
host cells than PLL microcapsules. These results, as you may note, are contradictory, which 
suggests that the type of polycation is not the most important determining factor for the 
biocompatibility of the membrane. 
Indeed, it has been recently stressed that the properties of the alginate that make up the 
core of the microcapsules (i.e. the gel matrix onto which the polycation must bind) may have an 
important effect on the biocompatibility of the complete microcapsule [104]. De Vos et al [165] 
clearly demonstrated that, in their laboratory, using alginates with an intermediate G content 
results in biocompatible APA microcapsules whereas using alginate with a high G content does 
not. These results support previous observations by Clayton et al [40], yet contradict the results 
of Kulseng et al [140], who concluded that APA microcapsules based on high G alginate are the 
less immunogenic. To add to the debate, Duvivier-Kali et al [52] observed no clear correlations 
between the type of alginate employed (high G vs. high M) and the extent of fibrosis induced by 
APA microcapsules. 
 
1.5 Physicochemical analyses to understand microcapsule biocompatibility 
As discussed in the previous section, when investigating the biocompatibility of alginate-
based microcapsules, relying on simple comparisons of different designs leads to contradictory 
results. This is undoubtedly related to the complexity of the microcapsule structure and 
properties, despite the apparent simplicity of the fabrication protocol. In order to better 
understand the microcapsules in relation to their performance and biocompatibility, a number of 
researchers have investigated the physicochemical properties of the devices using a range of 
techniques. Not only can this approach help us to understand why one microcapsule formulation 
may be more biocompatible than another, but the knowledge acquired will hopefully help us to 
“fine-tune” the more successful microcapsule designs as a step towards the standardization and 
regular clinical application of the devices. The physicochemical properties of alginate-based 
microcapsules that have already been explored with the intention of explaining biocompatibility 
are summarized in Table 1.1. These are then explained in more detail in the subsequent sections. 
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Table 1.1 Published studies that explore the physicochemical properties of alginate-based microcapsules 
with the intention of understanding biocompatibility 
Microcapsule 
property 
Technique for 
physicochemical analysis 
Correlation with microcapsule 
biocompatibility? 
Size Light microscopy [53, 178-180] Evidence that smaller is more 
biocompatible [53, 178-180] 
Surface 
morphology & 
topology 
SEM [183] 
AFM [14, 184-187] 
TEM [185] 
Scanning acoustic microscopy [188] 
Optical interferometer [132] 
Evidence that smoother is more 
biocompatible [183, 185, 132] 
Intermolecular 
interactions & 
polycation binding 
FTIR [189, 194, 195] 
Labelling techniques [190, 191] 
CLSM [192] 
Magnetic resonance microscopy 
[193] 
Single study suggests that greater uptake 
of PLL is less biocompatible [194]; Lack 
of studies directly testing correlation with 
biocompatibility 
Surface chemical 
composition 
XPS [131, 174, 195, 196] 
ToF-SIMS [195] 
Single group suggests that more PLL at 
surface is less biocompatible [174, 196]; 
Lack of studies directly testing correlation 
with biocompatibility 
Surface charge Zeta potential [131, 132, 198] 
Surface functional groups [199] 
Evidence that more positive charge is less 
biocompatible [131, 132, 198, 199] 
Elasticity or 
pliability  
Compression tests [47, 200-205] 
Microcapillary vacuum [206] 
AFM [187] 
Lack of studies directly testing correlation 
with biocompatibility 
Membrane 
degradation & 
leaching 
Labelling techniques [190, 191] 
ATR-FTIR with SEM [207-209] 
Lack of studies directly testing correlation 
with biocompatibility 
Surface 
hydrophilicity 
Contact angle [152, 131] Single study suggests no correlation [131] 
1.5.1 Size 
In our lab, we have shown that smaller APA microcapsules (326 ± 16 µm diameter) 
show a better in vivo biocompatibility than larger microcapsules (1247 ± 120 µm) of the same 
formulation [178]. To explain these results, it was proposed that the smaller microcapsules are 
less prone to breakage and defects, and are smoother than their larger counterparts, as well as 
induce less stress on surrounding tissues. Previous to our own study, Lum et al [179] had also 
suggested that smaller APA microcapsules (250-350 µm diameter) are more biocompatible than 
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standard-sized microcapsules. More recently, Sakai et al [180] also saw a correlation between 
smaller size and a reduced immune response towards agarose gel microcapsules ranging in 
diameter (90-925 µm). As well, Omer et al [53] recently noticed that, when enclosing islets, 
smaller barium alginate beads (500-700 µm diameter) were more stable and substantially more 
biocompatible in vivo than larger beads (800-1100 µm). Such similar trends despite the use of 
different microcapsule chemistries suggest that size may indeed have a large impact on 
microcapsule biocompatibility.  
1.5.2 Surface morphology and topography (smoothness) 
As previously mentioned, the topography of the implant can influence the composition 
of the foreign body reaction (section 1.3.1), and as a general rule, smooth surfaces have been 
associated with greater tissue biocompatibility [181]. Indeed, in 1991, Lanza et al [182] 
demonstrated that, for tubular diffusion chambers designed for islet encapsulation, the use of a 
smooth skin instead of a rough one resulted in significantly less fibrotic response when 
transplanted in rats. Since this study, there has been great interest in characterizing the surface 
morphology and topography of microcapsules designed for cell encapsulation in relation to their 
biocompatibility. Most of these studies have been carried out using atomic force microscopy 
(AFM), which allows one to examine samples while they are immersed in a liquid (see 
APPENDIX IV for more details on AFM), although other techniques have also been applied.  
In 1998, Chen et al [183] were among the first to have successfully correlated 
microcapsule surface smoothness with an improved in vivo biocompatibility. In their case, they 
evaluated the surface smoothness of APA microcapsules coated with PEG derivatives using 
scanning electron microscopy (SEM). 
In the same year, Xu et al [184] were, to our knowledge, the first to demonstrate the use 
of AFM to characterize the surface topography and quantify roughness of alginate-based 
microcapsules. While they demonstrated an effect of the cationic solution for gelation on these 
surface properties, no direct correlation with biocompatibility was investigated. A few years 
later, Zimmermann et al [14] used AFM to demonstrate that the smooth surface of their UHV 
alginate gels (films) could successfully prevent cell adhesion and migration in vitro. They also 
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exploited this technique to monitor changes in morphology on the gel bead surfaces due to 
mechanical shearing forces and/or deposition of fibrils after their implantation in vivo. 
By 2003, Bünger et al [185] used AFM, in combination with transmission electron 
microscopy (TEM), to clearly demonstrate that switching the type of polymer coating on 
alginate-PLL microcapsules (alginate vs. polyacrylic acid vs. heparin) had an impact on each the 
surface roughness and the biocompatibility of the samples. That is, the microcapsules coated 
with polyacrylic acid were both the smoothest and the most biocompatible in vivo. During the 
same period, both Zimmermann et al [186] used AFM to validate the surface smoothness of 
their newly developed alginate gel with enhanced gel stability, while Lekka et al [187] used 
AFM to demonstrate the influence of chemical composition on surface morphology (among 
other properties). Although both of the latter studies saw the value in verifying surface 
morphology, they did not attempt to directly correlate this property with the biocompatibility of 
their microcapsules. 
In recent years, other interesting methods have been proposed to examine the surface 
morphology and topography of hydrated alginate-based films and microcapsules. One of these 
was investigated by Klemenz et al [188], who used high frequency scanning acoustic 
microscopy to produce 3D images and topography profiles of the microcapsule surface with a 
lateral resolution of 1.5 µm. The implications of this technique for elaborating correlations with 
biocompatibility have yet to be demonstrated. As another example, Xie et al [132] used SEM in 
combination with a non-contact, three-dimensional optical interferometer to quantify surface 
roughness of ACA membranes. In their case, they correlated increased roughness (which was 
affected by each the alginate Mw and the chitosan concentration) with an increased adsorption 
of bovine plasma fibrinogen in vitro as well enhanced changes in the adsorbed protein 
conformation. 
1.5.3 Intermolecular interactions and polycation binding 
As previously mentioned (section 1.4.2), adding a polycationic membrane presents a risk 
in terms of microcapsule biocompatibility, since there is evidence that the unbound polycation 
(PLL) is immunogenic [176]. It naturally follows that researchers were curious to understand 
how the polycation binds to the alginate, and vice versa, since this may provide answers to 
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certain issues in membrane biocompatibility, but also explain other microcapsule features such 
as membrane stability and permeability. 
Having already understood the implications that such information could have for the cell 
encapsulation field, Dupuy et al [189], in 1994, used Fourier transform infrared spectroscopy 
(FTIR) to demonstrate the force of interactions between alginate and PLL within films. Their 
results suggested that high M alginate is more efficient for binding PLL than high G alginate. 
Indeed, this can be explained by the fact that the MG blocks in alginate are more flexible and 
are not involved in gelation by crosslinking with divalent cations as are the GG blocks [38]. 
Shortly later, Thu et al published a sophisticated study [190, 191] in which they used a range of 
labelling techniques to investigate the interactions between alginate and PLL during 
microcapsule formation. Not only did they confirm that PLL binds more rapidly to alginate gels 
of high M, but they also demonstrated that increasing the alginate concentration at the surface of 
the gel beads (to produce ‘inhomogeneous gel beads’) can enhance PLL binding, and that PLL 
binding depends as well on the choice of crosslinking ion in the alginate gel. In the same study, 
they also investigated the binding of the alginate coating to the alginate-PLL microcapsule, and 
demonstrated that more of this alginate binds to high G microcapsules, and that binding was 
enhanced by reducing the molecular weight of the alginate, although the M/G content of the 
coating had no effect on its binding efficiency. A few years later, Strand et al [192] used 
confocal laser scanning microscopy (CLSM) to visually and quantitatively study the distribution 
of polymers and cross-linking ions in APA microcapsules, and demonstrated that PLL is capable 
of diffusing into the microcapsule during storage in an ionic solution, as well as confirmed that 
the M/G content of the alginate coating had no effect on the its binding properties to the 
microcapsule. Most recently, Constantinidis et al [193] have demonstrated the use of 1H 
magnetic resonance microscopy to visualize and quantify the PLL, as well as monitor temporal 
changes in the alginate gel in vitro, without requiring labelling of the polymers. 
While the studies described above provided important information about alginate-PLL 
interactions that can be useful for interpreting and explaining microcapsule biocompatibility, 
Van Hoogmoed et al [194] were the first to directly correlate such evidence with the in vivo 
biocompatibility of APA microcapsules. They used attenuated total reflectance Fourier 
transform infrared spectroscopy (ATR-FTIR) to compare the properties of APA microcapsules 
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based on high G alginate (which are immunogenic) with microcapsules based on Int G alginate 
(which are biocompatible). The spectral peak areas allowed them to estimate that the 
membranes of the high G microcapsules contained about 20% more PLL than the membranes of 
the Int G microcapsules. They also suggested that variable degrees of binding existed between 
the alginate and PLL, as interpreted by the conformation of the PLL within the microcapsule 
membrane. The results of my Master’s research confirmed, using ATR-FTIR, that alginate-PLL 
binding is not always optimal (i.e. associated with α-helical conformations of the polycation) 
within our own APA microcapsules [195]. 
1.5.4 Surface chemical composition 
Intuitively, we understand that the surface chemical composition of a biomaterial 
influences its biocompatibility. In the case of alginate-based microcapsules, however, the 
chemical composition of their surface was not directly measured until issues with the 
immunogenicity of the membrane started to emerge. 
In 2002, de Vos et al  [174, 196] were, as far as we know, the first to directly analyse the 
chemical composition of the APA microcapsule surface, and they did this using x-ray 
photoelectron spectroscopy (XPS). Their results offered an explanation as to why their 
microcapsules based on High G alginate were more immunogenic than those based on Int G 
alginate. Specifically, they measured less negatively charged binding sites available for binding 
PLL on the surface of the High G alginate gel cores, and yet, the also detected higher quantities 
of PLL at the High G microcapsule surface. These results implied an increased risk of greater 
quantities of unbound PLL at the surface of the more immunogenic microcapsules. 
Simultaneously, they realised that since the PLL was present at the microcapsule surfaces, the 
outer alginate coatings did not exist as a distinct layer. A few years later, as part as my Master’s 
work [195], we confirmed the exposure of PLL at the surface of our own APA microcapsules 
using XPS in combination with time-of-flight secondary ion mass spectrometry (ToF-SIMS), 
which is even more surface sensitive (1-2 monolayers) than XPS. At the same time, using ToF-
SIMS imaging, we proved that this exposure was not due to defects in the microcapsule 
membrane, which was homogeneous in chemical composition. Using confocal laser scanning 
microscopy (CLSM), Strand et al [192] have previously demonstrated that, indeed, the alginate 
coating has rather a tendency to diffuse into the microcapsule membrane rather than bind to the 
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surface as a distinct layer. Most recently, the use of XPS to quantify the amount of polycation at 
the surface of alginate-based microcapsules has been expanded to the investigation of alginate-
chitosan microcapsules [131], although in their case the quantity of chitosan at the surface did 
not correlate with the extent of fibrinogen and IgG adsorption in vitro.  
1.5.5 Surface charge 
Most proteins bear a net negative charge, and thus anionic surfaces generally tend to 
adsorb less protein than cationic ones [37]. Similarly, macrophages and other cells also have a 
negative surface charge [197] and can therefore be expected to be attracted by positively 
charged surfaces. As previously discussed in section 1.3, protein adsorption and cell adhesion 
can define the immune response to implants. Moreover, the point of alginate coating is to 
neutralize the positive charges of the polycation, and it was already proven that this polycation 
is present at the microcapsule surface. Whether the positive charges are efficiently balanced by 
the alginate coating is another question. Therefore, there is an interest in knowing the surface 
charge of the microcapsules in order to explain their biocompatibility. However, these studies 
have only recently been published because of the apparent technical difficulties involved with 
measuring such a property. 
In 2007, De Vos et al [198] successfully used the streaming potential technique to 
measure the zeta potentials of APA microcapsules of different composition. This measurement 
is directly related to the average surface charge density of several microcapsules in a buffer 
solution. They observed that adding a PLL membrane (with alginate coating) to alginate gel 
beads consistently resulted in an increase in net positive charge. More interesting, the 
microcapsules that were associated with the greatest increase in net positive charge upon 
addition of the membrane were also the more immunogenic in vivo. This result supports the 
view that the positively charged PLL plays an important role in inducing an immune response to 
APA microcapsules. Also in line with this view are the results of Bakeine et al [199], who 
compared the in vivo biocompatibility of various synthetic latex microcapsules ranging in 
surface charge as well as APA microcapsules. They concluded that those microcapsules with a 
positively charged functional group at their surface (including the APA microcapsules) induced 
a significantly greater development of fibrosis. Most recently, Xie et al also measured zeta 
potentials to characterize the surface charge of alginate-chitosan microcapsules [131, 132]. 
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Interestingly, they saw a net negative charge on their microcapsules, rather than positive. Still, 
they found that the capsules with the “least negative charge” corresponded with a greater 
adsorption of fibrinogen and immunoglobulin G in vitro. 
1.5.6 Elasticity or pliability 
One of the main reasons that alginate gels are used for microencapsulation purposes is 
because of their pliability, which should minimize injury to surrounding tissues due to frictional 
or mechanical forces [36]. 
Traditionally, bulk elastic properties of alginate-based microcapsules have been 
measured by applying a controlled compressive force to a group of capsules (essentially 
‘squishing’ the capsules) and relating this force to the changing diameter of the microcapsules as 
they flatten and burst [47, 200-202]. Other more sophisticated methods for evaluating the 
pliability and elasticity of individual microcapsules have also been developed, including 
micromanipulation (involving a tiny probe that applies force) [203-205] and the use of a 
microcapillary to apply negative pressure to the membrane [206]. 
In principal, the more the microcapsule compresses (flattens) before bursting, the more 
elastic or pliable it is. The evidence shows that adding a polycationic membrane leads to a more 
rigid microcapsule that ‘squishes’ to a lesser extent when a compressive force is applied, 
although the specific material properties and fabrication protocol will affect the extent of this 
effect [47, 200-202, 207, 208]. While perhaps improving microcapsule strength (in terms of 
more force required to deform the sample), this feature may simultaneously present a problem 
for biocompatibility since the pliability of the hydrogel is compromised. However, such 
implications have not been directly explored by direct comparisons between elasticity and 
biocompatibility. 
The local elastic properties of alginate-based microcapsules (as opposed to their bulk 
elastic properties) have been examined closely by one group. Specifically, Lekka et al [187] 
expanded the use of AFM beyond surface topography measurements in order to measure local 
elastic properties of their alginate-polycation microcapsules, as well as correlate these results 
with bulk mechanical characteristics of the beads. Although they demonstrated the effect of 
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microcapsule composition on the local Young’s moduli, the implications for alginate 
biocompatibility were only implied, rather than tested directly.  
1.5.7 Membrane degradation and leaching 
Using labelling techniques, Thu et al [190, 191] demonstrated that PLL is capable of 
leaching out of the microcapsule when stored in an ionic solution. Given the apparent 
immunogenicity of unbound PLL [176], this observation has an important implication for the 
biocompatibility of the microcapsules in an in vivo environment. 
A decade later, and in the same line of thought, Thanos et al [207-209] started using 
ATR-FTIR and SEM to monitor the surface degradation of alginate-PLO microcapsules in vivo 
over time. Degradation was characterized by a relative increase in PLO content in the 
microcapsule membrane (ATR-FTIR) in correlation with surface pitting and erosion (visible by 
SEM). When comparing a range of commercially available alginates, they saw no clear 
influence of the alginate M/G content on the results, but associated alginates of higher molecular 
weight with greater degradation [207, 209]. However, when they compared a commercial 
alginate with an ultra-pure alginate developed at the University of Perugia, the latter performed 
significantly better in terms of resisting degradation in an in vivo environment [208]. The 
implications for microcapsule biocompatibility were not directly measured, but it stands to 
reason that degradation of the membrane leads to an increased risk of exposing the potentially 
immunogenic polycation to the host tissues. 
1.5.8 Surface hydrophilicity 
It is often emphasized that one of the reasons that alginates are used for cell 
encapsulation is because they, like all hydrogels, are highly hydrophilic and therefore expected 
to discourage protein adsorption [36, 37]. Despite this popular point of view, few have 
investigated this property directly for alginate-based microcapsules. Based on my Master’s work 
[152], we examined the effect of alginate purification on, among other properties, its 
hydrophilicity, as interpreted by the contact angle of water droplets on dry solution films. It 
turned out that hydrophilicity was a good predictor for alginate purity, and therefore in an 
indirect manner, alginate biocompatibility. More recently, at least one other group has decided 
to adapt the same technique in order to evaluate the immunological potential of their 
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microcapsules. Specifically, Xie et al [131] used the contact angle technique to measure the 
wettabilities of membranes representing alginate-chitosan-alginate microcapsules. In their case, 
they demonstrated that their samples were hydrophilic but failed to make a correlation between 
hydrophilicity and the adsorption of bovine fibrinogen and IgG on their microcapsules in vitro. 
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CHAPTER 2 
RESEARCH OBJECTIVE AND GENERAL APPROACH 
 
2.1 Research objective 
The objective of this research is to elucidate the relationships between the chemical makeup, the 
physicochemical properties, and the biological response to alginate-based microcapsules 
intended for islet transplantation. Our intention is to provide guidelines for optimizing the 
biocompatibility of the microcapsules, and thus contribute to the success of encapsulated islet 
transplantation. 
 
2.2 General approach 
The experimental research that was carried out can be divided into five phases. Each phase was 
directed by specific research aims, described here. The results of each phase are presented as 
separate chapters in this thesis. 
 
2.2.1 Phase I : Microcapsule fabrication and protein adsorption 
De Vos et al have developed alginate-poly-L-lysine-alginate (APA) microcapsules that are 
arguably the only ones worldwide that display a consistent biocompatibility, characterized by a 
high retrieval rate and minimal cellular overgrowth after long implantation periods in rodents. 
Interested in learning their “tricks of the trade”, I started my doctoral studies with a six-month 
internship in Dr de Vos’ lab at the University Medical Centre Groningen (the Netherlands). 
Aim 1. To learn, firsthand, how the Groningen group makes their microcapsules: This also 
included a crash course in basic biochemistry (don’t forget I’m an engineering student!). Since 
this was a learning objective, rather than a scientific study, per se, there are no results to present 
in this thesis. 
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Aim 2. To prove that immunoglobulins adsorb to the surface of APA microcapsules, and to 
correlate this adsorption with the microcapsule chemistry: We chose immunoglobulin 
adsorption as a research topic because protein adsorption is considered to be the first and 
governing phase of the biological response to implanted biomaterials. Moreover, the Groningen 
lab had already proved that proteins adsorb to their microcapsules upon their implantation in 
rats. The technique that we applied was relatively simple and easily accessible for any lab. 
Basically, APA microcapsules of different designs were incubated in vitro with human serum or 
peritoneal fluid, and then stained with fluorescently-marked antibodies to the immunoglobulins. 
The results of this collaborative study have been published in the Journal of Biomedical 
Materials Research Part A, and are presented in CHAPTER 3 of this thesis. 
 
2.2.2 Phase II : Interlaboratory comparisons of alginates and microcapsules 
Upon returning to Montreal, we wanted to see if we could produce biocompatible microcapsules 
if we imitated the Groningen protocol for capsule fabrication. This would have been very 
helpful for us, not only to understand what fabrication parameters may affect microcapsule 
biocompatibility, but if we had succeeded, to also have an appropriate negative control for 
subsequent studies. 
Aim 1. To verify the quality of our alginate in comparison to the alginate used by the Groningen 
group: We purchased the same brand (although different batch number) of alginate that the 
Groningen group uses, but followed different protocols to purify our alginates and to make our 
gel beads. Despite these differences, we wanted to determine whether our alginates could 
perform just as well as theirs, particularly since we preferred to use our own alginate for 
subsequent studies rather than relying on them for our materials for microcapsule fabrication. 
Comparing the alginates consisted of analysing their chemical composition and purity, and 
testing the in vivo biocompatibility of their gels.  
Aim 2. To reproduce Groningen style microcapsules in our lab and compare their 
biocompatibility with that of our own microcapsules: Using the first-hand experience that I 
gained in making microcapsules in the Groningen lab, we were curious to know whether we 
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were capable of making similarly biocompatible microcapsules using our own materials and lab 
equipment. Not only was this essentially a test of lab-to-lab reproducibility, but by comparing 
these microcapsules with our own, we expected to gather some important preliminary data on 
what fabrication parameters are important for microcapsule biocompatibility. 
The results for these studies were not submitted for publication, but are presented in 
CHAPTER 4 of this thesis. 
 
2.2.3 Phase III : Characterization and biocompatibility of alginates 
The first logical step towards understanding the biocompatibility of alginate-polycation 
microcapsules is to examine the characteristics and biocompatibility of the base material. 
Although alginate is generally considered to be non-immunogenic, several years of research 
have shown that this is not always the case. There is a continuing debate in the field about which 
combination of alginate properties can provide optimal biocompatibility for cell encapsulation 
purposes. 
Aim. To determine which properties of an alginate influence its biocompatibility: We chose to 
compare two commercially available alginates that are commonly employed for cell 
encapsulation. We quickly established that the in vivo biocompatibility of these alginates 
differed significantly, and we wanted to explain why this was so. To do so, we thoroughly 
characterized the alginates and their gels in terms of chemistry, purity, solution viscosity, and 
hydrophilicity. 
The results of this study should soon be published in the Journal of Biomedical Materials 
Research A (resubmitted after major revision), and are presented in CHAPTER 5 of this thesis. 
 
2.2.4 Phase IV : Microcapsule characterization and biocompatibility 
Here, the term ‘microcapsule’ refers to a bead of alginate gel having a polycationic membrane. 
With the exception of recent publications, the majority of studies that have investigated 
microcapsule biocompatibility have focussed primarily on the chemical makeup of the 
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microcapsules, without further analysis of their physicochemical properties. After establishing 
that our alginate was biocompatible, we were in a good position to focus on the role of the 
polycationic membrane, including polycation-alginate interactions, on both the physicochemical 
properties and the biocompatibility of the microcapsules. 
Aim. To explain how microcapsule biocompatibility is influenced by their chemistry, in terms of 
their physicochemical properties: As others, we investigated the effect of the type of alginate, 
gel, and polycation on microcapsule biocompatibility. However, we also included analyses of 
the elemental surface composition, molecular interactions within the membrane, wettability of 
the polyelectrolyte complexes, and stability of the polycationic membrane. We used these 
results to explain, in greater depth, how the different microcapsule designs can lead to their 
ranging in vivo biocompatibilities. 
The results of this have been submitted for publication in Acta Biomaterialia, and are presented 
in CHAPTER 6 of this thesis. 
 
2.2.5 Phase V : Inducing normoglycemia using encapsulated islets 
The ultimate application of our microcapsules is to immunoprotect transplanted islets in vivo so 
that they may efficiently normalize the blood sugar levels of a diabetic recipient. Most 
researchers believe that using a polycationic membrane is essential for achieving proper 
immunoprotection, despite that there is evidence that this membrane is responsible for 
microcapsule immunogenicity. Others have been trying to prove that microbeads without a 
membrane, which are more biocompatible, can still immunoprotect. We wanted to determine 
which of these two situations applied in our case. 
Aim 1. To determine whether a moderate immune response to the microcapsules is enough to 
hinder their ability to immunoprotect the islets within: Using our most biocompatible 
microcapsules (which still induce a moderate immune response), we encapsulated rat islets and 
transplanted them into immunocompetent diabetic mice. Graft success was measured by the 
ability of the encapsulated islets to normalize the blood glucose levels of the recipients. Upon 
graft failure, we examined the state of each the microcapsules and islets under the microscope. 
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Aim 2. To determine whether a membrane is even necessary for the immunoprotection of 
transplanted islets: We compared the ability of rat islets enclosed within gel beads (without a 
membrane) with islets enclosed within microcapsules (with a membrane) to reverse diabetes in 
mice. Normally, the gel beads should not induce a significant immune response, but may be too 
porous to effectively block out components of the host immune system. 
The results of this study were not submitted for publication, but are nevertheless presented in 
CHAPTER 7 of this thesis. 
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CHAPTER 3 
ARTICLE 1 : ADSORPTION OF HUMAN IMMUNOGLOBULIN TO 
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EFFECT OF MICROCAPSULE COMPOSITION 
 
PUBLISHED : J Biomed Mater Res A. 2009 Jun; 89(3): 609-15. 
 
Susan K. Tam 1,2 , Bart J. de Haan 3 , Marijke M. Faas 3 , Jean-Pierre Halle´ 2 , L’Hocine Yahia 1 
, Paul de Vos 3 
1
 Biomedical Engineering Institute, École Polytechnique de Montréal, Montréal, Québec, 
Canada 
2
 Maisonneuve-Rosemont Hospital Research Center, Montréal, Québec, Canada 
3
 Medical Biology Division, University Medical Center Groningen, Groningen, The Netherlands 
 
3.1 Abstract 
Alginate-poly-L-lysine-alginate (APA) microcapsules continue to be the most widely 
studied device for the immuno-protection of transplanted therapeutic cells. Producing APA 
microcapsules having a reproducible and high level of biocompatibility requires an 
understanding of the mechanisms of the immune response towards the implants. Here, we 
investigate the adsorption of immunoglobulins (IgG, IgM, and IgA) onto the surface of APA 
microcapsules in vitro after their exposure to human serum and peritoneal fluid. 
Immunoglobulins (Ig) are considered to be opsonizing proteins, thus they tend to mediate 
inflammation when adsorbed to foreign surfaces. Ig adsorption was monitored using direct 
immunofluorescence. The amount of Ig adsorbed to the microcapsule surface was not 
significantly influenced by the guluronic acid content nor the purity level of the alginate, 
although microcapsules of intermediate-G purified alginate corresponded with the lowest 
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adsorption levels. Ig adsorption was negligible when the poly-L-lysine membrane was omitted, 
suggesting that positive charges at the microcapsule surface are responsible for binding Ig. 
3.2 Keywords 
protein adsorption; immunofluorescence; biocompatibility; alginate; microcapsules 
3.3 Introduction 
Alginate-based microcapsules are commonly used for the immuno-protection of 
transplanted therapeutic cells. The biocompatibility of the encapsulated cell system, including 
the microcapsule itself, continues to be a subject of concern [1, 2]. In the 1990s, the 
development of fibrotic tissue around the implanted microcapsules was considered to be one of 
the major obstacles hampering the progress of encapsulated cell transplantation [3]; fibrosis 
arising from the normal wound-healing process was stated to hinder the diffusion of cell 
nutrients and therapeutic products across the capsule membrane. Moreover, fibrosis was 
frequently associated with graft failure. More recently, it was demonstrated that, by using 
optimal biomaterials and fabrication methods, it is feasible to produce alginate-poly-L-lysine-
alginate (APA) microcapsules that induce minimal fibrosis in vivo, even 2 years after 
implantation in rats [4]. Despite this encouraging step forward, the ultimate goal of these 
research efforts, i.e. permanent survival of the encapsulated cellular grafts, was unfortunately 
not achieved as graft survival varied between 4 and 6 months. 
During recent years it has become more accepted that the immune response against the 
encapsulated cell system is far more complicated than initially assumed. The complexity of this 
response partially explains the wide range of biocompatibility that the microcapsule system has 
displayed in the literature. The fact is activation of the immune system starts with the mandatory 
surgery to implant the microcapsules, that is before the implant is even introduced into the body. 
More precisely, injury to vascularized connective tissue caused by the incision induces an 
immediate inflammatory response associated with the influx of inflammatory cells and plasma 
proteins, as well as the release of bioactive factors such as cytokines and nitric oxide [5, 6].An 
important and likely event that can decide the ultimate biocompatibility of the microcapsule is 
the adsorption of opsonins onto its surface immediately upon its implantation. In general, the 
surface adsorption of opsonins is necessary for immune cells to recognize a pathogen or 
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biomaterial as being ‘‘foreign’’ and to subsequently attack it. To date, no one has verified 
experimentally whether this adsorption occurs in the case of microcapsules designed for cellular 
therapy. The immunoglobulins IgM, IgA, and especially IgG have the ability to opsonize 
foreign bodies, thus their capacity to adsorb to microcapsules is of interest when investigating 
their biocompatibility. IgG and IgM are particularly effective for complement activation, while 
IgG and IgA can mediate phagocytosis, though IgA is generally restricted to mucosal secretions 
[7-11]. 
In the present study, we investigate the adsorption of immunoglobulin (Ig) to the surface 
of APA microcapsules in vitro. This was done for microcapsules of different compositions. 
3.4 Materials and Methods 
3.4.1 Study Design 
The adsorption of human immunoglobulins IgG/IgM/IgA to the surface of APA 
microcapsules in vitro was monitored using direct immunofluorescence. Ig adsorption was 
achieved by incubating microcapsules in serum and/or peritoneal fluid (PF). These fluids were 
selected in order to simulate the in vivo situation where microcapsules come into contact with 
both blood and PF during implantation into the peritoneal cavity, i.e. the conventional 
transplantation site. Subsequent to incubation, the protein-covered microcapsules were rinsed 
then immersed in a solution containing a fluorescently labeled antibody to human 
immunoglobulin (Ig). The extent of Ig adsorption was measured in terms of fluorescence 
intensity. Ig adsorption levels to APA microcapsules composed of alginates varying in chemical 
composition (i.e. high vs. intermediate guluronic acid content) and in purity level were 
compared because these properties of alginate have a significant influence on the in vivo 
bioperformance of the microcapsules. Furthermore, to investigate the relative influence of the 
alginate matrix and the poly-L-lysine (PLL) membrane on Ig adsorption, the adsorption to 
complete APA microcapsules and to calcium alginate beads (having no PLL membrane) was 
compared. 
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3.4.2 Materials 
Intermediate-G sodium alginate (Keltone® LVCR, International Specialty Products Corp, 
UK) having 40% guluronic acid (as specified by the manufacturer) and high-G sodium alginate 
(Manugel® DMB, International Specialty Products Corp, UK) having 50% guluronic acid (as 
specified by the manufacturer) were used for microcapsule fabrication. The alginates were 
purified using previously described methods [12]. The alginates were dissolved in a 220 mOsm 
Ca2+–free Krebs-Ringer-Hepes (KRH) solution consisting of 90.0 mM NaCl, 4.7 mM KCl, 1.2 
mM KH2PO4, 1.2 mM MgSO4, and 25.0 mM Hepes. Alginates were dissolved at a concentration 
of 3.4% w/v for the unpurified intermediate-G alginate, 3.5% w/v for the purified intermediate-
G alginate and 1.9% w/v for each of the high-G alginates. These concentrations provided 
alginate solutions of appropriate viscosity for microcapsule fabrication. All alginate solutions 
were sterilized by filtration (0.22 µm). PLL hydrochloride (Sigma-Aldrich, USA) having a 
molecular weight of 22,200 (as specified by the manufacturer) was used to form the 
microcapsule membrane. For protein adsorption studies in vitro, human serum isolated from 
whole blood was donated by healthy volunteers. Human PF was obtained from a male donor 
within 12 h of his decease. For the experiments, only the PF supernatent was used. To detect the 
immunoglobulin adsorbed to the microcapsule surface, a fluorescein isothiocyanate (FITC)-
conjugated polyvalent antibody to human IgA/IgG/IgM developed in rabbit (Sigma-Aldrich, 
USA) was used. 
3.4.3 Microcapsule Fabrication 
Microcapsules were produced using an air-driven droplet generator following previously 
described methods [13]. Alginate solution was extruded from a 23G needle using a syringe and 
a co-axial air stream to produce droplets. The alginate droplets were immersed in a 100 mM 
CaCl2 solution and allowed to gel for 5 min after extrusion of the last droplet (the extrusion 
process lasted 2–4 min). Gelled calcium alginate beads measured 650–675 µm in diameter. To 
form the microcapsule membrane, the calcium alginate beads were rinsed and then immersed for 
10 min in a PLL solution that consisted of PLL dissolved 0.1% w/v in 310 mOsm Ca2+-free 
KRH (135.0 mM NaCl, 4.7 mM KCl, 25.0 mM Hepes, 1.2 mM KH2PO4, and 1.2 mM MgSO4). 
The microcapsules were rinsed again and then immersed in a 10× diluted solution of alginate 
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(i.e. 0.19%, 0.34% or 0.35% w/v in Ca2+-free KRH) for 5 min, with the aim of binding any 
unbound PLL at the surface. In all cases, the same type of alginate was used for both the 
microcapsule gel core and the coating step. After final rinsing, the microcapsules were stored in 
KRH until analysis. Final APA microcapsules measured 600–750 µm in diameter. All solutions 
used for microcapsule fabrication were sterilized by filtration (0.22 µm). 
3.4.4 Protein adsorption to microcapsules 
Samples of 30 microcapsules were transferred to a polypropylene test tube. The 
supernatant (i.e., KRH) was removed by aspiration. Serum was diluted 1:1 in KRH and 300 µL 
of the diluted serum was added to each test tube. Samples were incubated in a warm water bath 
at 37°C with gentle agitation for 1 h. Afterwards, the serum was removed and the microcapsules 
were rinsed five times with KRH. For certain experiments (see the results section), the serum 
was replaced with human PF or a 1:1 mixture of serum and PF. 
3.4.5 Measurement of Ig adsorption 
The amounts of Ig that adsorbed to the microcapsule surfaces were measured using 
direct immunofluorescence. Seventy-five microliters of dilute FITC-conjugated rabbit antibody 
to human IgG/IgM/IgA (diluted 1:600 in KRH) was added to each sample of microcapsules. 
Immediately afterwards, the samples were kept in the darkness at room temperature for 1 h. The 
microcapsules were then rinsed five times with KRH and subsequently transferred to a 96-well 
plate (Corning® flat bottom). The fluorescence intensity emitted from the samples was 
quantitatively measured using a Bio-Tek FL600TM fluorescence microplate reader (Bio-Tek 
Instruments, USA). An excitation wavelength of 485 nm and emission wavelength of 530 nm 
was used in order to detect the FITC label. A top-reading measurement was taken at a sensitivity 
setting of 200. Readings were always taken in triplicate. The labeling efficiency of the antibody 
was also confirmed by fluorescence microscopy using an Olympus IMT-2 inverted microscope 
(Olympus, Japan). 
3.4.6 Statistical Analysis 
Measured values were compared using the Wilcoxon Signed Ranks Test with the aid of 
SPSS® statistical analysis software (SPSS, USA). A difference for which p < 0.05 was 
62 
considered to be statistically significant. In general, quantitative results (represented as bar 
graphs) are expressed as the mean fluorescence intensity over an n value of 6 ± the standard 
error of the mean (SEM). 
3.5 Results 
Direct immunofluorescence was applied in order to quantify the extent of 
immunoglobulin (Ig) adsorption to microcapsules preincubated in either serum or PF. A 
microscopic examination of APA microcapsules prepared of purified intermediate-G alginate 
and preincubated in serum (Figure 3.1), confirmed that the fluorescence staining was specific for 
the protein-covered microcapsule surface. These results not only confirm that Ig adsorbs to APA 
microcapsules, but also demonstrate the adequacy of our experimental approach. 
 
Figure 3.1 Fluorescent signal emitted from alginate-poly-L-lysine-alginate (APA) microcapsules upon 
excitation by a light having a wavelength (λ) of 485 nm, as observed by microscopy. Microcapsules were 
either pre-incubated in serum then incubated with a FITC-labeled antibody to human immunoglobulins 
IgG/IgM/IgA (‘‘serum + fluor’’), incubated with only the FITC-labeled antibody (‘‘fluor only’’), or 
incubated with neither (‘‘blank’’). 
In the case of in vivo studies, the microcapsules are in contact with both blood and PF 
upon their implantation in the peritoneal cavity (i.e., the conventional transplantation site). 
Therefore, we quantified and compared the adsorption of Ig onto APA microcapsules after 
incubation in serum, PF, and a 1:1 mixture of PF and serum. As shown in Figure 3.2, the Ig 
adsorbed in significantly greater amounts (p < 0.05) to the microcapsules when they were 
incubated in serum (8.4 ± 1.8 arbitrary fluorescent units, AFU) compared to those that were 
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incubated in either PF (2.9 ± 0.9 AFU) or the serum/PF mix (3.4±0.7 AFU). Since incubation in 
serum was associated with the highest adsorption levels, we used serum as the Ig source for 
subsequent studies. 
 
 
Figure 3.2 Extent of immunoglobulin (Ig) adsorption to APA microcapsules that were incubated in 
serum, peritoneal fluid (PF) or a 1:1 mixture of serum and PF. Ig adsorption is proportional to the 
intensity of fluorescence emitted from the samples upon excitation. (a) Quantification of Ig adsorption, 
which is represented by an ‘‘intensity increase’’ (i.e. the average increase in fluorescence intensity vs. 
microcapsules that were incubated with only the FITC-labelled antibody) ± standard error of the mean, 
SEM (n = 6). AFU = arbitrary fluorescent units, * p < 0.05. (b) Microscope observation of the 
fluorescent light emitted by the microcapsules. 
(a) 
(b) 
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Figure 3.3 Extent of Ig adsorption to APA microcapsules that were incubated in serum. The 
microcapsules were prepared of alginates varying in chemical composition (intermediate-G vs. high-G) 
and in purity (purified vs. nonpurified). Ig adsorption is proportional to the intensity of fluorescence 
emitted from the samples. (a) Quantification of Ig adsorption, which is represented by an ‘‘intensity 
increase’’ (i.e. the average increase in fluorescence intensity vs. microcapsules that were incubated with 
only the FITC-labeled antibody) ± SEM (n = 6). AFU = arbitrary fluorescent units. (b) Microscope 
observation of the fluorescent light emitted by the microcapsules. 
(a) 
(b) 
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Figure 3.4 Extent of Ig adsorption to APA microcapsules (‘‘with PLL’’) or to calcium alginate beads 
(‘‘without PLL’’) that were incubated in serum. The samples were prepared of purified intermediate-G 
alginate. Ig adsorption is proportional to the intensity of fluorescence emitted from the samples. (a) 
Quantification of Ig adsorption, which is represented by an ‘‘intensity increase’’ (i.e. the average 
increase in fluorescence intensity vs. samples that were incubated with only the FITC-labeled antibody) 
± SEM (n = 6). AFU = arbitrary fluorescent units, * p < 0.05. (b) Microscope observation of the 
fluorescent light emitted by the samples. 
To investigate the influence of the microcapsule characteristics on the extent of Ig 
adsorption, we quantified and compared the adsorption onto APA microcapsules prepared of 
purified versus nonpurified alginates, and of intermediate-G versus high-G alginates. There 
were no statistically significant differences between the amounts of Ig adsorbed onto each of the 
samples tested (Figure 3.3). 
(b) 
(a) 
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Next, we investigated whether it is the PLL-based membrane or the alginate matrix that 
is responsible for the observed adsorption of Ig to the capsules. To do this, we compared the 
extent of Ig adsorption onto calcium alginate beads to the adsorption onto APA microcapsules 
after incubating each in serum. As shown in Figure 3.4 (a), in the case of samples prepared of 
purified intermediate-G alginate, the measured fluorescence intensity was fourfold higher when 
PLL was included in the membrane. The experiments were repeated for samples prepared of 
high-G alginates and nonpurified alginates; the results (not shown) consistently confirmed that 
the PLL membrane is a principal mediator of Ig adsorption to APA microcapsules. 
3.6 Discussion 
Generally speaking, following the implantation of a medical device such as 
microcapsules, the typical sequence of events is as follows: Immediately after injury, there is 
acute inflammation that, if persists, leads to chronic inflammation, granulation tissue, foreign 
body reaction, and finally fibrosis [5, 6, 14-17]. Acute inflammation, the first phase upon injury, 
is characterized by the exudation of fluid and plasma proteins, as well as the attraction of 
leukocytes to the site of injury. Subsequently, neutrophils and macrophages become activated. 
In general, these immune cells will recognize the implant as being ‘‘foreign’’ only if it is coated 
by opsonins, i.e. serum proteins for which these cells have specific membrane receptors [17-19]. 
Several immunoglobulins, particularly IgG but also IgA and IgM, are considered to be opsonins. 
In the case of cell-containing microcapsules, opsonization of the implant during acute 
inflammation plausibly leads to events that can be disastrous for graft viability, particularly the 
further release of cytotoxic cytokines associated with chronic inflammation and frustrated 
phagocytosis, as well as the formation of fibrotic tissue during the final stage of the healing 
process. 
It is well recognized that the biological response to APA microcapsules is significantly 
influenced by the chemical properties and the quality of the alginate. We have observed that 
microcapsules prepared of purified intermediate-G alginate remain free of any significant 
foreign body response for prolonged periods of time after implantation, while microcapsules 
prepared of high-G alginate are consistently associated with low recovery rates and extensive 
overgrowth [20, 21]. It is also well known that microcapsules composed of alginates that are not 
properly purified induce a severe inflammatory response [12, 22-24]. Yet, the mechanisms that 
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explain the influence of the alginate properties on the overall biocompatibility of the 
microcapsule are still not well understood. Therefore, we investigated the extent of 
immunoglobulin (Ig) adsorption onto the surface of APA microcapsules composed of alginates 
varying in chemistry and purity level as these microcapsules consistently demonstrate various 
degrees of biocompatibility when implanted. This approach was based on the hypothesis that 
opsonization by Ig is the principal event that mediates or leads to the immune response to 
implanted microcapsules. However, it was observed that altering the alginate properties had no 
statistically significant effect on the quantity of Ig that adsorbed to the corresponding APA 
microcapsules. Taking into account our previously observed in vivo response to microcapsules 
of the same chemical composition, these results suggest that Ig adsorption plays a negligible or a 
minor role in mediating an immune response to the implanted microcapsules. At the same time, 
it is worth noting that the microcapsules prepared of purified intermediate- G alginate adsorbed 
the lowest amount of Ig. This finding corroborates our in vivo observation that microcapsules 
prepared of this particular alginate provoke a minor inflammatory response compared to 
microcapsules prepared of high-G or impure alginates [20, 21]. Thus, it remains plausible that Ig 
adsorption has a certain degree of influence on the inflammatory response to implanted APA 
microcapsules. 
We observed that the extent of Ig adsorption to the microcapsules was significantly 
lower in the absence of the PLL-based membrane. Since we have recently confirmed, using zeta 
potential measurements, that adding the PLL membrane creates a net charge at the surface of 
APA microcapsules [25], the results of this study indicate that the positive charges of the 
polycation are attracting the immunoglobulin. This is in alignment with the general observation 
that, as opposed to highly charged surfaces, neutral (and hydrophilic) polymers have minimal or 
weak interactions with most aqueous proteins [26]. The biological implications of these results 
can be interpreted in two ways. On one hand, if it is to be assumed that Ig adsorption inevitably 
leads to inflammation, then the observation that the PLL attracts Ig to the microcapsule surface 
supports the numerous published studies which imply that exposed PLL is mainly responsible 
for the inflammatory response to APA microcapsules [15, 21, 27, 28]. On the other hand, these 
results do not necessarily reflect our own in vivo observations. We have seen that, in the case of 
APA microcapsules prepared of purified intermediate-G alginate, complete microcapsules that 
include the PLL membrane are just as biocompatible as the corresponding alginate gel beads. 
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From this point of view, our results suggest that Ig adsorption to the microcapsule surface does 
not always lead to a severe inflammatory response or fibrosis. 
In this study, we observed that Ig adsorption to the microcapsules was greater from 
serum than from PF or from a serum/PF mix. This is explained by the differences in protein 
concentrations between the two fluids. PF is a transudate of plasma, thus they share similar 
protein compositions. However, due to the fact that the peritoneal membrane limits the diffusion 
of larger molecules (>20 kDa), PF contains similar concentrations of smaller solutes, lower 
concentrations of high molecular-weight molecules, and an overall protein concentration of 
∼50% that of plasma protein concentrations [29-32]. The molecular weight of human 
immunoglobulin ranges from about 150 to 900 kDa [11], thus their concentration is expected to 
be lower in PF than in serum. In turn, protein adsorption patterns from mixed solutions are 
influenced by (among other factors) the relative bulk concentrations and molecular weights of 
each protein type. For instance, smaller proteins at higher concentrations tend to adsorb before 
larger proteins [26, 33]. 
The results of this study provide indications that Ig adsorption may influence the 
inflammatory response to APA microcapsules, yet it is clear that the combined effect of IgG, 
IgM, and IgA adsorption is not the only determining factor for microcapsule biocompatibility. 
While IgG is known to be a highly effective opsonizer, there are a number of other serum 
proteins that have also been seen to influence implant biocompatibility, for example the 
complement factor C3b, whose potential role in these experiments must not be ignored [17]. A 
growing number of researchers recognize that proteins of all types are very important to 
biomaterials science because of their tendency to deposit on surfaces as a tightly bound 
adsorbate, and more importantly due to the strong influence that these deposits have on 
subsequent cellular interactions with an implant surface [34]. Proteins have been measured on 
biomaterial surfaces within 1 s of implantation, thus protein adsorption occurs well before cells 
arrive at the surface [35]. On another note, in the particular case of microcapsules for cell 
therapy, protein adsorption should be considered not only in terms of its influence on the 
cellular response to the implants, but also in its influence on the capsule bioperformance by its 
potential to alter the selective permeability of the microcapsule’s immuno-protective membrane. 
While this aspect has not been directly studied in the case of alginate microcapsules, protein 
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adsorption has been seen to reduce the hydraulic permeability and solute sieving of 
polysulphone membranes [36, 37]. 
3.7 Conclusions 
It was clearly proven that human immunoglobulin (IgG/IgM/IgA) adsorbs to the surface 
of APA microcapsules in vitro. This was demonstrated using the relatively simple method of 
direct immunofluorescence. The extent of immunoglobulin (Ig) adsorption is not significantly 
influenced by the chemical composition and purity of the alginate used for microcapsule 
fabrication, yet it is highly dependent on the presence of the polylysine membrane, indicating 
that the positive charges of the polycation are mainly responsible for binding the Ig. Since IgG, 
IgM, and IgA are known to be opsonizing proteins that lead to complement activation upon their 
adsorption to foreign surfaces, these findings are useful for explaining the mechanisms of the 
immune response to APA microcapsules. 
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CHAPTER 4 
AN INTERLABORATORY COMPARISON OF ALGINATES AND APA 
MICROCAPSULES (GRONINGEN VS. MONTRÉAL) 
 
NOT SUBMITTED FOR PUBLICATION 
 
4.1 Abstract 
The Groningen lab is known for producing biocompatible alginate-poly(L-lysine)-
alginate (APA) microcapsules. We attempted to reproduce their results by following their 
protocol for microcapsule fabrication but using the materials and the equipment available in the 
Montréal lab. Alginate that we purchased and purified ourselves was slightly contaminated, but 
similar in composition than the alginate provided by the Groningen lab. Nevertheless, both 
alginates were biocompatible in vivo. Both alginates also produced APA microcapsules of 
similar immunogenicity. Using the Montréal alginate, we could make perfectly biocompatible 
gel beads regardless of the protocol for bead fabrication employed. However, our version of the 
Groningen protocol for APA microcapsule fabrication resulted in microcapsules that were more 
immunogenic (p < 0.01) than those fabricated using the Montréal protocol. This discrepancy 
was attributed to deviations that were taken from the original Groningen protocols, including the 
method for droplet generation and choice of animal model. The results of this study demonstrate 
the difficulty of achieving lab-to-lab reproducibility. Moreover, Montréal protocols for alginate 
purification, bead fabrication and APA microcapsule fabrication may be considered adequate for 
subsequent implantation studies. 
4.2 Introduction 
The Groningen lab is known for producing alginate-poly(L-lysine)-alginate (APA) 
microcapsules that are biocompatible in vivo. Since the late 1990’s, they have been 
demonstrating that when they implant their microcapsules into the peritoneal cavity of Albino 
Oxford (AO) rats, only minimal cell overgrowth and fibrosis is induced, even after several 
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months [1, 2]. Although other research groups have also reported adequate biocompatibility of 
their APA microcapsules under specific conditions [3-5], these studies tend to lack follow-up, 
which puts into question the reproducibility of their results. Other groups have published the 
fact that the APA microcapsules that they produced in their labs (sometimes as controls) 
induced some type of an immune response in vivo [6-8]. 
After having studied the Groningen protocol for APA microcapsule fabrication first-
hand, we (the Montréal group) attempted to reproduce their results using their protocol but our 
own lab equipment and materials. First, we tested whether the alginate that we purchased and 
purified ourselves performed as well as the Groningen group’s alginate. Next, we wanted to 
know if we were capable of producing biocompatible APA microcapsules if we followed (as 
closely as possible) their protocol for microcapsule fabrication. If we were to succeed, we would 
not only be able to move forward with the study of other aspects of microcapsule 
bioperformance using immunocompetent mice, but we would also have a very useful control for 
our studies on capsule biocompatibility. 
4.3 Materials and Methods 
4.3.1 Materials 
IntGGron:  Keltone® LVCR sodium alginate, lot #015821A, was purchased from ISP 
Corp (UK). This alginate was purified in the Groningen lab according to their own protocol, 
described in ref [1]. 
IntGMtl : Keltone® LVCR sodium alginate, lot #721322, was provided by ISP Corp 
(New Jersey, USA). We purified the alginate in Montréal according to our own protocol, 
described in refs [9, 10]. 
PLL : Poly(L-lysine) hydrobromide was purchased from Sigma (St Louis, USA) and had 
a molecular weight of 15,000 - 30,000 by viscosity (as specified by the manufacturer). 
All solutions used in this study were made in Montréal. Their formulae are described in 
APPENDIX I. Solutions were sterilized by filtration (0.22 µm) before their use. Labware and 
other laboratory equipment were sterilized whenever possible. 
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4.3.2 Protein and Endotoxin measurements 
For the alginates purified in Montréal, the protein and endotoxin content was measured 
using the microBCA and LAL assays, respectively. Details on these techniques for evaluating 
alginate contamination are described in section 5.4.2 [11]. 
4.3.3 Proton nuclear magnetic resonance (1H-NMR) 
The composition and sequential structure of the alginates were determined using 1H-
NMR. The protocol details for this technique are described in section 5.4.5 [11]. 
4.3.4 Contact angle technique 
The wettabilities of the samples were estimated by measuring the static contact angles of 
1 µL water droplets on dry films. Alginate films were cast from aqueous solutions directly onto 
glass microscope slides. Details for film fabrication and the contact angle technique are 
described in section 5.4.9. 
4.3.5 Gel bead and APA microcapsule fabrication 
Gel beads and APA microcapsules were fabricated using either the Montréal protocols 
(“Montréal”) or modified versions of the Groningen protocols (“Groningenmod”). Details for the 
Montréal protocol for bead and microcapsule fabrication are described in section 5.4.3 and 
section 6.4.2, respectively. The original Groningen protocols (“Groningenorig”) are described in 
section 3.4.3 and have been published in [12]. In this study, slight modifications from the 
original protocols were necessary in order to adapt to the lab equipment and materials available 
for sample fabrication. The principal steps for the each of the protocols for bead and 
microcapsule fabrication are compared in Error! Reference source not found. and Error! 
Reference source not found.. 
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Table 4.1 Comparison of fabrication protocols for gel beads 
Step Groningenorig Groningenmod Montréal 
Alginate 
solution 
IntGGron 2.7% w/v 
in 220 mOsm Ca2+-free 
KRH 
IntGMtl 1.75% w/v 
in 220 mOsm Ca2+-free KRH 
IntGMtl 1.63% w/v 
in 154 mM saline 
 
IntGGron 2.80% w/v 
In 154 mM saline 
Droplet 
production 
Co-axial air-jet 
with 23G needle 
Electrostatic pulse 
with 25G needle 
Electrostatic pulse 
with 25G needle 
Gelation 8+ min 
in 10 mM BaCl2(Gron) 
8+ min 
in 10 mM BaCl2(Gron) 
30 min 
In 10 mM BaCl2(Mtl) 
Rinse 1 × 1 min in 310 mOsm 
Ca2+-free KRH 
 
3 × 1 min in 25 mM KRH 
3 × 5 min in Ringer 3 × 5 min in Ringer 
 
Table 4.2 Comparison of fabrication protocols for APA microcapsules 
Step  Groningenorig Groningenmod Montreal 
Alginate 
solution 
IntGGron 2.7% w/v 
in 220 mOsm Ca2+-free 
KRH 
IntGMtl 1.75% w/v 
in 220 mOsm Ca2+-free KRH 
IntGMtl 1.63% w/v 
in 154 mM saline 
 
IntGGron 2.80% w/v in 
154 mM saline 
Droplet 
production 
Co-axial air-jet 
with 23G needle 
Electrostatic pulse 
with 25G needle 
Electrostatic pulse 
with 25G needle 
Gelation 8+ min 
in 100 mM CaCl2 
8+ min 
in 100 mM CaCl2 
30 min 
In 100 mM Ca Lactate 
Rinse 1 min in Spoelhepes 2 min in Spoelhepes n/a 
PLL coating 10 min in 0.1% w/v PLL 
in 310 mOsm Ca2+-free 
KRH 
5 min in 0.05% w/v PLL 
in 310 mOsm Ca2+-free KRH 
5 min in 0.05% w/v PLL 
In 154 mM saline 
Rinse 3 × 1 min in 310 mOsm 
Ca2+-free KRH 
3 × 3 min in 310 mOsm 
Ca2+-free KRH 
5 min in 154 mM saline 
Alginate 
coating 
5 min in alg diluted 1:10 in 
310 mOsm Ca2+-free KRH 
5 min in alg diluted 1:10 in 
310 mOsm Ca2+-free KRH 
5 min in alg diluted 1:10 
in 154 mM saline 
Rinse 1 × 1 min in 310 mOsm 
Ca2+-free KRH 
 
3 × 1 min in 25 mM KRH 
1 × 2 min in 310 mOsm 
Ca2+-free KRH 
 
3 × 2 min in 25 mM KRH 
3 × 5 min in 154 mM 
saline 
76 
4.3.6 In vivo biocompatibility 
The protocol for evaluating the in vivo biocompatibility of the microcapsules is 
described in detail in section 6.4.3. Briefly, 500 beads or microcapsules were handpicked and 
then implanted into the peritoneal cavity of male C57BL/6J mice. After two days, the samples 
were explanted and individual beads/capsules were classified into one of four categories 
according to how much of their surface was covered with immune cells. This classification 
system allowed a calculation of a weighted ‘cell adhesion score’ that ranges from 0 (no cell 
adhesion) to 10 (complete coverage by cells and fibrosis). 
4.3.7 Statistical Analysis 
Samples were compared using the unpaired Student t-test. Differences for which p < 0.05 
were considered to be statistically significant. 
4.4 Results 
4.4.1 Further characteristics of the alginates 
Alginate characteristics that were either measured directly or extracted from the 
literature are compared in Table 4.3. Our alginate (IntGMtl) and the alginate provided by the 
Groningen group (IntGGron) contained similar proportions of guluronate (G) and mannuronate 
(M) both before and after their purification. The alginate that was purified in Montreal had 
negligible amounts of proteins and slight quantities of endotoxins [11]. In comparison, we did 
not directly measure the contamination levels of the Groningen-purified alginate, although a 
published study indicated a minimal amount of endotoxins (< 0.01 EU/mL) without specifying 
the concentration of the solution tested [12]. However, we previously demonstrated that the 
contact angle of water on alginate films is a good indicator of their purity level [13]. Using this 
approach, we observed that (after purification) the IntGMtl alginate had a slightly greater contact 
angle than the IntGGron alginate, which suggests that the Groningen group’s alginate was slightly 
more pure. 
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Table 4.3 Further characteristics of the alginates 
 IntGGron IntGMtl 
Composition Crude : 43%G : 57%M (n = 1) 
Pure : 40%G : 60%M (ref [1]) 
Crude : 36%G : 54%M (n = 2) 
Pure : 44:%G : 56%M (n = 3)  
Contaminants 
(after purif) 
Proteins : no data 
Endotoxins : < 0.01 EU/mL (ref [12]) 
Proteins : 3.7 ± 0.4 µg/g (n = 3) 
Endotoxins : 231 ± 127 EU/g (n = 4) 
Contact angle Crude : 68.5 ± 2.0° (n = 4) 
Pure : 33.1 ± 2.1° (n = 4)  
Crude : 50.0 ± 8.1° (n = 2) 
Pure : 39.5 ± 4.1° (n = 5) 
4.4.2 Characteristics of the beads and microcapsules 
As detailed in Error! Reference source not found., we had to slightly modify the Groningen 
protocol for bead fabrication before we could implant the beads. We initially tried to use the 
rinsing solutions described in the original protocol, but when we placed the barium gel beads in 
contact with 310 mOsm Ca2+-free KRH, some sort of precipitation developed on their surfaces 
(Figure 4.1). We determined that this was some sort of reaction between the 10 mM 
BaCl2(Gron) and the 310 mOsm Ca2+-free KRH because when we mixed these two solutions 
together (in the absence of beads), the same type of precipitation was observed on the bottom of 
the petri dish (Figure 4.1). Because of this inconvenience, we simply substituted the KRH with 
Ringer’s solution for rinsing the beads. The resulting gel beads looked just fine, as did the 
Montréal-style gel beads. 
 
Figure 4.1 View through optical microscope of (a) barium alginate gel beads in 10 mM BaCl2(Gron), (b) 
the same gel beads after transferring them into 310 mOsm Ca2+-free KRH, and (c) a mixture of 10 mM 
BaCl2(Gron) and 310 mOsm Ca2+-free KRH solutions. 
(a) (b) (c) 
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Similarly, slight deviations from the original Groningen protocol for APA microcapsule 
fabrication were necessary in order to produce an implantable sample (Error! Reference source 
not found.). When we attempted to follow the original coating protocols for membrane 
formation on our smaller gel beads, the membrane was much too thick (Figure 4.2). Therefore, 
we reduced the concentration and incubation time for the PLL coating step. The resulting APA 
microcapsules looked similar to the capsules made using the Montréal protocol for fabrication. 
However, these microcapsules swelled less during membrane formation (154% diameter 
increase) than did the microcapsules from the Montréal protocol (200% diameter increase). 
 
Figure 4.2 View through optical microscope of APA microcapsules when following (a) the Groningenorig 
protocol (excluding the use of co-axial air-jet) (b) the Groningenmod protocol, and (c) the Montréal 
protocol. 
4.4.3 In vivo biocompatibility 
The in vivo biocompatibilities of the samples were evaluated in terms of the extent of 
immune cell adhesion after two days in the peritoneal cavity of C57BL/6J mice. In all cases, the 
APA microcapsules showed a moderate immune response that corresponded to cell adhesion 
scores between 4.0 and 7.0. When the PLL membrane was omitted, the gel beads were very 
biocompatible, as cell adhesion scores were consistently below 1.5. 
The biocompatibility of the IntGGron and the IntGMtl alginates were compared by 
implanting barium alginate gel beads that were fabricated using the Montréal protocol. The 
Groningen alginate showed signs of being slightly immunogenic while the Montréal alginate 
was perfectly biocompatible (Figure 4.3). However, the difference between their cell adhesion 
(a) (b) (c) 
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scores was not statistically significant. When these alginates were used to make APA 
microcapsules (Montréal protocol), their in vivo performance was almost identical. 
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Figure 4.3 Effect of alginate source (IntGGron vs IntGMtl) on the in vivo biocompatibility of gel beads and 
APA microcapsules. Samples were made using the Montreal fabrication protocol. Bars represent the 
mean cell adhesion score ± SEM. 
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Figure 4.4 Effect of fabrication protocol (Groningenmod vs Montreal) on the in vivo biocompatibility of 
gel beads and APA microcapsules. Samples were made using the IntGMtl alginate. Bars represent the 
mean cell adhesion score ± SEM. ** p < 0.01. 
The Groningenmod and Montréal fabrication protocols were compared using the same 
alginate (IntGMtl). Both protocols for gel bead fabrication resulted in perfectly biocompatible 
beads (Figure 4.4). The different protocols for APA microcapsule fabrication, however, gave 
significantly different results (p < 0.01). That is, the Montréal protocol for fabrication resulted in 
APA microcapsules that were more biocompatible. 
80 
4.5 Discussion 
Despite originating from different lots, each the IntGGron and the IntGMtl alginates were 
purchased from the same company and under the same brand name (Keltone® LVCR). 
Therefore, they were expected to have similar characteristics before being processed in the lab. 
Once purchased, however, the alginates were subjected to two different protocols for 
purification. While the final purity of the alginates could not be directly compared (we did not 
analyse the Groningen alginate for contaminants), both types of alginate proved to be 
biocompatible, with no significant difference in their performance in vivo. This result 
demonstrates that both purification protocols are suitable for treating alginates to be used in in 
vivo studies. 
That said, caution must be made when generalizing the effectiveness of the purification 
protocols applied. We have previously shown that, under certain conditions, the Groningen 
protocol for purification was not effective for removing all contaminants [10] and resulted in 
non-biocompatible alginates [14]. It is likely that, in these earlier studies, the Groningen 
protocol for purification was rendered ineffective because, first of all, it was adapted to the 
Montreal lab, and second of all, it was applied to purify an alginate having a higher guluronate 
content (Protanal® LF10/60). In contrast, the “Groningen alginate” used in this study was 
actually purified in the Groningen lab and it was applied to an alginate having an intermediate 
guluronate content.  
Once the PLL membrane was added to the alginate beads to form complete APA 
microcapsules, the type of alginate (IntGGron vs IntGMtl) had absolutely no effect on 
biocompatibility. This could be expected, as we have shown that the main factor governing the 
immune response to APA microcapsules is the interaction between the polycation and alginate 
gel (CHAPTER 6). Since the alginates had similar characteristics to begin with, and the same 
PLL as well as the same fabrication protocol were employed, the microcapsules also had similar 
biocompatibilities. 
Gel beads of IntGMtl alginate were consistently biocompatible, regardless of fabrication 
protocol applied to make the gel beads. Therefore, both the Groningenmod and the Montréal 
protocols for bead fabrication are appropriate for implantation studies. More importantly, this 
confirms that the Montréal alginate is adequately biocompatible. 
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When we used a modified version of the Groningen protocol (Groningenmod) for APA 
microcapsule fabrication, the resulting samples were significantly more immunogenic than 
Montréal-style APA microcapsules (p < 0.01). This was despite the fact that we used the same 
alginate (IntGMtl) in both cases. This result was unexpected since de Vos et al have proven that 
their protocol leads to very biocompatible APA microcapsules [1, 2]. It can be presumed that the 
modifications that we made to the Groningen protocol when we adapted it to the Montreal lab 
were responsible for inducing an immunogenicity of the microcapsules. 
The most important discrepancy between the original version and our modified version 
of the Groningen protocol for APA microcapsule fabrication is the method for droplet 
generation. The Groningen group uses a co-axial airjet system that results in droplets with a 
diameter of approximately 600 µm. In contrast, the Montréal lab is equipped with a pulsed 
electrostatic system that generates droplets that are closer to 300 µm in diameter. In 
collaboration with Stöver et al of McMaster University, we are currently collecting data that 
demonstrates that PLL penetrates deeper into smaller alginate gel beads compared to larger gel 
beads. This is exactly the effect that we observed when trying to apply the Groningen procedure 
for PLL coating to our smaller gel beads (Figure 4.2). In order to reduce the membrane 
thickness, we were obliged to use a 0.05% w/v solution of PLL in place of a 0.1% w/v PLL 
solution, as the original Groningen protocol requires. The collapse of smaller capsules with the 
addition of PLL was also seen by Strand et al [15], although they managed to counter this effect 
by rinsing the beads with 0.3 M mannitol solution instead of saline before the exposure to PLL. 
Since we also provided evidence that the ability of the PLL to diffuse into and bind to the 
alginate gel bead is a crucial factor in determining APA microcapsule biocompatibility 
(CHAPTER 6), this deviation from the original Groningen protocol for microcapsule 
fabrication could very well have induced the immunogenicity that we observed in this study. 
Another possible explanation for our inability to reproduce the Groningen results for 
APA microcapsule biocompatibility lies in the choice of animal model. In Groningen, AO rats 
were used as implant recipients, whereas in this study we used C57BL/6J mice. Studies have 
shown that the choice of animal model can significantly influence the severity of immune 
response to alginate-based microcapsules [8, 16], and C57BL/6J mice may be particularly 
sensitive to this effect [17]. Since we did not test the microcapsules that we fabricated in AO 
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rats, we cannot exclude the possibility that the C57BL/6J mice are simply more sensitive as a 
species. Although, it should be pointed out that De Vos et al have tried implanting their APA 
microcapsules in pre-diabetic BB rats (which are reportedly highly responsive to these capsule 
types [8]) and still saw less than 10% overgrowth at 1 month [1].  
This study serves as a good example of how difficult it is to reproduce in vivo results for 
APA microcapsules between labs. We failed to reproduce the results achieved by the Groningen 
group despite having had firsthand experience in fabricating their microcapsules in their lab. 
One can imagine that reproducing results is even more difficult when relying solely on the 
published protocol for microcapsule fabrication. This situation is one of the greatest obstacles to 
the standardization of alginate microcapsules for implantation and to the understanding of their 
biocompatibility. 
Overall, since both the IntGGron and the IntGMtl alginates performed similarly, and the 
Montréal protocol for APA microcapsule fabrication resulted in a better biocompatibility than 
the Groningenmod protocol, we feel that it is appropriate to use our own materials and protocols 
for alginate purification and microcapsule fabrication for subsequent studies. 
4.6 Conclusions 
The alginate purchased and purified by the Montréal group had similar characteristics to 
the alginate provided by the Groningen group. Moreover, our alginate was proven to be just as 
biocompatible, if not a slight more, than the Groningen alginate. Using our alginate, we showed 
that both the Groningen and Montréal protocols for fabrication were adequate for producing 
biocompatible gel beads. However, when we attempted to follow the Groningen protocol for 
APA microcapsule fabrication, the resulting microcapsules were even more immunogenic than 
APA microcapsules that were produced using our usual protocol for fabrication. Since the 
Groningen protocol was expected to result in biocompatible APA microcapsules, it was 
assumed that the parameters that were necessarily modified when adapting the protocol to the 
Montréal lab were responsible for inducing immunogenicity. While we did not succeed in 
producing biocompatible APA microcapsules by following the Groningen protocol (which is a 
good example of how difficult it is to reproduce implantation results between labs), we showed 
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that the Montréal protocols for alginate purification, bead fabrication, and microcapsule 
fabrication are adequate for subsequent implantation studies. 
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5.1 Abstract 
Alginate remains the most popular polymer used for cell encapsulation, yet its 
biocompatibility is inconsistent. Two commercially available alginates were compared, one with 
71% guluronate (HiG), and the other with 44% (IntG). Both alginates were purified, and their 
purities were verified. After two days in the peritoneal cavity of C57BL/6J mice, barium (Ba)-
gel and calcium (Ca)-gel beads of IntG alginate were clean, while host cells were adhered to 
beads of HiG alginate. IntG gel beads, however, showed fragmentation in vivo while HiG gel 
beads stayed firm. The physicochemical properties of the sodium alginates and their gels were 
thoroughly characterized. The intrinsic viscosity of IntG alginate was 2.5-fold higher than that 
of HiG alginate, suggesting a greater molecular mass. X-ray photoelectron spectroscopy 
indicated that both alginates were similar in elemental composition, including low levels of 
counterions in all gels. The wettabilities of the alginates and gels were also identical, as 
measured by contact angles of water on dry films. Ba-gel beads of HiG alginate resisted 
swelling and degradation when immersed in water, much more than the other gel beads. These 
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results suggest that the main factors contributing to the biocompatibility of gels of purified 
alginate are the mannuronate/guluronate content and/or intrinsic viscosity. 
5.2 Keywords 
alginate; hydrogel; biocompatibility; microcapsules; cell encapsulation 
5.3 Introduction 
Alginate remains the most popular polymer used for cell encapsulation [1-3]. This 
natural polysaccharide is a preferred choice for this application because of its low toxicity and 
its ability to gel in conditions that are compatible with living cells [4]. Molecularly speaking, 
alginate is an unbranched copolymer with blocks of (1-4)-linked β-D-mannuronate (M) and α-G-
guluronate (G) residues. A schematic of a -GGMM- segment of alginate is illustrated in Figure 
5.1. For alginates derived from algae, the distribution of the M and G residues along the alginate 
chains, as well as their molecular mass, generally varies with the algal source and processing 
treatment of the biopolymer [5]. 
 
Figure 5.1 Molecular structure of alginate. M = mannuronate residue ; G = guluronate residue. 
Because of this variability, the biocompatibility of alginates, particularly commercially 
available alginates, is not guaranteed [6]. First and foremost, before an alginate can be used for 
any medical applications, it must be properly purified in order to minimize the risk of an 
immune response stimulated by contaminants, such as proteins or endotoxins, that are often 
contained in crude alginates. The importance of alginate purity for bioperformance has been 
clearly emphasized in the literature [7-11]. Beyond purity level, published studies have 
suggested an effect of alginate’s molecular weight [12, 13], solution viscosity [14, 15], or 
mannuronic (M) and guluronic (G) acid content [16-19] on the biocompatibility of alginate-
based microcapsules or microbeads for cell therapy. However, the conclusions of such studies 
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are not always in agreement. Moreover, very few published works have focussed on the 
biocompatibility of properly purified alginates in the absence of a polycation, despite that 
uncoated alginate microbeads are becoming increasingly popular in the cell encapsulation field 
[18, 20, 21]. Indeed, there is still a need for a better understanding of the factors influencing 
alginate biocompatibility. 
In this study, we compared two commercially available sodium alginates, one having a 
high guluronate (G) content, and the other having an intermediate G content. The alginates were 
purified in-house, and purity levels were verified in order to exclude the effect of contaminants 
on the results. For the analyses, the alginates were either in the form of an aqueous solution or 
crosslinked with Ba2+ or Ca2+ ions to form a gel. The samples in this study did not incorporate 
any polycations that could potentially induce an immune response or otherwise interfere with 
the interpretation of results. Both Ba2+- and Ca2+-crosslinked alginates were evaluated because 
barium alginate gel beads (without a polycationic membrane) have become a feasible option for 
immunoisolated transplantation [18, 20] and calcium alginate gels are most frequently employed 
to form the inner core of immunoprotecting microcapsules (having a polycationic membrane) 
[1]. This study aims to correlate an observed variation in biocompatibility with the physical and 
chemical details of the alginates and their gels, as this type of information would directly 
contribute to the rational selection and standardization of alginates for implantation purposes 
[22]. As mentioned above, others have observed (often contradictory) effects of each the M/G 
distribution and the solution viscosity on the biocompatibility of alginates [14-19], therefore 
these two properties were also evaluated in this study. In addition, the elemental compositions 
and molecular details of the alginates and their gels were assessed so as to monitor the possible 
role of counterion-alginate interactions on gel biocompatibility. Finally, the wettabilities of the 
alginates and their gels, as well as the swelling/degradation behaviour of the gel beads in water, 
were evaluated since alginate biocompatibility is often attributed to its properties as a 
hydrophilic and water-absorbing hydrogel [2] and because bead stability is an important feature 
for long-term bioperformance. 
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5.4 Materials and Methods 
5.4.1 Materials 
Sodium alginate Protanal® LF10/60 (Batch no. S13636) was provided by FMC 
BioPolymer (Drammen, Norway). Keltone® LVCR (CAS no. 9005-38-3, Lot no. 721322) was 
provided by ISP Corporation (NJ, USA). These alginates are denoted “HiG” and “IntG”, 
respectively. Sterile water for irrigation, USP, was purchased from Baxter (Toronto, ON, 
Canada). All solutions were sterilized by filtration (0.22 µm) before their use. Reusable labware 
was specially cleaned and then sterilized by either Pasteur oven (200°C for 2h), autoclave or 
ethylene oxide gas before each use ; disposable plastic materials were considered as sterile and 
pyrogen-free. 
5.4.2 Alginate purification 
Sodium alginates were purified as previously described [9, 23]. Briefly, sodium alginate 
powder was extracted three times with chloroform then dissolved in sterile water (1.5% w/v for 
HiG ; 1.8% w/v for IntG). The solution was charcoal treated, filtered (0.22 µm), and then 
converted into gel beads using 50 mM BaCl2. The gel beads were extracted over several days 
using 1M acetic acid, 500 mM sodium citrate, 50% ethanol, and then 70% ethanol. The beads 
were rinsed (water, 20 mM BaCl2) and then dissolved in 250 mM EDTA. The resulting alginate 
solution was filtered (0.22 µm) and then dialysed against 150 mM saline and sterile water, 
successively (50,000 MWCO). Finally, the alginate was precipitated from the solution using 
100% ethanol, freeze-dried, and stored at 4°C until its use. 
Alginate purity was evaluated in terms of endotoxin and protein content, as well as the 
presence of foreign elements. For these tests, alginates were first dissolved in sterile water then 
filtered 0.2 µm. A commercially available Limulus amebocyte lysate (LAL) assay (E-toxateTM 
Kit, Sigma-Aldrich #ETO300, St Louis, MO, USA) was used to estimate the endotoxin content 
of alginates dissolved 1% w/v and diluted sequentially from 1:2 to 1:8000. The sensitivity limit 
of the LAL assay ranged between 0.03 - 0.125 EU/mL. E.coli 0.55:B5 lipopolysaccharide (LPS) 
included in the kit was used as a standard. A commercially available bicinchoninic acid (BCA) 
protein assay (Pierce Micro BCATM Protein Assay Kit, Thermo Fisher Scientific, Rockford, IL, 
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USA) was used to quantify proteins in 1% w/v alginate solutions. The solutions were diluted 
1:10 in sterile water in order to meet the kit’s linear range of protein concentrations (0.5 - 20 
µg/mL). Bovine serum albumin (BSA) included in the kit was used for the standard curve. Each 
measurement represents the mean of duplicate readings. Dry films of alginate solutions (2% 
w/v) were analyzed by x-ray photoelectron spectroscopy (XPS) in order to detect foreign 
elements. Details for the XPS technique are described elsewhere in Materials and Methods. For 
both HiG and IntG alginates, at least two purification batches were tested using each assay (n = 
2 to 4). 
5.4.3 Alginate gelation 
Alginates were dissolved at a concentration of 2.0% w/v (HiG) or 1.63% w/v (IntG) in 
154 mM saline (12.5 mM HEPES, pH 7.4) and then filtered 0.22 µm. These concentrations were 
selected to target a suitable viscosity (220 ± 20 cps) for droplet production. For gel beads, the 
alginate solution was first converted into tiny droplets using a pulsed electrostatic droplet 
generator equipped with a 25G blunt tip needle. For gel films, 200 µL of alginate solution was 
first spread uniformly over a glass microscope slide pre-coated with poly-L-lysine. Gelation 
consisted of immersing the alginate solution (droplets or films) for 30 minutes in a cross-linking 
solution, followed by rinsing the gel three times with Ringer’s solution (154 mM NaCl, 5.6 mM 
KCl, 1.7 mM CaCl2, 5 mM HEPES, pH 7.4). Either 10 mM BaCl2 (16 mM HEPES, pH 7.4) or 
100 mM Ca lactate was used as the cross-linking solution. 
5.4.4 In vivo biocompatibility studies 
Each sample consisted of 500 gel beads suspended in ∼ 0.5 mL of Ringer’s solution. 
Samples were injected via a 22G catheter into the peritoneal cavity of male C57BL/6J mice 
aged 8 to 12 weeks (Jackson Laboratory, Bar Harbor, Maine, USA). Two days later, the beads 
were explanted. To do this, the mice were euthanized by cervical dislocation and a small ventral 
incision was made. The peritoneal cavity was flushed several times using ∼ 30 mL of Ringer’s 
solution. After flushing, the cavity was opened and inspected for beads adhered to the organs or 
peritoneal wall. The explanted beads were separated from free-floating cells by rinsing with ∼ 
20 mL of Ringer’s solution over a 41 µm nylon mesh. The explanted samples were examined 
90 
under optical microscope. Each bead retrieved was classified into one of four categories, 
according to the extent of host cell adhesion to its surface, as described in Table 5.1. 
For each sample, the cell adhesion score was calculated according to Eq. 5.1 where A, B, 
C, and D are the number of beads retrieved that fall into categories A, B, C, or D, respectively, 
and tot is the total number of beads that were retrieved for that sample. The retrieval rate for a 
given sample was calculated according to Eq. 5.2. 
Protocols for these in vivo studies were approved by the animal care ethics committee of 
the Maisonneuve-Rosemont Hospital Research Centre and have been stated to conform to the 
ethical guidelines of the Canadian Council for Animal Care. These guidelines were respected 
throughout this study. 
Table 5.1 Classification of alginate gel beads retrieved after two days in the peritoneal cavity of 
C57BL/6J mice, according to the extent of host cell adhesion to the bead surface. This classification 
system is used to calculate the cell adhesion score (Eq. 5.1) and the retrieval rate (Eq. 5.2) of the 
explanted beads.  
Category A B C D 
Portion of bead 
surface covered 
by host cells 
none 
 
< 50% 
 
> 50% 
 
100% 
 
Score 0 3.3 6.6 10 
Eq. 5.1  
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scoreadhesioncell 106.63.30   
Eq. 5.2  %100
500
×=
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rateretrieval   
5.4.5 Proton Nuclear Magnetic Resonance (1H NMR) 
NMR was used to determine the composition and sequential structure of the alginates, 
closely following the protocol described in the ASTM International Standard F 2259-03 [24], 
based on the work by Grasdalen et al [25-27]. Briefly, alginate powder was dissolved 0.1% w/v 
91 
in sterile water and filtered 0.22 µm. The alginate was acid hydrolyzed by lowering the solution 
pH to 5.6 (using HCl) and putting the sample in a water bath at 100°C for 1 h. The solution pH 
was then adjusted to 3.8 and put back in the water bath at 100°C for 30 min. After bringing the 
solution pH back to 7-8 using NaOH, the sample was freeze-dried. Next, 11 ± 1 mg of each 
sample was dissolved in 99.9% D2O and freeze-dried again. Less than 24h before NMR 
analysis, the alginates were dissolved in 1 mL D2O and mixed with 29 µL of 0.3 M TTHA (pH* 
5-5.5). For spectral acquisition, sample temperature was maintained at 80°C. Spectra were 
acquired using a Bruker Avance 500 MHz NMR spectrometer (Bruker Biospin). Spectra were 
acquired without pre-saturation and with a 2 s relaxation delay. For each spectrum, 64 scans 
were made over a range of 0 to 7 ppm. Spectra were processed using Spinworks software 
(www.umanitoba.ca). The assignments and intensities of the 1H NMR signals were interpreted 
as described in the ASTM Standard [24]. 
5.4.6 Viscometry 
Alginates were dissolved ≤ 2.0% w/v in 154 mM saline (12.5 mM HEPES, pH 7.4) then 
filtered 0.22 µm, followed by sequential dilutions with saline down to 0.1% w/v. The viscosities 
of alginate solutions, η, were measured using a Brookefield synchro-lectric rotational 
viscometer (LV Model, Brookefield Engineering Laboratories, Stoughton, MA, USA) equipped 
with a no. 18 spindle and connected to a heating bath / circulator (Model D8-G, Haake Mess-
Technik GmbH u. Co., Germany). During viscosity measurements, the solution temperature was 
maintained at 25.0 ± 0.1°C. Viscometer dial readings were allowed to stabilize (generally > 5 
min of rotation) before they were recorded. Readings were taken at rotational speeds ranging 
from 0.3 to 60 revolutions per minute (rpm). One viscosity measurement represents the average 
of four dial readings (two speeds, two readings per speed). Three measurements were taken for 
each sample (n = 3). At least two purification batches were tested for each alginate type. 
The intrinsic viscosity [η] of each alginate type was estimated by plotting each the 
reduced viscosity, ( )
c
red
10 −
=
ηηη , and the inherent viscosity, ( )
c
inh
0ln ηηη = , as a function of 
solution concentration, c, and then extrapolating these plots to zero concentration [28]. These 
plots were constructed using the measured viscosities of the alginate solutions, η, for a range of 
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concentrations, as well as the measured viscosity of the solvent (154 mM saline), η0. Reduced 
viscosity ηred is generally related to intrinsic viscosity [η] by a power series (Eq. 5.3) [29], 
where k1, k2, k3 … are dimensionless constants. Truncating Eq. 5.3 to the second term gives the 
Huggins equation (Eq. 5.4) [30] that is commonly used to describe viscosity data at low polymer 
concentrations. Similarly, the inherent viscosity ηinh is related to the intrinsic viscosity [η] by 
the Kraemer equation (Eq. 5.5) [31]. Eq. 5.4 and Eq. 5.5 dictate that, for dilute polymer solutions, 
plots of ηred vs. c and ηinh vs. c are expected to be linear. Moreover, these plots should normally 
converge to almost the same value for [η] when extrapolated to inifinite dilution  (c = 0). 
Eq. 5.3  [ ] [ ] [ ] [ ] ...34323221 ++++= cnkckckred ηηηη  
Eq. 5.4  [ ] [ ] ckHred 2ηηη +=  
Eq. 5.5  [ ] [ ] ckKinh 2ηηη +=  
5.4.7 X-Ray Photoelectron Spectroscopy (XPS) 
XPS was used to quantitatively determine the elemental composition of the alginates and 
their gel beads (with the exception of hydrogen, H, which is not detectable by XPS). Because 
XPS is carried out in an ultra-high vacuum environment, it was necessary to dehydrate the 
samples before their analysis. For the alginates, sodium alginate powder was dissolved 2.0 % 
w/v in sterile water then filtered 0.22 µm. The solutions were then subjected to ultrasonic 
stirring for 30 min (Branson 5210 Ultrasonic Cleaner, Branson Ultrasonic, Danbury, CT, USA) 
in order to homogenize the solution. The solution was gently pipetted onto a 1 cm × 1 cm square 
of silicon wafer. For the Ba- and Ca- gels, ∼ 1 mL of gel beads was quickly rinsed with 10 mL 
of sterile water. Excess water was removed and the beads were transferred onto a square of 
silicon wafer. All samples were then allowed to dry ≥ 24h under a sterile flowhood and ≥ 24h in 
a vacuum before being analyzed by XPS. 
XPS spectra were acquired and processed using an Escalab MKII Surface Analysis 
System  equipped with an Avantage data system (Thermo VG Scientific, West Sussex, UK). An 
unmonochromated Mg Kα source anode operated at 216 W (18 mA, 12 kV) was used to 
generate x-rays. Survey spectra were recorded for a single scan of 0-1200 eV binding energy 
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range, at a pass energy of 100 eV. Charge shift corrections of the spectra were made by setting 
the C1s peak to 285.0 eV. Peaks integrations were calculated with subtraction of a Shirley 
background. Each sample type was analyzed at least twice by XPS (n ≥ 2), and at least two 
purification batches were analyzed for each alginate type. 
5.4.8 Micro-Attenuated Total Reflectance Fourier Transform Infrared 
Spectroscopy (ATR-FTIR) 
MicroATR-FTIR was used to qualitatively examine the molecular groups found in the 
alginates and their gel beads. FTIR spectra were acquired using a Varian 7000 FT-IR Research 
Spectrometer equipped with a UMA 600 microscope and germanium microATR crystal 
(Digilab®, Randolph, MA, USA). Because water produces a strong absorption band in the 
spectral region of interest, the alginates and gel beads were prepared and dehydrated onto 
squares of silicon wafer as described for XPS measurements. Using the microscope view as a 
guide, the microATR crystal was gently pressed against the alginate film or against a single gel 
bead for analysis. Sample spectra were recorded for a range of 4000 to 700 cm-1 at a resolution 
of 4 cm-1, with 128 scans co-added per spectrum. Background spectra consisted of the bare 
crystal under the same experimental conditions. Each sample type was examined twice by 
microATR-FTIR (n = 2), and at least two purification batches were analyzed for each alginate 
type. 
5.4.9 Contact angle technique 
Sample films were cast on microscope slides pre-coated with poly-L-lysine (PLL). The 
PLL enhanced adhesion of the cast films to the slides yet had no impact on the contact angle 
measurements (results not published). To coat the slides, they were first cleaned for 10 min in 1 
M HCl at 100°C then rinsed extensively with distilled water. The slides were then immersed for 
10 min in a solution containing 20 mg PLL-HBr (Sigma-Aldrich, Product no. P7890, St-Louis, 
MO, USA), 296 mL of distilled water, and 4 mL of 1 M Tris, and then allowed to dry under a 
sterile flowhood. For the sodium alginate films, alginates were dissolved 2.0% w/v in sterile 
water and then filtered 0.22 µm. 200 µL of each solution was gently spread over a slide surface. 
For the gels, alginate was dissolved in 154 mM saline at 2.0% w/v (HiG) or 1.63% w/v (IntG). 
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The solution was filtered 0.22 µm and then 200 µL was spread over a glass slide. The alginate-
covered slide was then placed into a large Petri dish and the appropriate solutions (30 mL at a 
time) were poured over the film in order to form a gel, as described in the section Alginate 
gelation. To remove excess salts that can interfere with the results, the gel films were rinsed 
once for 60 ± 15 sec using 30 mL of sterile water. All films were allowed to dry overnight under 
a sterile flowhood before contact angle analysis. 
Contact angle measurements were made using a VCA Optima Contact Angle Surface 
Analysis System (AST Products, Inc., Billerica, MA, USA). One (1) µL of sterile water was 
dispensed from a mechanically controlled 100 µL syringe fitted with a 22G blunt tip needle. The 
sample was raised to touch the suspended water drop. Within 2 sec of contact with the water 
drop, a photo was taken. The contact angle of the droplet to the surface was measured using the 
provided software. Each measurement represents the average of 2 to 4 spots on the same film. 
At least three measurements were made for each sample type (n ≥ 3), and at least two 
purification batches were tested per alginate type. 
5.4.10 Swelling and degradation 
For each sample, 30 ± 5 gel beads (suspended in Ringer’s solution) were transferred to a 
24-well polystyrene plate. Their diameters were measured using the gradient scale mounted in 
the eyepiece of an optical microscope. Using a pipette, as much of the Ringer’s solution as 
possible was carefully removed from the well containing the gel beads and then 1 mL of sterile 
water was added. After 5-10 min within adding the water, the diameters were measured again. 
Beads that were not clearly visible using the microscope, and thus their diameters were not 
measureable, were considered to have been degraded. This water rinse and examination by 
microscope was repeated twice more. For each sample type, swelling / degradation tests were 
made for three different batches of beads (n = 3), and at least two purification batches were 
tested per alginate type. 
5.4.11 Statistical analysis 
In cases where n ≥ 3, samples were compared using the unpaired Student t-test. 
Differences for which p < 0.05 were considered to be statistically significant. 
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5.5 Results 
5.5.1 Alginate composition and monomer sequence 
The composition and monomer sequence of each alginate type used in this study was 
measured using Proton Nuclear Magnetic Resonance (1H NMR). The results for the purified 
alginates are shown in Table 5.2. The HiG alginate was composed of 71% guluronate (G) and 
29% mannuronate (M), while the IntG alginate was composed of 44% G and 56% M. On 
average, blocks of consecutive guluronate monomers were both more frequent and longer in 
length for the HiG alginate than for the IntG alginate, as interpreted by the values for FGG, FGGG, 
and NG>1. 
Table 5.2 Composition and monomer sequence of purified sodium alginates, as determined by 1H NMR. 
Values represent the mean ± SEM for at least two purification batches (n = 3). Fx = frequency of monad 
/diad /triad x ; NG>1 = average number of consecutive G monomers in G-blocks. 
 FG FM FGG FMM 
FGM 
FMG 
FGGG 
FGGM 
FMGG 
FMGM NG>1 
HiG 0.71 ± .01 
0.29 
± .01 
0.60 
± .00 
0.18 
± .02 
0.11 
± .01 
0.56 
± .00 
0.04 
± .01 
0.07 
± .00 
16.8 
± 1.7 
IntG 0.44 ± .01 
0.56 
± .01 
0.27 
± .01 
0.39 
± .01 
0.17 
± .00 
0.23 
± .00 
0.05 
± .00 
0.12 
± .00 
7.1 
± 0.1 
5.5.2 Alginate purity 
The effectiveness of the alginate purification process is demonstrated by the results 
presented in Table 5.3. Before their purification, the commercial alginates contained high levels 
of endotoxins (> 12 000 EU/g) and a significant amount of proteins (∼ 9 mg/g). XPS analyses 
were not performed on the non-purified alginates, although previously published results indicate 
that the HiG alginate contained traces of sulphur, phosphorus, and nitrogen [32]. After 
purification, endotoxin levels were reduced 50- to 4000-fold and protein levels were 
significantly lowered (p < 0.05). XPS analyses confirmed that the purified alginates contained 
no detectable traces of foreign elements (i.e. elements other than C, O, and Na) that should be of 
concern for immunogenicity. Chlorine, detected in amounts of < 1 at%, was presumably derived 
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from the NaCl used in the alginate purification process. For a single measurement, silicon (Si) 
was detected, indicating that the silicon wafer substrate was not completely covered by the 
alginate film for this particular sample. Statistically, the purified alginates did not differ 
significantly in purity level. 
Table 5.3 Measured levels of endotoxin, proteins, and foreign elements in sodium alginates before and 
after their purification, as measured by LAL assay, microBCA assay, and XPS. Alginates were dissolved 
in sterile water (1% or 2% w/v). Values represent the mean ± SEM (n = 3 for proteins and for foreign 
elements ; n = 2 (before purification) or n = 4 (after purification) for endotoxins). EU = endotoxin units ; 
at% = relative atomic percentage. 
 
 Proteins Endotoxins Foreign Elements 
Before 
purification 8.6 ± 0.6 mg/g 37000 ± 13000 EU/g n/a 
HiG 
After 
purification 4.3 ± 0.4 mg/g 9 ± 3 EU/g Cl: 0.38 ± 0.28 at% 
Before 
purification 9.3 ± 0.7 mg/g 12250 ± 250 EU/g n/a IntG 
 After 
purification 3.7 ± 0.4 mg/g 231 ± 127 EU/g 
Cl: 0.68 ± 0.40 at% 
Si: 0.64 ± 0.64 at% 
5.5.3 Alginate viscosity 
Solutions of IntG alginate were noticeably more viscous than solutions of HiG alginate. 
Their reduced viscosities ηred and inherent viscosities ηinh were graphed as a function of solution 
concentration, c, for concentrations of ≤ 0.01 g/mL (Figure 5.S1). The plots of ηinh vs. c were 
fairly linear and could therefore be fitted using Kraemer’s equation (Eq. 5.5). However, the plots 
for ηred vs. c were more accurately described by a 2nd order polynomial rather than by a linear 
fit. Therefore, Eq. 5.3 truncated to the 3rd term was used instead of the Huggins equation (Eq. 
5.4) to fit this data. The intercepts of these plots at c = 0 were interpreted as the intrinsic 
viscosities [η] of the alginates. The values of the intercepts are listed in Table 5.4, along with the 
coefficients of determination (R2 values) for the polynomial / linear regressions applied. For the 
same alginate, the values for [η], as estimated by the plot intercepts at c = 0, were in close 
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agreement with each other. The average value for [η] was 213 mL/g for the HiG alginate and 
523 mL/g for the IntG alginate. 
Table 5.4 Intrinsic viscosities [η] of purified sodium alginates as calculated using extrapolations of the 
reduced viscosity (ηred) and the inherent viscosity (ηinh) to zero solute concentration (c = 0). 
 [η] = (ηred)c = 0 [η] = (ηinh)c = 0 Mean [η] 
 
Polynomial 
(R2)  
Intercept 
(c = 0) 
Linear 
(R2) 
Intercept 
(c = 0)  
HiG > 0.99 203 mL/g 0.60 223 mL/g 213 mL/g 
IntG 0.99 546 mL/g 0.90 500 mL/g 523 mL/g 
5.5.4 Alginate gel biocompatibility 
After two days in the peritoneal cavity of C57BL/6J mice, gel beads of IntG alginate 
were consistently almost free of host cell adhesion. This is reflected in a cell adhesion score of < 
1.00 for all mice tested (Figure 5.2(a)). In contrast, gel beads of HiG alginate beads were 
consistently covered with host cells, with cell adhesion scores ranging from 3.20 to 7.70. This 
result was independent of the type of gelling cation (Ca2+ or Ba2+) employed. The difference in 
biocompatibility between the IntG and the HiG alginate was statistically significant for both Ba-
gels (p < 0.001) and Ca-gels (p < 0.05).  
The retrieval rates of the gel beads were variable, ranging from 20 to 90% for individual 
samples (Figure 5.3). Factors that appeared to lower retrieval rates included the poor visibility of 
beads adhered to the recipient organs, the degradation of the beads in vivo, and on the rare 
occasion, leaky catheters or sticking to tubes. The mean retrieval rate for HiG Ba-gel beads 
(38%) was significantly lower (p < 0.05) than for the other three bead types (57% - 62%). In this 
case, sample loss was mainly due to the poor biocompatibility of the HiG beads, which 
generally leads to their adhesion to the peritoneal wall or organs. Furthermore, it was observed 
that explanted beads of IntG alginate tended to be damaged or fragmented (Figure 5.2(c)), while 
beads of HiG alginate were more often intact (Figure 5.2(b)). Despite the apparent fragility of 
the IntG samples, these biocompatible beads were, on average, recovered in higher proportions 
than the HiG gel beads. 
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Figure 5.2 Extent of host cell adhesion to Ba- and Ca-gel beads of purified alginate retrieved after 2 days 
in the peritoneal cavity of C57BL/6J mice. (a) Cell adhesion is represented by a score, on a scale of 0 (no 
cell adhesion) to 10 (complete coverage by host cells), as described in Table 5.1. Each point represents 
an individual mouse. Bars represent the mean cell adhesion score ± SEM. *** p < 0.001, * p < 0.05. 
Typical samples of (b) HiG Ba-gel beads and (c) IntG Ba-gel beads upon explantation, as viewed 
through optical microscope. 
 
 
(a) 
(c) (b) 
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Figure 5.3 Proportion of Ba- and Ca-gel beads of purified alginate retrieved after 2 days in the peritoneal 
cavity of C57BL/6J mice. Retrieval rates represent the percentage of 500 implanted beads that were 
recovered intact upon explantation. Each point represents an individual mouse. Bars represent the mean 
retrieval rate ± SEM. * p < 0.05. 
5.5.5 Elemental composition of alginates and gels 
The survey scans acquired by XPS indicate that the elemental composition of the HiG 
and the IntG alginate were similar in many aspects (Table 5.5). The basic structure of the 
alginate, which is represented by the relative proportions of carbon and oxygen, was consistent 
for all the samples tested, as C/O ratios were maintained between 1.2 and 1.6. 
The relative quantities of the counterions, namely sodium (Na), barium (Ba), and 
calcium (Ca) were also measured in each sample, thus providing an estimate of the replacement 
of Na+ by Ba2+ and Ca2+ counterions upon gelation. In the sodium alginates, Na was detected in 
amounts of 2.0 ± 0.6 at% for the HiG alginate and 5.1 ± 1.4 at% for the IntG alginate. This 
difference was not statistically significant. As the alginates were converted to gel beads, Na 
levels increased in most cases, reaching amounts of 4.4 to 6.8 at%. This excess sodium was 
attributed to NaCl salt deposits on the dehydrated samples since chlorine (Cl) was detected on 
numerous occasions (results not shown), and crystallization could be observed when the films 
were examined through a microscope. On the surface of Ba-gel beads, barium was detected only 
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in minimal amounts ( ≤ 0.6 at%). These gels were also contaminated with traces of calcium (≤ 
0.6 at%), which were assumed to originate from the Ringer’s solution used to rinse the beads 
during sample preparation. As for the Ca-gels, calcium quantities were also quite low, with 
values ≤ 1.5 at%. 
Table 5.5 Results from XPS survey scans of purified sodium alginate (Na-Alg), beads of Ba2+-
crosslinked alginate (Ba-gel), and beads of Ca2+-crosslinked alginate (Ca-gel). Values represent the mean 
± SEM (n = 3 for Na-Alg ; n = 2 for gels). at% = relative atomic percentage. 
  Alginate structure Counterions 
  C/O ratio C at% O at% Na at% Ba at% Ca at% 
HiG 1.5 ± 0.1 59.1 ± 1.9 38.5 ± 1.5 2.0 ± 0.6 - - 
Na-Alg 
IntG 1.4 ± 0.1 54.3 ± 1.4 37.9 ± 2.0 5.7 ± 1.6 - - 
HiG 1.4 ± 0.1 48.1 ± 0.1 33.6 ± 1.6 6.7 ± 1.4 0.6 ± 0.0 0.3 ± 0.3 
Ba-gel 
IntG 1.6 ± 0.1 49.7 ± 2.2 31.2 ± 3.7 6.8 ± 1.0 0.3 ± 0.3 0.6 ± 0.0 
HiG 1.2 ± 0.2 43.6 ± 2.2 36.1 ± 3.7 6.4 ± 4.2 - 1.4 ± 0.0 
Ca-gel 
IntG 1.3 ± 0.1 48.6 ± 3.6 37.1 ± 0.5 4.4 ± 3.1 - 1.5 ± 0.1 
5.5.6 Molecular composition of alginates and gels 
FTIR spectra of the sodium alginates (Figure 5.4) reflected their differing M/G content, 
as interpreted by the placement and intensity of absorbance peaks that have been previously 
associated with varying G or M content in alginates [33, 34]. In this case, the higher G content 
of the HiG alginate was represented by more prominent peaks at 1320 cm-1, 1125 cm-1, 950 cm-1 
and 940 cm-1, as well as a peak at 905 cm-1 and a distinct shoulder at 1000 cm-1. For the IntG 
alginate, the higher M content was associated with a more prominent peak at 1300 cm-1, a 
shoulder at 1180 cm-1, increased absorbance at 1150 cm-1, slight shoulders at 1100 cm-1 and 
1040 cm-1, and a peak at 890 cm-1. Also indicative of the differing M/G content [34], the peak 
associated with OH bending was at a slightly higher wavenumber in the spectrum for IntG 
alginate (1027 cm-1) compared to the peak placement in the HiG alginate spectrum (1024 cm-1). 
Moreover, the ratio of absorbances for the peaks at 1030 cm-1 and 1080 cm-1 was 1.6 ± 0.1 for 
the HiG sample and 1.7 ± 0.1 for the IntG sample. 
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Figure 5.4 Fingerprint region of FTIR spectra for purified sodium alginate (Na-Alg), beads of Ba2+-
crosslinked alginate (Ba-gel), and beads Ca2+-crosslinked alginate (Ca-gel). Spectra are representative of 
each sample type. Positions for labelled peaks are listed in Table 5.6. 
When the alginates took the form of Ba- and Ca-gels, a number of slight changes in the 
IR absorbance spectra confirmed the exchange of counterions [33, 35]. The most obvious was a 
shift of the COO− asymmetric stretch peak (∼ 1600 cm-1) to values 5-6 cm-1 lower (Table 5.6). 
Also observed were a slight shift of the COO− symmetric stretch peak (∼ 1410 cm-1) to higher 
wavenumbers, C-C stretch peak (∼ 1125 cm-1) and C-O-C stretch peak (∼ 1080 cm-1) to lower 
wavenumbers, and more pronounced shoulders of the O-H bend peak at ∼ 1025 cm-1. The ratio 
of absorbances of the peaks at 1080 cm-1 and 1125 cm-1 decreased from 1.7 ± 0.1 (Na-Alg) to 
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1.5 ± 0.1 (Ba-gel) and 1.6 ± 0.0 (Ca-gel) for the HiG alginate. Similarly, this ratio decreased 
from 1.8 ± 0.1 (Na-Alg) to 1.7 ± 0.0 (Ca-gel) for the IntG alginate (the ratio remained 1.8 ± 0.0 
for the Ba-gel). This is also a sign of the Na+ ions being exchanged for Ba2+ or Ca2+ ions [33]. 
Overall, peak shifts associated with ion exchange during the conversion from sodium alginate to 
gel were similar in magnitude between the HiG and the IntG samples (Table 5.6). 
Table 5.6 Characteristic peaks in the FTIR spectra of purified sodium alginate (Na-Alg), beads of Ba2+-
crosslinked alginate (Ba-gel), and beads Ca2+-crosslinked alginate (Ca-gel). Values represent the mean 
wavenumber ± SEM (n=2). 
Peak assignment Peak wavenumber (cm-1) 
 
HiG IntG 
 Na-Alg Ba-gel Ca-gel Na-Alg Ba-gel Ca-gel 
COO−  str (asym) 1599 ± 1 1594 ± 1 1593 ± 0 1598 ± 1 1592 ± 1 1593 ± 0 
COO− str (sym) 1408 ± 0 1407 ± 1 1409 ± 1 1407 ± 1 1409 ± 1 1410 ± 0 
C-C str 1123 ± 0 1120 ± 4 1121 ± 2 1124 ± 0 1123 ± 0 1123 ± 0 
C-O-C str (ring) 1083 ± 1 1080 ± 0 1079 ± 1 1083 ± 1 1080 ± 0 1078 ± 0 
O-H bend 1024 ± 0 1023 ± 1 1024 ± 0 1027 ± 1 1027 ± 1 1028 ± 0  
5.5.7 Alginate and gel wettability 
The contact angle values of 1.0 µL water droplets on sample films are graphed in Figure 
5.5. Films made from sodium alginate solutions (2.0% w/v in water) produced contact angles of 
44.6 ± 2.8° for HiG alginate and 45.7 ± 2.5° for IntG alginate. When the same alginates were 
crosslinked with Ba2+ ions (Ba-gel) or Ca2+ ions (Ca-gel), the films became significantly more 
hydrophilic; the water droplets spread quickly and their contact angles were lower, ranging from 
10.0° to 14.2°. The contact angles were statistically equal between the two alginate types, 
regardless of whether the films were based on an aqueous solution or a gel. 
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Figure 5.5 Wettability of dry films of purified sodium alginate (Na-Alg), Ba-gel, and Ca-gel. Wettability 
is represented by the contact angle of a 1.0 µL water droplet on the film, with lower angles indicating a 
greater wettability. Bars represent the mean contact angle ± SEM (n = 3 for Na-Alg ; n = 5 for the gels). 
5.5.8 Swelling and degradation of alginate gel beads 
As shown in Figure 5.6, all of the gel beads tested behaved similarly as they were 
immersed in the first rinse of 1 mL of sterile water. That is, all samples swelled to an average of 
183 – 197% of their original diameter. Moreover, less than 13% of the beads underwent 
degradation, as defined by an inability to see the beads or measure their diameters using light 
microscopy. As the beads were subjected to a second rinse of pure water, the HiG Ba-gel beads 
showed to be much more stable than the rest. This was the only sample type to not degrade any 
further. In contrast, the HiG Ca-gel beads as well as both types of IntG beads were > 80% 
degraded. Also at the second rinse, judging from what remained measureable, the IntG Ba-gel 
beads were on average much more swollen (351% of the original diameter) than the other gel 
types (232 - 249% of the original diameter). By the third rinse, the HiG Ba-gel beads were the 
only bead type that remained relatively intact with 22% degraded, vs. 91% of the HiG Ca-gel 
beads and 100% of the IntG beads degraded (Figure 5.6 (b)). 
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Figure 5.6 Swelling and degradation of gel beads of purified alginate with successive rinses in water. 
Each rinse consists of immersing 30 ± 5 beads in 1 mL of pure water for 5 – 10 min. (a) Swelling is 
represented by the percentage increase in bead diameter, as measured using optical microscopy. (b) 
Degradation is associated with an inability to see the bead or to measure its diameter using the 
microscope. Bars represent the mean percentage ± SEM (n = 3).  
 
 
(b) 
(a) 
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5.6 Discussion 
The in vivo biocompatibility of alginate gels was significantly different for the two types 
of commercially available alginates studied, namely one alginate with a high guluronate content 
(HiG) and one with an intermediate guluronate content (IntG). Biocompatibility was evaluated 
in terms of host cell adhesion to alginate gel beads after two days in the peritoneal cavity of 
male C57BL/6J mice, as well as the proportion of beads that could be retrieved upon 
explantation. After the implantation period, gel beads of IntG alginate were consistently free of 
cell adhesion, while gel beads of HiG alginate were almost always covered with host cells 
(Figure 5.2). The use of IntG alginate also led to higher retrieval rates (Figure 5.3). This 
discrepancy between the biocompatibility of HiG and IntG gel beads was observed regardless of 
the crosslinking ion used (Ba2+ vs. Ca2+). 
Purity is essential for achieving the biocompatibility of alginates intended for cell 
encapsulation, as well as to be able to pinpoint the influence of alginate characteristics on 
biocompatibility without the interference of immunogenic contaminants. Once purified, the 
alginates used in this study were confirmed to have relatively low levels of proteins (< 5 mg/g) 
and endotoxins (< 250 EU/g), and no detectable traces of foreign elements. When the same 
purification method was applied earlier in our lab, protein levels were reduced to as little as 0.5 
mg/g in the HiG alginate [9]. Between different batches of purified IntG alginate, we also 
noticed a tendency for the endotoxin content to vary (by several hundred EU/g). These 
fluctuations in purity demonstrate one of the potential drawbacks of purifying alginates in-
house, as the final quality of the alginate can depend on the person applying the protocol or the 
specific purification batch. As an alternative option, a number of companies now offer a range 
of ultrapure alginates that may be suitable for overcoming such limitations. However, we chose 
to purify own alginates for this study because we have observed that (for HiG alginate) our in-
house purified alginate can be more pure than at least one brand of industrially purified alginate 
[9]. Between the two alginates that were investigated in this study, the IntG alginate tended to 
have higher endotoxin levels (231 EU/g) than the HiG alginate (9 EU/g), while quantities of 
detected proteins and foreign elements were similar in both cases. Despite their higher 
endotoxin content, the purified IntG alginate did not induce a significant immune response, as 
indicated by the lack of immune cell adhesion to the gel beads in vivo. Thus, the possibility that 
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contamination was responsible for the immune response to the HiG alginate beads was 
excluded. 
One of the most obvious differences between the alginates studied was the fraction and 
distribution of guluronate (G) and mannuronate (M) residues within the samples (Table 5.2). In 
this case, gel beads based on the alginate with less guluronate (IntG : 44%G), including fewer 
and shorter blocks of consecutive G residues, were clearly more biocompatible than gels of an 
alginate with a high G content (HiG : 71%G). Earlier studies have stirred somewhat of a debate 
about the effect of M/G content of alginates on their biocompatibilities : The M-blocks of 
soluble alginate have been held responsible for stimulating monocytes to produce cytokines [36, 
37] and induce antibody responses [19]. When in the form of implantable microcapsules with a 
poly-L-lysine (PLL) membrane, samples based on alginates with a higher M content have shown 
to be more immunogenic by some [19, 38], yet less immunogenic by others [16, 17]. More 
recently, Duvivier-Kali et al compared the biocompatibility of gel beads (without PLL) made 
with alginates having similar M/G contents to the alginates in this study [18]. Despite their use 
of mouse species that differed from ours (NOD and BalB/c) as transplant recipients, their results 
were similar to our own. This included a tendency for less cell adhesion, yet more fragmentation 
and swelling, for the gel beads of ‘High M’ alginate (61%M) in comparison with gel beads of 
‘High G’ alginate (70%G). The same group later published another study that included a 
comparison of the in vivo biocompatibility of barium alginate gel beads made from 
commercially available alginates that varied in M/G content [39]. This time, they observed that 
the alginate M/G content had only a modest effect on the proportion of explanted beads with 
adherent cells. Although this shift in perspective could have been explained by the fact that they 
switched to Lewis rats as transplant recipients, others have also seen that, as long as the alginate 
is purified, it can be biocompatible, regardless of the M/G content [8, 17, 40]. In this study, 
various other physico-chemical details of the alginates and their gels were examined in an 
attempt to either clarify the role of M/G content in influencing biocompatibility, or to offer 
alternative explanations for their different immunogenicities. 
The elemental compositions of the alginates and gels were analyzed in order to verify 
whether different effects of the alginate structure on counterion exchange could explain their 
difference in biocompatibility. In particular, there is published evidence that unbound ions 
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(particularly Ba2+) can be cytotoxic [41] and are capable of leaching out of alginate-based 
microcapsules [42] , therefore higher concentrations of counterions may hypothetically 
contribute to non-biocompatibility of the implant. Moreover, alginate with a higher G content is 
expected to bind more gelling ions because consecutive GG blocks provide the binding sites for 
crosslinking divalent cations in association with an ‘egg-box’ structure [4, 43]. However, our 
XPS results showed that the HiG alginate did not crosslink greater amounts of Ba2+ ions (nor 
Ca2+ ions) than the IntG alginate (Table 5.5), thus the hypothesis that the HiG alginate gel was 
more immunogenic because it contained higher concentrations of barium that could potentially 
leach out was excluded. 
As a useful technique for monitoring intermolecular interactions, FTIR was also 
employed in this study in an attempt to explain the gel biocompatibility results in terms of the 
efficiency of alginate-counterion binding. Our results (Figure 5.4, Table 5.6) confirmed that there 
was indeed counterion exchange during gelation of the alginates, but also that molecular 
changes during this transformation were fairly minor, as peak alterations associated with ion 
exchange were quite subtle in this case, at least compared to observations made by others [33, 
35]. Although the FTIR results also confirmed the difference in M/G content between the HiG 
alginate and the IntG alginate, there was no strong evidence that one alginate type interacted 
with the counterions more strongly than the other. These results supported those of the XPS 
analyses. 
The biocompatibility of alginates and other hydrogels is often said to be attributed to the 
hydrophilic nature of these materials [2], which explains our interest in measuring the 
interaction of our samples with water. However, the HiG alginate and the IntG alginate samples 
showed similar wettabilities, as measured by the contact angle of water on dry films (Figure 
5.5). This result indicates that both alginates had the same proportion of hydrophilic groups 
available for rehydration, regardless of the counterion (Na+, Ca2+, Ba2+) involved. While this 
also confirms our previous observations that the contact angle is directly associated with the 
purity level of the alginates [32] (which was very similar for the two alginates studied here), this 
parameter did not correlate with the biocompatibility of the alginates. This situation highlights 
the limitation of using dry samples to interpret the relationship between alginate hydrophilicity 
and biocompatibility. Indeed, the alginate gels are fully hydrated when in contact with 
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biological tissues and fluids in vivo. In an attempt to better represent the in vivo situation, 
preliminary investigations of the wettability of hydrated alginate gels have been performed by 
measuring the contact angle of air bubbles on gels immersed in liquids. We observed that the air 
bubbles rolled off of all of the alginate gels that were studied (results unpublished), indicating 
complete hydrophilicity of the gels in their hydrated state regardless of the quality of the 
alginate, and furthermore, confirming that hydrophilicity is not a determining factor for alginate 
biocompatibility. 
By extrapolating the values of reduced and inherent viscosities of dilute solutions to zero 
concentration (c → 0), the intrinsic viscosity of a polymer can be estimated according to 
relations developed by Huggins [30, 44] and Kraemer [31]. In this study, the plots of ηred vs. c 
were better described by a 2nd order polynomial fit, corresponding to Eq. 5.3 truncated to the 3rd 
term, rather than by a linear fit associated with Huggins’ equation. The intrinsic viscosity was 
nevertheless estimated using the c = 0 intercept of this plot. This was justified by the fact that 
the intercepts of the two plots coincided nicely (Table 5.4) and that others have also used non-
linear fits to estimate the intrinsic viscosity of alginate samples [45, 46]. Using this approach, it 
was determined that the HiG alginate had an intrinsic viscosity of 213 mL/g, a value that was 
less than half of that for the IntG alginate (523 mL/g). Assuming the applicability of the Mark-
Houwink equation (Eq. 5.6) [47], the intrinsic viscosity [η] is directly associated with the 
viscosity average molecular mass of the sample, vM . 
Eq. 5.6  [ ] avMK=η   
In Eq. 5.6, K and a are constants for a particular polymer, solvent and temperature. For 
alginates dissolved in 0.1 M NaCl, the value for a is generally close to unity [22]. This implies 
that, based on the measured values for intrinsic viscosity, the average molecular mass of the 
IntG alginate is 2.5 times greater than that of the HiG alginate. Overall, this data suggests that a 
higher average molecular mass, or a higher intrinsic viscosity, could be favourable for the 
biocompatibility of alginate gels. We are not the first to observe this trend [12]. In our case, 
however, it is highly unlikely that oligosaccharides are responsible for the immunogenicity of 
HiG alginate, since the purification process, which included chemical extractions of Ba-gel 
beads and solution dialysis through a 50,000 Da MWCO membrane, should have rid the alginate 
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samples of low molecular weight fractions that are not properly bound during the gelation 
process. Indeed, we have observed that purifying our alginates has the effect of increasing their 
solution viscosity [32]. Otterlei et al observed that higher molecular weights of mannuronic acid 
favour cytokine production by monocytes [48], but this effect was observed for alginate 
solutions in vitro, and may not be comparable to our results using alginate gels in vivo. 
Zimmermann et al have stressed the importance of the use of a ultra-high viscosity (UHV) 
alginate for the improved biocompatibility of alginate gels, in association with the influence of 
vicosity on gelation properties, including swelling and surface roughness [15, 49, 50]. Although 
the alginates used in this study cannot be considered as UHV, our results support the notion that 
higher viscosity (or higher molecular mass) leads to better biocompatibility when the alginates 
are in the form of gel beads. 
Because of the difference in molecular mass between the two alginates studied, we were 
obliged to use two different concentrations of alginates (2.0% w/v  for HiG ; 1.63% w/v for 
IntG) in order to target the optimal solution viscosity for spherical bead production (220 ± 20 
cps). The alginate concentration is considered to have an effect on the strength and rigidity of 
the gel [51], which is important to keep in mind because such physical properties of the gel may 
in turn influence the gel biocompatibility, as discussed in the next paragraph. 
The stability of the alginate gels were tested in vitro by rinsing gel beads with pure water 
and observing to what extent they swelled and degraded. It was observed that gels of HiG 
alginate, particularly the Ba-gels, were remarkably more resistant to swelling and degradation 
than the IntG gels (Figure 5.6). Moreover, after two days in the peritoneal cavity of mice, the 
IntG alginate gel beads showed signs of damage and fragmentation (Figure 5.2(c)), while the 
HiG gel beads stayed firm and round (Figure 5.2(b)). Since it is mainly the longer, and stiffer, 
blocks of consecutive G residues that participate in the crosslinking of alginate chains [4, 52], 
these results were not unexpected. As confirmed by NMR (Table 5.2), the value for NG>1 was 
16.8 for the HiG alginate, but only 7.1 for the IntG alginate. Despite the observation that the 
IntG gel was less stable both in water and in vivo, retrieval rates were higher than for the HiG 
gel. This illustrates that fragmentation of the beads was less of a problem for retrieval rates than 
the immunogenicity of the HiG gel beads, which tended to be overgrown with cells and adhered 
to recipient organs and peritoneal wall. While the lower stability of the IntG gel may make this 
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alginate less suitable for immobilizing cells and tissues, its biocompatibility was not 
compromised. In fact, it is quite possible that the swelling properties of the alginate gels 
contributed to their difference in biocompatibility. The biocompatibility of hydrogels is 
generally attributed to their hydrophilicity, chain mobility at the surface, decreased interfacial 
tension with surrounding biological fluids and tissues, softness and pliability [53]. These 
characteristics of hydrogels are believed to minimize the adsorption of proteins and cells that 
lead to an immune response, as well as reduce frictional forces with surrounding tissues that can 
lead to fibrosis. For those gels that are more apt to swelling and taking up water, these 
favourable properties of hydrogels for biocompatibility are perhaps better enhanced. Indeed, it 
was observed that the IntG gels that swelled more in vitro and in vivo were also the more 
biocompatible. As for the HiG alginate gels, although the Ca-gel was more prone to swelling 
than the Ba-gel upon immersion in pure water, the Ca-gel remained just as firm as the Ba-gel 
when placed in an in vivo environment, explaining why an enhanced biocompatibility associated 
with swelling was not observed for the Ca-gels of HiG alginate. 
An overview of the results of this study suggest that the main factors that determine 
alginate gel biocompatibility are the relative proportion of guluronate (G) and mannuronate (M) 
and the intrinsic viscosity (related to molecular mass) of the alginate. Without being able to 
isolate and change one variable at a time, however, no definite conclusions can be made about 
the relative importance of these parameters for gel biocompatibility. In most likelihood, it is a 
combined effect of the alginate’s M/G content and molecular mass that ultimately governs its 
biocompatibility, via the influence of these characteristics on the physical properties of the 
crosslinked gel such as stability and swelling [52, 54]. Such a statement should nevertheless be 
verified experimentally in future studies. This would require the use of alginates with tightly 
controlled properties, such as epimerized alginates with tailored MG composition [55] or 
alginates that are extracted directly from freshly harvested stipes of algae rather than industrially 
processed [56]. 
5.7 Conclusion 
Results of this study indicate that the biocompatibility of purified alginate gels is 
influenced by the proportion and distribution of mannuronate (M) and guluronate (G) residues 
within the alginate, as well as its intrinsic viscosity, although the relative importance of each 
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parameter remains to be determined. This can be explained by the effects of both monomer 
conformation and distribution and polymer chain length on the physical properties of the 
resulting cross-linked gels, including the swelling ability and stability of the hydrated gel. In 
contrast, neither the elemental composition of the alginates, including counterion amounts, nor 
the wettability of the samples, were a predictive factor for their biocompatibility. In this study, 
the alginate with intermediate G content (44 %G) and higher intrinsic viscosity (523 mL/g) 
resulted in gel beads that were much more biocompatible than those made from an alginate 
having 71% G and an intrinsic viscosity of 213 mL/g. The superior biocompatibility of the IntG 
gel beads was not affected by their susceptibility to swelling and fragmentation; in contrast, the 
tendency of these beads to swell up with water could be favourable to their biocompatibility. 
Overall, the use of an alginate of ∼ 40% G and high molecular mass is recommended for the 
production of biocompatible gels, although caution should be made when using such gels for 
cell immobilization purposes due to its lack of stability in vivo. 
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5.10 Supplementary data 
 
Figure 5.S1 Plots of reduced viscosity, ηred (circles), and inherent viscosity, ηinh (diamonds), against 
concentration, c, for sodium alginates dissolved ≤ 0.01 g/mL in 154 mM saline (12.5 mM HEPES, pH 
7.4). Data points represent the mean value ± SEM for two different purification batches (n = 3). 
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6.1 Abstract 
There is a need to better understand the biocompatibility of alginate-polycation 
microcapsules based on their physicochemical characteristics. Microcapsules composed of 
alginate with 44% (IntG) or 71% (HiG) guluronate, gelled with calcium (Ca) or barium (Ba), 
and coated with poly-L-lysine (PLL) or poly-L-ornithine (PLO), followed by IntG alginate were 
compared. For microcapsules with an IntG(Ca) gel core, using PLO instead of PLL resulted in 
less immune cell adhesion after two days in C57BL/6J mice. The PLO microcapsules were also 
characterized by a greater hydrophilicity and superior resistance to swelling and damage under 
osmotic stress. For microcapsules with a PLL membrane, replacing the IntG(Ca) gel core with 
IntG(Ba) or HiG(Ca) gel resulted in stronger immune responses (p < 0.05). This was explained 
by poor penetration of PLL into the gel, as demonstrated by FTIR analyses and membrane 
rupturing during osmotic swelling. XPS analyses show that all microcapsules had the same 
amount of polycation at their surface. Moreover, alginate coatings had non-significant effects on 
the biocompatibility and physicochemical properties of the microcapsules. Thus, alginate-
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polycation interactions for membrane formation are more important for biocompatibility than 
each the quantity of polycation at the surface and the alginate coating. 
6.2 Keywords 
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6.3 Introduction 
Alginate-polycation microcapsules are still the most commonly studied devices for the 
immunoprotection of transplanted therapeutic cells and tissues [1-4], yet their biocompatibility 
remains variable and insufficiently understood [5, 6]. In the case of inadequate biocompatibility, 
the release of cytokines from nearby activated macrophages, cellular overgrowth and the 
development of fibrotic tissue surrounding the implant contribute greatly to encapsulated graft 
failure [7-9]. While at least one group has demonstrated that it is possible to produce alginate-
polycation microcapsules that induce a minimal immune response [10], first-hand experience 
and an overview of published works indicate that such promising results are difficult to 
reproduce despite the use of similar capsule structures [11, 12]. Indeed, the design and 
production of microcapsules intended for cell transplantation lacks official standardization, 
which is the result of in-house protocols and an incomplete understanding the physicochemical 
details of the microcapsule in relation to bioperformance [13]. This situation has the unfortunate 
consequence of hindering our ability to predict and reproduce the in vivo performance of the 
microcapsules, and ultimately delaying the progress of encapsulated cell transplantation towards 
regular clinical application. 
Of the various types of the alginate-polycation microcapsules that have been studied 
over the past three decades, the alginate-poly-L-lysine-alginate (APA) microcapsule, based on 
the early work of Lim and Sun [14], represents the “classic” design. Other variations of the APA 
microcapsule have been investigated in more recent years, including the replacement of poly-L-
lysine (PLL) with chitosan [15, 16], poly(methylene-co-guanidine) (PMCG) [17], poly-L-
ornithine (PLO) [18, 19], or the use of multilayers [20, 21]. However, alginate-PLL-alginate and 
alginate-PLO-alginate  microcapsules have dominated the few clinical trials of 
microencapsulated cell transplantation that have been attempted to date [22-24]. Using each of 
these microcapsule designs, the applicability of encapsulated cell transplantation has 
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successfully been demonstrated in humans, but long-term viability of the grafts has been proven 
difficult to maintain, thus highlighting the need to continue optimizing the microcapsule design.  
As a strategy to optimizing the microcapsule design, we chose to investigate the 
relationships between the in vivo biocompatibility and the physicochemical characteristics of 
alginate-polycation microcapsules of different design. In addition to characterising the “classic” 
alginate-PLL-alginate microcapsule, the effect of replacing the PLL with the PLO was 
examined. PLO is an interesting candidate for biocompatibility studies not only because of its 
recent role in clinical trials of encapsulated cell transplantation, but also because it is so 
similarly structured to PLL. Furthermore, we investigated the consequence of altering the gel 
core properties as a strategy to increasing capsule stability, i.e. by substituting the crosslinking 
ion (Ba2+ for Ca2+) or the type of alginate (high guluronate content for intermediate) before 
adding the capsule membrane. Samples without a polycation or an alginate coating were also 
analysed in order to study the roles of these fabrication steps on the microcapsule properties and 
bioperformance. The aim of this work was to elucidate correlations between the structure, 
physicochemical properties, and the in vivo biocompatibility of alginate-polycation 
microcapsules, with the intent of developing the necessary tools for optimizing the microcapsule 
design. The study was designed to provide information about polymer-to-polymer interactions 
within the capsule membrane and the exposure of functional groups on the capsule surface, as 
these factors are expected to directly influence the stability and immunogenicity of the 
microcapsule. Studies that focus on this kind of analytical approach have rarely been published 
in the case of alginate-polycation microcapsules for cell encapsulation, despite a clear need for 
this type of work in order to establish standards necessary for the advancement of cell 
encapsulation technology to clinical trials. 
6.4 Materials and Methods 
6.4.1 Materials 
Sodium alginates. “IntG” alginate (Keltone® LVCR, CAS 9005-383-3, lot 721322) was 
provided by ISP Corporation (NJ, USA). “HiG” alginate (Protanal® LF10/60, batch S13636) 
was provided by FMC BioPolymer (Drammen, Norway). The alginates were purified in-house 
before their use, as previously described [25, 26]. After their purification, the alginates 
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contained < 5 mg/g of proteins (microBCA assay), < 250 EU/g of endotoxins (LAL assay), and 
no traces of foreign elements (XPS). The proportion and distribution of guluronate to 
mannuronate monomers and the intrinsic viscometries of each type of alginate (after their 
purification) are shown in Table 6.1. 
Polycations. Poly-L-lysine (PLL) hydrobromide (product no. P7890; CAS 25988-63-0) 
and Poly-L-ornithine (PLO) hydrochloride (product no. P2533; CAS 26982-21-8) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). The degree of polymerization and 
molecular weights of these polycations are presented in Table 6.1. 
Table 6.1 Description of polymers used for microcapsule fabrication. 
Alginate IntG HiG 
Molecular structure 1 
 
Composition 2 FG = 0.44 ; FGG = 0.27 ; FMM = 0.39 ; FGM = 0.17 ; NG>1 = 7.1 
FG = 0.71 ; FGG = 0.60 ; FMM = 0.18 ; 
FGM = 0.11 ; NG>1 = 16.8 
Intrinsic viscosity 3 523 mL/g 213 mL/g 
Polycation PLL PLO 
Molecular structure 
 
 
Degree of 
polymerization 4 126 VIS 192 VIS ; 113 MALLS 
Molecular weight 4 26 300 VIS ; 15 000 MALLS 28 900 VIS ; 17 070 MALLS 
1
 Example of a –GGMM– segment within an alginate molecule 
2
 As determined by proton nuclear magnetic resonance 
3
 As determined by rotational viscometry 
4
 As specified by the manufacturer 
G = guluronate residue ; M = mannuronate residue 
VIS = viscometry ; MALLS = multi-angle laser light scattering 
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All solutions were sterilized by filtration (0.22 µm) before their use. Reusable labware 
was specially cleaned and sterilized by Pasteur oven (200°C for 2h), ethylene oxide (EO) or 
autoclave before their use. Disposable plastic materials were considered as sterile. 
Manipulations were performed under sterile conditions whenever possible. 
6.4.2 Microcapsule fabrication 
Alginates were dissolved at a concentration of either 1.63% w/v (IntG) or 2.0% w/v 
(HiG) in 154 mM saline (12.5 mM HEPES, pH 7.4) and filtered 0.22 µm. These concentrations 
were selected to target a suitable viscosity (220 ± 20 cps) for droplet production. The alginate 
solution was extruded through a 25G blunt tip needle using a mechanically driven syringe, while 
droplets were detached from the needle tip using a pulsed electrostatic droplet generator. The 
droplets were converted into gel beads by immersing them in a crosslinking solution for 30 min, 
either 10 mM BaCl2 (16 mM HEPES, pH 7.4) or 100 mM Ca Lactate. If no membrane was 
added, the gel beads were rinsed three times and then stored in Ringer’s solution (154 mM 
NaCl, 5.6 mM KCl, 1.7 mM CaCl2, 5 mM HEPES, pH 7.4), noting that Ringer’s solution 
induced less swelling of the gel beads than saline. To form microcapsules, polycationic 
membranes were added to the gel beads by immersing them for 5 min in a solution of either 
PLL or PLO (0.05% w/v in saline, filtered 0.22 µm). For certain microcapsules, alginate was 
also added to the membrane by rinsing once with saline then immersing for 5 min in alginate 
solution (diluted 1:10 in saline). Microcapsules were then rinsed three times and stored in saline. 
Throughout the manuscript, beads and microcapsules are described according to their 
components, using the notation “alginate(crosslinker)/polycation/alginate”. 
6.4.3 In vivo Biocompatibility 
Samples of 500 gel beads or microcapsules were handpicked to exclude individual 
beads/capsules with defects. The samples were injected, via a 22G catheter, into the peritoneal 
cavity of male C57BL/6J mice (Jackson Laboratory, Maine, USA). After two days, the beads or 
capsules were explanted. To do so, the mice were euthanized by cervical dislocation and a small 
ventral incision was made. The peritoneal cavity was flushed using ∼ 30 mL of either Ringer’s 
solution (for beads) or saline (for capsules). After flushing, the cavity was opened and inspected 
for samples adhered to the organs or wall of the peritoneum. The explanted beads/capsules were 
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separated from free-floating cells by rinsing the samples over a 41 µm nylon mesh. The 
explanted samples were then inspected under optical microscope. Each bead or capsule retrieved 
was classified into one of four categories according to the extent of host cell adhesion to its 
surface, as described in Table 6.2. For each capsule type, at least two separate batches of 
capsules were tested in a minimum of three mice (n ≥ 3). 
For each explanted sample, a ‘cell adhesion score’ was calculated using a weighted 
scoring system described by Eq. 6.1. The parameters A, B, C, and D are the number of 
beads/capsules retrieved that fall into categories A, B, C, or D, respectively (Table 6.2), and tot 
is the total number of beads that were retrieved for that sample. On average, the value for tot 
was 50% ± 15%, and this value did not change significantly between different microcapsule 
designs. 
Table 6.2 Classification of beads/capsules retrieved after two days in the peritoneal cavity of C57BL/6J 
mice, according to the extent of host cell adhesion to the bead surface. This classification system is used 
to calculate the cell adhesion score (Eq. 6.1). 
Category A B C D 
Portion of bead 
surface covered 
by host cells 
none 
 
< 50% 
 
> 50% 
 
100% 
 
Score 0 3.3 6.6 10 
Eq. 6.1  





×+





×+





×+





×=
tot
D
tot
C
tot
B
tot
A
scoreadhesioncell 106.63.30  
Protocols for in vivo studies were approved by the animal care ethics committee of the 
Maisonneuve-Rosemont Hospital Research Centre and have been stated to conform to the 
ethical guidelines of the Canadian Council for Animal Care. These guidelines were respected 
throughout this study. 
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6.4.4 X-Ray Photoelectron Spectroscopy (XPS) 
XPS was used to quantitatively determine the elemental composition of the bead and 
capsule surfaces (with the exception of hydrogen, H, which is not detectable by XPS). Before 
their analysis, the samples (∼ 1 mL of beads/capsules) were quickly rinsed with 10 mL of sterile 
water in order to remove excess salts that could interfere with the interpretation of the results. 
The water was removed and the samples were transferred onto a 1 cm × 1 cm square of silicon 
wafer. For the polycation controls, 1.0% w/v aqueous solutions of PLL or PLO were spread on 
the wafer squares to form films. All samples were allowed to dry ≥ 24h under a sterile flowhood 
followed by ≥ 24h in a vacuum before being analyzed by XPS. 
XPS spectra were acquired and processed using an Escalab MKII Surface Analysis 
System equipped with an Avantage data system (Thermo VG Scientific, West Sussex, UK). An 
unmonochromated Mg Kα source anode operated at 216 W (18 mA, 12 kV) was used to 
generate x-rays. Survey spectra were recorded for a single scan of 0-1200 eV binding energy 
range, at a pass energy of 100 eV. Charge shift corrections of the spectra were made by setting 
the C1s peak to 285.0 eV. Peaks integrations were calculated with subtraction of a Shirley 
background. For each bead or capsule type, two separate batches were analyzed (n = 2). 
6.4.5 Micro-Attenuated Total Reflectance Fourier Transform Infrared 
Spectroscopy (ATR-FTIR) 
MicroATR-FTIR was used to estimate the relative proportions of alginate to polycation 
within the capsule membranes, as well as observe the molecular interactions between these 
polymers. FTIR spectra were acquired using a Varian 7000 FT-IR Research Spectrometer 
equipped with a UMA 600 microscope and germanium microATR crystal (Digilab®, Randolph, 
MA, USA). Samples and controls were prepared and dehydrated onto squares of silicon wafer as 
described in section 6.4.4. Using the microscope view as a guide, the microATR crystal was 
gently pressed against a single bead/capsule (or a film, for the controls). Sample spectra were 
recorded for a range of 4000 to 700 cm-1 at a resolution of 4 cm-1, with 128 scans co-added per 
spectrum. Background spectra consisted of the bare crystal under the same experimental 
conditions. For each bead or capsule type, two separate batches were analyzed (n = 2). 
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6.4.6 Contact angle technique 
Sample films were cast on microscope slides pre-coated with poly-L-lysine (PLL). The 
PLL enhanced film adhesion to the slides yet had no impact on contact angle values (results not 
published). To coat the slides, they were cleaned (10 min in 1M HCl at 100°C), rinsed with 
distilled water, immersed for 10 min in a PLL solution (20 mg PLL-HBr, 296 mL distilled 
water, 4 mL 1M Tris), then dried under a sterile flowhood. The films were constructed so as to 
mimic the capsule fabrication process described in section 6.4.2. Briefly, 200 µL of alginate 
solution (1.63% or 2.0% w/v in saline) was spread over a slide. The alginate-covered slide was 
then immersed in 20-30 mL of the necessary solutions to form a gel or polymer complex 
mimicking the bead or capsule composition. To remove excess salts that can interfere with the 
results, the films were quickly rinsed with sterile water before being allowed to dry overnight 
under a sterile flowhood. For the polycation controls, 1.0% w/v aqueous solutions of PLL or 
PLO were spread on the slides and allowed to dry overnight under a sterile flowhood. 
Contact angle measurements were made using a VCA Optima Contact Angle Surface 
Analysis System (AST Products, Inc., Billerica, MA, USA). One (1) µL of sterile water was 
dispensed from a mechanically controlled 100 µL syringe fitted with a 22G blunt tip needle. The 
sample was raised to touch the suspended water droplet. Care was taken to place the droplet on a 
clear area of the film in order to minimize the interaction between the water and any residual 
salts on the samples. Within 2 sec of contact with the water droplet, a photo was taken. The 
contact angle of the droplet to the surface was measured using the provided software. Each 
measurement represents the average of 2 to 4 spots on the same film. Five measurements were 
made for each sample type (n = 5), and at least two batches were tested per sample type. 
6.4.7 Explosion assay 
This assay is a modified version of a published protocol [27]. Samples of 30 ± 5 beads or 
microcapsules (suspended in Ringer or saline) were transferred to a 24-well plate. Using a 
gradient mounted in the eyepiece of an optical microscope, their diameters were measured. On 
average, initial diameters were 339 ± 17 µm for the gel beads, 368 ± 40 µm for the alginate-
polycation microcapsules (no alginate coating), and 387 ± 42 µm for the complete 
microcapsules (with alginate coating), regardless of the choice of alginate, crosslinking ion, or 
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polycation. Samples were rinsed by carefully aspirating the fluid then adding 1 mL of sterile 
water, causing the beads/capsules to swell. After 5 min, the diameters were re-measured and 
beads/capsules were classified as either intact, damaged (i.e. splitting or other membrane 
defects), or exploded. This procedure was repeated twice more for a total of three rinses. For 
each sample type, explosion assays were completed for three different batches of capsules or 
beads (n = 3).  
6.4.8 Statistical analysis 
Samples means were compared using the one-way ANOVA test. In the case of a 
significant difference between the means, multiple comparisons of the means were carried out 
using Tukey’s HSD post hoc test.. Differences for which p < 0.05 were considered to be 
statistically significant. 
6.5 Results and discussion 
6.5.1 In vivo biocompatibility 
Microcapsule biocompatibility was evaluated by the extent of host cell adhesion to their 
surfaces after two days in the peritoneal cavity of C57BL/6J mice. Cell adhesion was quantified 
using a cell adhesion score (Eq. 6.1) ranging from 0 (no cell adhesion) to 10 (complete surface 
coverage by immune cells). Figure 6.1 compares the cell adhesion scores for different capsule 
formulations. The majority of the samples tested were fabricated using the IntG alginate because 
we had observed that, in its gelled form, this alginate is more biocompatible than the HiG 
alginate. In fact, HiG(Ca)/PLL microcapsules were excluded from the biocompatibility tests 
since it was judged to be non-ethical to implant mice with capsules that were expected to be 
immunogenic. 
The IntG(Ca)/PLL/IntG microcapsules gave a mean cell adhesion score of 4.5 ± 0.6 (n = 
13). This corresponded to the observation that the majority of the recovered microcapsules had 
surfaces partially adhered with cells (Figure 6.2(a)). Moreover, a number of the explanted 
capsules appeared to be collapsed, forming “lemon” shapes. These damaged capsules tended to 
have more cell adhesion than those that stayed round. Moreover, the biocompatibility of these 
IntG(Ca)/PLL/IntG microcapsules tended to vary depending on the capsule batch (cell adhesion 
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scores for individual mice ranged from 1.7 to 7.7). Such inconsistencies in cell adhesion indicate 
an inhomogeneity among capsule batches induced by the PLL coating process. 
 
Figure 6.1 Biocompatibility of microcapsules of different design. Biocompatibility is measured by the 
extent of host cell adhesion after two days implantation in the peritoneal cavity of C57BL/6J mice, and is 
quantified by a cell adhesion score (0 = no cell adhesion ; 10 = complete coverage by cells). Bars 
represent the mean cell adhesion score ± SEM (n ≥ 3). * p < 0.05 
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Figure 6.2 Observation of alginate-polycation microcapsules under light microscope after two days in 
the peritoneal cavity of C57BL/6J mice. Photos represent typical samples of (a) IntG(Ca)/PLL/IntG, (b) 
IntG(Ca)/PLO/IntG, (c) IntG(Ba)/PLL/IntG, and (d) HiG(Ca)/PLL/IntG microcapsules upon their 
explantation. 
When the PLL was replaced with PLO, the extent of cell adhesion to the microcapsules 
dropped noticeably, yielding a mean score of 2.8 ± 0.4 for the IntG(Ca)/PLO/IntG samples (n = 
6). Under the microscope (Figure 6.2(b)), the explanted samples looked similar to those with a 
PLL membrane, including the presence of collapsed capsules with cells adhered to their 
surfaces. However, cell adhesion scores were more consistent, ranging from 1.6 to 4.0 for 
individual mice. In at least one other study that directly compared the effect of PLL vs PLO on 
alginate microcapsule biocompatibility, the opposite result was observed [28], despite their use 
of similar methods and materials. 
In an attempt to minimise the proportion of collapsed capsules that attract immune cells, 
the gel cores of the alginate-PLL-alginate (APA) microcapsules were replaced with either 
barium alginate or an alginate having a higher G content. Such modifications are expected to 
increase the strength and stability of the crosslinked gel core [29], and may therefore protect the 
127 
microcapsules from compressive forces or excessive swelling during the implantation period. As 
expected, the explanted capsules tended to stay round (Figure 6.2(c) and Figure 6.2(d)). 
However, biocompatibility clearly worsened (p < 0.05), as cell adhesion scores went up to 8.3 ± 
0.4 for IntG(Ba)/PLL/IntG (n = 5) and 7.2 ± 0.3 for HiG(Ca)/PLL/IntG (n = 4). Moreover, these 
capsules were often found in clusters held together by host cells and the beginnings of fibrosis. 
These results support de Vos’ observations that APA microcapsule biocompatibility is 
diminished by the use of high G alginate in the core [28, 30]. However, to our knowledge, such 
a negative effect of switching to a barium alginate gel core on APA capsule biocompatibility has 
not been seen before [31]. 
To confirm the respective roles of alginate and polycation in microcapsule 
immunogenicity, complete alginate-polycation-alginate microcapsules were compared to 
alginate gel beads (no membrane) and alginate-polycation microcapsules with no alginate 
coating (Figure 6.1). For all the samples tested, adding a polycation clearly augmented the 
immune response (cell adhesion scores increased by 3 to 8 points when compared to the gel 
beads ; p < 0.05). Immunogenicity of the polycationic membrane has often been suggested in 
the literature [28, 30, 32, 33]. More interestingly, adding an alginate coating had only the 
slightest (statistically non-significant) effect of reducing the immunogenicity that was induced 
by the polycation. This result puts into question the usefulness of adding an alginate coating to 
“counterbalance” or “neutralize” the positively charged polycation as a strategy to enhance the 
biocompatibility of alginate-polycation microcapsules. 
6.5.2 Surface chemistry 
As demonstrated in Figure 6.1, the polycationic component of the microcapsules had a 
profound effect on their biocompatibility. It is therefore of interest to evaluate the quantity of 
polycation that is present at the surface of each microcapsule type. Using XPS, the elemental 
composition of the outer 10 nm of the microcapsules was measured. The elements representing 
the gel crosslinking ions (Ca2+ and Ba2+) were undetectable for all samples having a membrane, 
confirming that only the outermost portion of the capsule surfaces was being analysed. 
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Figure 6.3 Effect of polycation and alginate coating on the quantity of nitrogen (N) detected on the 
surface of microcapsules of different design, as measured by XPS. Bars represent the mean value ± SD 
(n = 2) ; at% = relative atomic percentage. 
The most direct indicator of polycation quantity is the relative atomic percentage (at%) 
of nitrogen. The alginate gel beads showed only traces of nitrogen (< 1.5 at% N) that were later 
attributed to slight contamination of the sample substrates. When polycationic membranes were 
added to the gel beads, nitrogen levels consistently increased to values between 4.5 and 5.5 at%, 
regardless of whether the alginate coating was added or not (Figure 6.3). Examination of the 
high resolution spectra confirmed that the nitrogen originated principally from the PLL or PLO 
molecules (results not shown). In comparison, pure PLL had 9.6 at% N when analysed by XPS, 
suggesting a blend of polycation and alginate at the microcapsule surfaces [34]. More 
importantly, surface nitrogen levels did not vary significantly with different formulations of 
microcapsules, and thus did not correlate with microcapsule biocompatibility. 
These results demonstrate that, although the choice of polycation and gel type clearly 
influenced microcapsule biocompatibility, these parameters did not have an effect on the 
amount of polycation at the microcapsule surface, which was consistent (5.0 ± 0.5 at% N) 
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between sample types. In comparison, using similar XPS analyses, Ponce et al [28] saw a 
difference of 3.3 at% N (n = 1) between PLL and PLO capsules (using HiG alginate), while de 
Vos et al [35] saw a difference of 1.4 at% N (n = 4) between IntG and HiG alginate-PLL 
capsules. In each of these studies, the authors claimed a relationship between the estimated 
amounts of polycation and the in vivo biocompatibility of the microcapsules. 
6.5.3 Membrane composition and intermolecular interactions 
With an analytical depth of 2-3 µm, ATR-FTIR can provide insights into the relative 
amount of polycation that diffuses into the alginate gel core to form a membrane a few microns 
thick [36]. Moreover, shifting of peaks associated with functional groups can provide 
information about intermolecular interactions within the membrane. 
The spectra for the microcapsules with a polycationic membrane always displayed peaks 
characteristic of both the polycation and the alginate, confirming the co-presence of these 
polymers within the membrane. Moreover, the addition of an alginate coating had very little 
influence on the peak heights and shapes, demonstrating once again the minimal influence of 
this coating on the microcapsule membrane properties. 
For the microcapsules with a barium alginate gel core, the characteristic peaks for the 
polycation were much less prominent than for the other capsule types. This effect can be 
observed in Figure 6.4, which compares the spectra for alginate-PLL microcapsules that differ 
only in the choice of crosslinking ion in the gel core, Ca2+ vs Ba2+. Notice the peak shapes in the 
areas highlighted in grey. For the capsules with a IntG(Ca) gel core, one can clearly see the 
presence of peak shoulders associated with the PLL molecule (NH3+ at ∼ 3050 cm-1 ; Amide II 
at ∼ 1530 cm-1 ), yet these shoulders are barely visible for the capsules with an IntG(Ba) gel 
core. This is a good indicator that relatively lower amounts of PLL could penetrate into and/or 
bind to the barium alginate gel. 
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Figure 6.4 FTIR absorbance spectra for alginate-PLL microcapsules having a (a) calcium alginate gel 
core, or a (b) barium alginate gel core. Regions of particular interest are highlighted in grey. The peak 
shoulder near 1560 cm-1 is quantified in Figure 6.5. 
The relative quantities of polycation and alginate within the microcapsule membranes 
were estimated semi-quantitatively using the height ratio of the peaks associated with Amide II 
of the polycation backbone (∼ 1526 cm-1, shoulder) and the COO− of the alginate (∼ 1593 cm-1). 
The results are shown in Figure 6.5, where a higher Amide II / COO− ratio indicates a greater 
quantity of PLL or PLO within the membrane. One can now more clearly observe that the 
microcapsules with a barium alginate gel core had less polycation incorporated in their 
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membranes than the capsules with a calcium alginate gel core. A poor penetration of PLL into 
the barium alginate gel can be explained by the higher affinity of Ba2+ ions for alginate than 
Ca2+ ions [37], making it energetically less favourable for the PLL to displace the barium in 
order to electrostatically bind to the alginate. A similar decrease in PLL binding efficiency by 
alginate gel beads was seen by Thu et al when they substituted calcium ions for strontium ions 
to crosslink the alginate [27]. The poor biocompatibility of the IntG(Ba)/PLL/IntG 
microcapsules can be explained by this reduced penetration of PLL into the barium alginate gel, 
as a thinner and/or less stable membrane may present a higher risk of exposing unbound PLL 
that can attract the immune system. 
 
Figure 6.5 Relative heights of the FTIR spectral peaks associated with Amide II (∼ 1526 cm-1, shoulder) 
of the polycation and COO− (∼ 1593 cm-1) of the alginate for microcapsules of different design. Bars 
represent the mean ratio value ± SD (n = 2). 
The FTIR spectra of the two most biocompatible microcapsule types, IntG(Ca)/PLL/IntG 
and IntG(Ca)/PLO/IntG shared common features. Specifically, the Amide II / COO− ratios 
(Figure 6.5) demonstrate that the polycation diffused efficiently into their IntG(Ca) gel cores 
(black bars), and moreover, that the alginate coating had an effect of lowering the 
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polycation/alginate ratio (grey bars). Since their surface compositions did not change 
significantly with the alginate coating (section 6.5.2), this result suggests that the dilute alginate 
successfully diffused into the membrane of these two capsule types during the coating process. 
An indicator of the strength of ionic interaction between alginate and its counterion is the 
shift of the FTIR peaks associated with the asymmetric (∼ 1593 cm-1) and symmetric (∼ 1410 
cm-1) stretching vibrations of the COO− groups of the alginate [39, 40]. The shifting positions 
(wavenumbers) of these two peaks as the various components of the microcapsules were added 
are shown in Table 6.3. In general, as the polycation was added to the alginate gel bead to form a 
membrane, the peak near 1593 cm-1 consistently shifted to higher wavenumbers, while the peak 
near 1410 cm-1 shifted to lower wavenumbers. These shifts were slightly more pronounced for 
the two microcapsule types having an IntG(Ca) gel core, supporting the view that this gel type 
bound the polycation more efficiently than the barium alginate gel or gel of HiG alginate. When 
alginate coatings were added, however, there were no clear patterns in the peak shifts, leaving 
any interpretations about the extent of interaction between gel-bound polycation and solubilised 
alginate ambiguous. 
Table 6.3 Placements of FTIR absorbance peaks associated with the assymmetric and symmetric 
stretching vibrations of the COO− functional groups of the alginate. Values represent the mean 
wavenumber ± SEM (n = 2). 
 COO− asym COO− sym 
 Wavenumber 
(cm-1) 
Shift vs. gel 
bead (cm-1) 
Wavenumber 
(cm-1) 
Shift vs. gel 
bead (cm-1) 
IntG(Ca) 1593 ± 0  1410 ± 0  
IntG(Ca) + PLL 1599 ± 2 + 6 1404 ± 2 - 6 
IntG(Ca) + PLL + IntG 1602 ± 3 + 9 1408 ± 2 - 2 
IntG(Ca) 1593 ± 0  1410 ± 0  
IntG(Ca) + PLO 1597 ± 2 + 4 1402 ± 0 - 8 
IntG(Ca) + PLO + IntG 1598 ± 3 + 5 1407 ± 1 - 3 
IntG(Ba)  1592 ± 1  1408 ± 0  
IntG(Ba) + PLL 1596 ± 1 + 4 1405 ± 1 - 3 
IntG(Ba) + PLL + IntG 1595 ± 2 + 3 1404 ± 0 - 4 
HiG(Ca) 1593 ± 0  1409 ± 1  
HiG(Ca) + PLL 1595 ± 0 + 2 1405 ± 1 - 4 
HiG(Ca) + PLL + IntG 1596 ± 1 + 3 1404 ± 2 - 5 
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6.5.4 Exposure of hydrophilic groups 
It has been stated that, as a hydrogel, alginate is biocompatible because of its superior 
hydrophilicity, which allows for minimal protein and cell adhesion [6]. It is therefore of interest 
to know the surface wettability of alginate-based microcapsules. In this study, sample 
wettability was estimated by the static contact angle of 1 µl water droplets on the surface of 
dehydrated films mimicking the chemistry of the microcapsules under study. While this 
measurement may not be directly representative of the wettability of hydrated gels, it is 
nevertheless a good indicator of the proportion of hydrophilic groups (-OH, -COO−, -NH3+) that 
are exposed at the sample surface and are available for rehydration.  
 
Figure 6.6 Wettability of films representing the composition of microcapsules of different design. 
Wettability is measured by the static contact angle of 1 µl droplet of pure water on the dry film surface. 
Bars represent the mean contact angle ± SEM (n = 5). * p < 0.05. 
As can be seen in Figure 6.6, the alginate gels were indeed very hydrophilic with average 
contact angles measuring below 15°. The water droplets immediately spread along the film 
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surfaces as the gel rehydrated. When polycations were incorporated into the films, the water 
droplets spread less and, for all sample types, contact angles increased significantly (p < 0.05) to 
values above 50°. Adding the polycation also induced a large variation in the results, revealing 
an inhomogeneity of the polyelectrolyte complexes that can also explain the variability in cell 
adhesion scores between individual capsules. In comparison, pure PLL and PLO had contact 
angles of 20.4 ± 0.2° and 24.6 ± 0.6°, respectively. Therefore, it is not the polycation itself, but 
rather the alginate-polycation complex that has hydrophobic qualities. This can be visualized as 
the oppositely charged functional groups of the polymers are busy interacting with eachother 
and are therefore unavailable for interaction with water. Adding an alginate coating lowered the 
contact angles by 3° to 14°, but this effect was not statistically significant and the hydrophilic  
properties of the alginate gels were never completely restored. Similar results for alginate-PLL 
complexes have been seen before in the literature [40]. 
The films containing PLO were slightly more hydrophilic than those samples containing 
PLL. When the alginate coating was added, this difference was statistically significant (p < 
0.05) in one case, as indicated on Figure 6.6. This result may be a reflection of the slightly 
higher ratio of hydrophilic NH3 to hydrophobic CH2 in the PLO side chain (1:3) compared to 
PLL (1:4). It may also suggest a less efficient binding between the PLO and alginate, thus 
allowing for the charged groups to interact with the water molecules, but the FTIR results 
contradict this hypothesis. In any case, the more wettable PLO-based samples also represent the 
most biocompatible microcapsules, thus supporting the opinion that hydrophilicity is indeed 
important for minimizing biomaterial immunogenicity. 
6.5.5 Microcapsule swelling and membrane strength 
When alginate-based microcapsules are immersed in pure water, the extent to which they 
swell is dependent on the gel characteristics, while the tendency of the capsule membrane to 
deform or split when swelling occurs is a reasonable indicator of membrane strength and 
homogeneity. The reactions of complete alginate-polycation-alginate microcapsules to water 
rinses are shown in Figure 6.7. 
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Figure 6.7 Resistance of microcapsules of different design to swelling and damage  when rinsed with 
pure water : (a) IntG(Ca)/PLL/IntG, (b) IntG(Ca)/PLO/IntG, (c) IntG(Ba)/PLL/IntG, (d) 
HiG(Ca)/PLL/IntG microcapsules. Bars show the mean proportion of capsules within a sample that are 
intact  , damaged  , exploded  , or lost  before and after each of three water rinses (n = 3). The 
line graph  indicates mean the percentage increase in diameter of intact and damaged capsules ± 
SEM (n = 3). Each rinse consists of immersing 30 ± 5 microcapsules in 1 mL of pure water for 5 - 10 
min. 
As indicated by the proportion of undamaged capsules with each water rinse (black bars 
in Figure 6.7), the PLO microcapsules were clearly the most resistant to swelling and damage. 
Even after three water rinses, these microcapsules never swelled more than 108% of their 
original diameter, and less than 15% of the capsules were exploded or lost. At least two other 
studies have compared the osmotic swelling and stability of PLO vs PLL alginate microcapsules 
and have concluded that PLO membranes performed better [19, 41], although the opposite result 
has also been published [28]. The resistance of the PLO membrane to swelling and rupture is in 
concordance with the FTIR results that suggest that PLO penetrates well into the gel core to 
form a membrane (section 6.5.3). More importantly, these damage-resistant capsules were also 
the most biocompatible when implanted (Figure 6.1), thus emphasizing the importance of 
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membrane stability and strength for avoiding an immune response. Ironically, PLO capsules 
showed a tendency to collapse during their implantation period (Figure 6.2(b)) despite their 
superior stability in the explosion assay. Since IntG(Ca) gel is quite pliable, this implies that the 
damage that was induced in vivo was due to compression forces and shear stresses rather than to 
osmotic swelling. 
On the other end of the spectrum, microcapsules having a barium alginate gel core were 
clearly the most prone to rupture when swelling was induced (Figure 6.7(c)). With the first water 
rinse, diameters increased to 127% and over 90% of the capsules were destroyed; in no cases 
did these capsules survive the second rinse. The fragility of these microcapsules is likely to be a 
result of the poor incorporation of the PLL into the gel core that was observed by FTIR. More 
importantly, these microcapsules were also the most immunogenic despite that most of them 
stayed round during their implantation period (Figure 6.2). This observation emphasizes once 
again that the quality and strength of the polycationic membrane is more important in governing 
biocompatibility than the ability of the gel core to resist compression forces in vivo. 
In between these two opposites were the PLL microcapsules with calcium alginate gel 
cores. Of these samples, those with an IntG alginate core tended to swell more (up to 137%) 
than those with a HiG alginate core, as could be expected since high guluronate alginate forms 
stiffer gels that are less prone to swelling [42]. Additionally, the higher concentration of HiG 
alginate within the capsule core could have contributed to its greater resistance to swelling. Yet, 
those capsules with a HiG alginate core had membranes that more readily split despite minimal 
swelling, demonstrating a stiffer and less elastic membrane than their IntG counterparts. 
Similarly to the case of the capsules with an IntG(Ba) gel core, the poor resistance of the 
membrane to swelling is possibly related to an inadequate interaction between the HiG alginate 
gel and the PLL, either because of the higher proportion of GG blocks (which are involved in 
binding the Ca2+ ions, leaving less alginate available for binding the PLL) or the higher 
proportion of low molecular weight fractions within this alginate (as reflected by its low 
intrinsic viscosity). As far as the implications for biocompatibility, the stiffer membranes of the 
microcapsules with the HiG alginate core seem to be the greater problem for inducing 
immunogenicity. 
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When the alginate coatings were omitted, the results (not shown) were almost identical 
as those presented in Figure 6.6. Thus, the alginate coating had no effect on the microcapsule’s 
resistance to swelling and damage in water. In contrast, alginate beads without a membrane 
swelled to over 200% of their original diameter before disintegrating (results not shown), 
demonstrating the role of the alginate-polycation membrane in limiting the swelling of the 
capsule.  
6.6 Conclusions 
The results of this study provide evidence that the biocompatibility of alginate-
polycation microcapsules is influenced by each the alginate composition, gelling ion, and 
polycation. In our case, the use of PLO rather than PLL as the polycation resulted in 
microcapsules with better biocompatibility in vivo. The PLO capsules were also associated with 
a greater hydrophilicity and adequate diffusion of polycation into the gel to form a membrane 
that resisted swelling and rupture when subjected to osmotic stress. These features can be 
attributed to the shorter side chains of the PLO compared to PLL, which may influence 
hydrophilic/hydrophobic (NH3+/CH2) balance as well as the manner in which the polymer 
interacts with the alginate gel. As for the influence of crosslinking ion and alginate type on 
biocompatibility, the use of a barium alginate gel or an alginate with a higher guluronate content 
as the capsule core resulted in a stronger immune response to the microcapsules. This was 
explained by a poor diffusion and integration of the PLL into these gel types, particularly the 
barium alginate. In this case, it was probably energetically unfavourable for the polycation to 
displace the gelling ion in order to crosslink with alginate and form a membrane. This is a 
natural consequence of the stronger affinity of the barium ions to alginate, and the stronger 
affinity of the guluronate blocks to bind the divalent cation. While these microcapsules better 
resisted the compressive forces in vivo, as evidenced by their rounder appearance upon 
explantation, their membranes were more prone to splitting when the capsules swelled under 
osmotic stress. Indeed, a low quality of membrane is expected to be more susceptible to 
inhomogeneity and defects that increase the risks of unbound PLL of being exposed at the 
capsule surface and attracting proteins and cells of the immune system. In contrast, it was shown 
that the quantity of polycation at the surface had little to do with biocompatibility, and 
moreover, that the alginate coating had very little effect on each the biocompatibility and 
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various physicochemical properties that were investigated in this study. Thus, it is not the 
alginate coating’s ability to “neutralize” the positively charged groups of the membrane that 
governs the biocompatibility and physicochemical properties of alginate-polycation 
microcapsules, but it is rather the membrane forming step of polycation diffusing into and 
binding to the alginate gel that is of importance. 
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CHAPTER 7 
INDUCING NORMOGLYCEMIA IN DIABETIC MICE USING 
MICROENCAPSULATED ISLETS: WITH OR WITHOUT A MEMBRANE 
 
NOT SUBMITTED FOR PUBLICATION 
 
7.1 Abstract 
The polycationic membrane is supposed to give alginate-polycation microcapsules a 
controlled permeability and increased stability, but its biocompatibility is not optimal. This 
study seeks to determine whether a modestly immunogenic membrane hinders or helps the 
ability of the microcapsule to immunoprotect. We thus tested the ability of 300 rat islets, 
encapsulated in either alginate-PLO microcapsules or in barium alginate beads, to normalize the 
blood glucose levels of immunocompetent diabetic mice. One of the four mice that were 
transplanted with islets in PLO microcapsules became normoglycemic (for 14 days), while the 
other three remained diabetic. All four of the mice that received islets immobilized in gel beads 
were normoglycemic for periods ranging from 16 to 50+ days. Once hyperglycemia was 
established, the samples were explanted and examined under microscope in an attempt find out 
why the grafts failed. In the case of PLO microcapsules, graft failure seemed to have been due 
to fragmentation and degradation of the samples in vivo. In the case of gel beads, reasons for 
graft failure were less clear. Many of the explanted beads were damaged and/or adhered with 
host cells. As well, ∼10% of the islets could be recovered, although some were unhealthy or 
degraded. The length of graft survival did not correlate with the proportion of recovered islets 
nor with the extent of host cell adhesion. In conclusion, the PLO membrane was clearly not 
beneficial for islet function in vivo, although it remains uncertain as to whether some type of 
membrane is still necessary for immunoprotection. 
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7.2 Introduction 
In our research lab, the main purpose for developing alginate-polycation microcapsules 
is to allow the safe transplantation of islets of Langerhans (i.e. clusters of insulin-secreting cells) 
for the treatment of insulin-dependent diabetes. Ideally, our encapsulated islet system should 
normalize the blood glucose levels of diabetic recipients without the administration of 
exogeneous insulin (by syringe) and without the use of immunosuppressive agents. 
The purpose of adding a polycationic membrane to alginate-based microcapsules is to 
reduce and control their permeability as well as enhance their stability. These qualities are 
expected to enhance the immunoprotective abilities of the microcapsules. However, as we have 
shown, the biocompatibility of the polycationic membrane has not yet been optimized 
(CHAPTER 6). We were interested to know whether a mild immune response to the 
microcapsules is actually enough to hinder their performance as immunoprotective devices, or if 
the membrane was even necessary at all. In order to answer these questions, we encapsulated 
islets in gel beads (without a membrane) or microcapsules (with a PLO membrane), and then 
tested their ability to normalize the blood glucose levels of immunocompetent, diabetic mice.  
7.3 Materials and Methods 
7.3.1 Materials 
Keltone® LVCR sodium alginate, lot #721322, was provided by ISP Corp (New Jersey, 
USA). The alginate was purified according to protocols that were optimized in our lab [1, 2]. 
The purity and biocompatibility of the alginate was verified (CHAPTER 5) [3]. Further details 
about this alginate can be found in Table 6.1. 
Poly-L-ornithine (PLO) hydrochloride (product no. P2533; CAS 26982-21-8) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Characteristics of this polymer are 
described in Table 6.1. 
All solutions were sterilized by filtration (0.22 µm) before their use. Solution formulae 
are described in APPENDIX I. Reusable labware was specially cleaned and sterilized by 
Pasteur oven (200°C for 2h), ethylene oxide (EO) or autoclave before their use. Disposable 
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plastic materials were considered as sterile. Manipulations were performed under sterile 
conditions whenever possible.  
7.3.2 Islet isolation 
Islets were isolated from the pancreata of adult male Wistar rats (250 - 400 g, Charles 
River Institute, St-Constant, QC). The islet isolation procedure, based on methods published by 
Lacy et al [4], has been previously described [5]. Briefly, type V collagenase (diluted 1 mg/mL 
in Hank’s balanced salt solution) was infused into the pancreas via the common bile duct. The 
inflated pancreas was excised and further digested for 30 min at 37°C. Islets were purified by 
consecutive filtration (800 µm ; 250 µm) followed by a discontinuous Euroficoll gradient. Islets 
were then handpicked to > 95% purity under light microscope and then cultured overnight in a 
supplemented RPMI 1640 medium at 37°C and 5% CO2. Approximately 400 islet-equivalents 
(ieqs) were isolated from each rat. These manipulations were done under the approval of the 
Maisonneuve-Rosemont Hospital Animal Ethics Committee. 
7.3.3 Islet encapsulation 
Islets were suspended in a viscous solution of purified alginate (1.63% w/v in saline). 
The suspensions were extruded from a 25G blunt-tip needle using a mechanically controlled 
syringe and electrostatic pulsed generator. This formed tiny droplets that were immersed for 30 
min in a crosslinking solution (10 mM BaCl2 for beads ; 100 mM Ca Lactate for microcapsules) 
to form gel beads with islets immobilized within. To form a membrane, the beads were 
immersed for 5 min in a PLO solution (0.05% w/v in saline), rinsed 3 min in saline, immersed 5 
min in dilute alginate solution (0.163% w/v in saline), and rinsed twice in saline. Gel beads 
without a membrane were rinsed twice with Ringer’s solution. Finally, beads and microcapsules 
were rinsed and cultured overnight (37°C ; 5% CO2) in Ultraculture medium supplemented with 
1% v/v penicillin-streptomycin-glutamine. 
7.3.4 Transplantation 
Male C57BL/6J mice weighing 14-26 g (Jackson Laboratory, Maine, USA) were used as 
transplant recipients. Diabetes was induced by intraperitoneal injection of Streptozotocin, STZ 
(22.5 mg/mL in sodium citrate, pH 4.5) at a dosage of 150 mg/kg of body weight. Glucose 
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levels in blood samples taken from the tail vein were measured using an Accu-Chek® meter. 
Mice were transplanted if two subsequent blood glucose readings were ≥ 15 mmol/L. To do so, 
samples of 300 encapsulated islets (i.e. 280 ± 50 islet equivalents, ieqs, thus representing a 
marginal mass islet cell transplantation) were handpicked and injected, via a 22G catheter, into 
the peritoneal cavity. Throughout the in vivo studies, blood glucose levels and body weights 
were monitored as often as every second day. Four mice were transplanted per condition 
(barium gel beads vs PLO microcapsules), divided over two batches of mice (n = 4). Empty 
beads and microcapsules, as well as non-encapsulated islets (300), served as controls. 
7.3.5  Explantation 
Mice that displayed signs of hyperglycemia (blood glucose levels ≥ 20 mmol/L, 
difficulty in weight gain, excessive urination) were euthanized by cervical dislocation and 
samples were explanted by peritoneal washings. Explanted samples were examined by light 
microscopy and their biocompatibility was quantified using a cell adhesion score, as described 
in section 5.4.4 and section 6.4.3. 
7.4 Results 
7.4.1 Normalization of blood glucose 
Blood glucose levels of the transplanted mice, along with the controls, are graphed in 
Figure 7.1. The length of graft survival for each mouse is indicated in Table 7.1. Within 48h of 
transplantation, normoglycemia (i.e. blood glucose levels ≤ 12.0 mmol/L) was induced in all 
four of the mice that received islets immobilized in gel beads. Graft survival periods for this 
group varied from 16 days to 50+ days. In contrast, only one of the mice that received islets 
encapsulated in PLO microcapsules achieved normoglycemia (for 14 days), while the other 
three mice in this group remained hyperglycemic after the transplantation. 
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Figure 7.1 Blood glucose levels of STZ-induced diabetic C57BL/6J mice after being transplanted with 
encapsulated islets (n = 4), non-encapsulated islets (n = 1), or empty beads or microcapsules (n = 1). 
Each line graph represents an individual mouse. The upper limit for normoglycemia (12 mmol/L) is 
indicated by a red line. 
7.4.2 Examination of explanted samples 
At the end of each transplantation period, the samples were explanted and examined 
under light microscope. With the exception of one mouse, samples were explanted after the 
recipient experienced prolonged hyperglycemia, i.e. after the transplanted islets had already 
begun to fail. 
As shown in Table 7.1, only a small portion of the encapsulated islets were recovered 
upon explantation. On average, of 10 ± 1% of the islets immobilized in beads were recuperated. 
In contrast, islets encapsulated in PLO microcapsules could be retrieved from one mouse only, 
and this represented just 2% of the islets that were implanted. In the case of zero islet recovery, 
nothing recognizable was recovered by peritoneal washings (not even empty microcapsules). 
Non-encapsulated islets (x300) 
Islets in beads (x300)     1      2      3      4 
Islets in PLO microcapsules (x300)     1     2      3     4 
Empty      beads (x500)       PLO microcapsules (x150) 
No implant 
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Table 7.1 Evaluation of samples explanted from the peritoneal cavity of STZ-induced diabetic C57BL/6J 
mice after graft failure. Parameters evaluated include the proportion of islets recovered and the immune 
response to the transplants. TX = transplantation. 
Cell adhesion 
score Transplant Mouse 
Graft 
survival 
(days) 
Explantation  
(days after 
TX) 
Islets 
recovered 
Empty With islets 
Non-encapsulated islets (×300) < 2 26 0% n/a n/a 
Islets in beads (×300) 1 18 46 7% 7.62 9.05 
 2 40 50 13% 3.07 3.58 
  3a > 50  .  50a 9% 3.15 2.69 
 4 16 50 10% 2.46 2.18 
1 14 46 2% 5.65 6.19 Islets in PLO 
microcapsules (×300) 2 < 2  26 0% n/a n/a 
 3 < 2 43 0% n/a n/a 
 4 < 2 26 0% n/a n/a 
Empty beads (×500)  < 2 26 n/a 1.32 n/a 
Empty PLO microcapsules (×150) < 2 18 n/a 6.31 n/a 
No implant  < 2 n/a n/a n/a n/a 
   a
 normoglycemic upon explantation 
Several empty beads or microcapsules were also explanted. Although a number of these 
were empty because the islets within were lost in vivo, most were actually empty when they 
were implanted (they were picked up during the hand-picking process). Overall, more beads 
than PLO microcapsules were retrieved. The beads tended to be deformed while the PLO 
microcapsules were rather collapsed or squished, although fragments were commonly observed 
in both cases (Figure 7.2). The extent of host cell adhesion to empty vs. islet-containing 
beads/capsules was compared for each sample explanted (Table 7.1). For one mouse only, the 
cell adhesion score was considerably higher for islet-containing beads/capsules than for empty 
ones (∆  =  +1.43). Otherwise, the presence of islets within the beads/capsules did not appear to 
have an influence on the extent of host cell adhesion to those beads/capsules.   
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Figure 7.2 Examples of explanted samples as viewed under light microscope. 
On several occasions, a “phantom” was observed in the alginate gel where the islet used 
to be, as shown in Figure 7.3. In place of the islet, there was a hole in the gel along with single 
dispersed cells. In some cases, the islet was still intact but had been displaced within the gel. 
 
Figure 7.3 Observations of “phantoms” left by islets that were immobilized in the alginate gels. 
 Fissures could also be observed in the explanted gel beads. These fissures would lead 
into the bead center towards the islet, which would generally be unhealthy or degraded into 
single cells. Moreover, host cells could often be seen to be adhered along the inside walls of the 
fissure. This phenomenon is shown in Figure 7.4. 
 
Figure 7.4 Observations of fissures leading into the centers of beads that contained islets. 
Beads : Day 46 Beads : Day 50 Capsules : Day 46 
Bead : Day 46 Bead : Day 18 Bead : Day 50 
Capsule : Day 46 Bead : Day 50 Bead : Day 18 
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7.5 Discussion 
The primary function of the polycationic membrane is to reduce and control the 
permeability of the microcapsule, as well as improve its stability [6]. In principle, this should 
lead to improved immunoprotection by the microcapsule. However, it has been difficult to 
optimize the biocompatibility of the polycationic membrane. For this reason, a handful of 
research groups have started advocating the use of alginate gel microbeads (without a 
membrane) for cell encapsulation [7-10]. Despite some promising results of islet transplantation 
using uncoated alginate gel beads, the higher permeability of these devices (vs. microcapsules 
with a membrane) remains a concern as adequate immunoprotection might not be achievable 
despite manipulations of the alginate and gelation techniques [11, 12]. 
And yet, in this study, the gel beads without a polycationic membrane were clearly more 
efficient than the microcapsules with a PLO membrane for protecting the viability and function 
of islets transplanted into immunocompetent mice. We are not the only ones to have observed 
that adding a polycationic membrane hinders the success of encapsulated islet transplantation 
rather than enhances it. For example, Safley et al [13, 14] showed that, compared to barium 
alginate gel beads without a membrane, the use of a PLL membrane greatly reduced the 
efficiency of adult porcine islets to induce normoglycemia in non-obese diabetic mice. 
Once the recipients became hyperglycemic, we explanted and examined the transplants 
in order to understand the possible reasons for graft failure. In the case of the PLO 
microcapsules, the extremely low retrieval rates and observations of collapsed or fragmented 
capsules covered with host cells seems to suggest that the microcapsules simply started to fall 
apart after a few days in vivo. If this was indeed the case, the islets within would quickly have 
been unprotected and attacked by the host immune system. Similarities between the in vivo 
performance of islets in PLO microcapsules and non-encapsulated islets support this view. 
In the case of the alginate gel beads, the results were quite variable. First of all, graft 
survival ranged from 16 to 50+ days. Upon explantation, we saw signs of an immune response 
to the transplants, particularly host cell adhesion to the bead surfaces. In some cases, it appears 
that the host cells managed to enter the bead via fissures in order to directly attack the islet 
within. That said, there were no correlations between the extent of cell adhesion and the length 
of graft survival, suggesting that host cell adhesion was not the main contributor to graft failure. 
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We are not the first to fail to see a correlation between the duration of graft function and extent 
of overgrowth to microencapsulated islets [15]. Similarly, although we observed a massive loss 
of islets (averaging 90% loss), there were no clear correlations between the proportion of islets 
recovered and the length of graft survival.  
These results tell us that factors other than host response and islet loss (i.e. that were 
invisible by optical microscope) were likely the main cause for the eventual dysfunction and/or 
death of the islets encapsulated within alginate gel beads. Such factors could have been the 
penetration of tiny cytokines into the porous gel [7, 11] or the poor diffusion of oxygen into the 
center of the beads and islets [16, 17]. However, until a closer examination of the biological 
state of the islet cells (including cellular stress signals, apoptosis, and necrosis) is carried out, we 
have no definite proof of either of these phenomena.  
7.6 Conclusions 
As immunoprotective devices for transplanted islets, barium alginate gel beads (without 
a membrane) were much more effective for inducing normoglycemia in immunocompetent 
diabetic mice than alginate microcapsules with a PLO membrane. It appears that the PLO 
microcapsules failed to protect the transplanted islets because they fragmented and degraded in 
vivo. The reasons for eventual graft failure of islets immobilized in gel beads could not be 
clearly determined based on the results of this study. 
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CHAPTER 8 
GENERAL DISCUSSION 
 
Within the field of encapsulated islet transplantation, the biocompatibility of alginate-
polycation microcapsules is still both difficult to control and reproduce. This situation stems 
from the combination of a lack of standardization for microcapsule fabrication and an 
insufficient understanding of what physical and chemical properties influence the biological 
response to these devices. With the intention of contributing to the optimization of microcapsule 
biocompatibility, this research aimed to elucidate the relationships between the fabrication 
parameters, physicochemical properties, and in vivo biocompatibility of alginate-based 
microcapsules. 
 
8.1 Can protein adsorption predict APA microcapsule biocompatibility ? 
Protein adsorption was chosen as a starting point for this research, for practical purposes 
(related to my internship in Groningen) as well as for scientific reasons. Not only is protein 
adsorption considered to be the first event to occur upon implantation [1, 2], thereby governing 
all subsequent biological events [3, 4], but the Groningen lab had previously demonstrated that 
proteins adsorb to alginate-polycation microcapsules in vivo (according to an increasing 
nitrogen signal detected by XPS), and this seemed to correlate with the severity of inflammatory 
response towards the implants [5, 6]. In a few short months, we managed to prove, for the first 
time, that human immunoglobulin adsorbs to alginate-PLL microcapsules in vitro. Not only this, 
we demonstrated how to quantify protein adsorption using a simple and accessible technique 
that also allows direct visualization of the proteins. While I was in Groningen, Julie was 
simultaneously using an elution technique in combination with mass spectrometry to prove that 
not only immunoglobulins, but a whole range of proteins (from mouse serum and plasma) 
adsorb to the surface of APA microcapsules in vitro [7]. Since this research, few other studies 
have been published that demonstrate protein adsorption to alginate-based microcapsules [8, 9]. 
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We clearly showed that the polycation is mainly responsible for adsorption of 
immunoglobulins. This implies that the positive electric charge of the surface played an 
important role in binding the proteins. This supports the theoretical view that electrostatic 
attraction or repulsion is one of the main interactions between biological proteins and surface 
[3]. However, when the same microcapsules were previously analyzed using zeta potential 
measurements, the HiG microcapsules had a greater net surface charge than the IntG 
microcapsules [10]. This difference in net surface charge did not correlate with a different extent 
in immunoglobulin adsorption, implying that immunoglobulin adsorption is also affected by 
other factors other than electrostatic forces, such as hydrophobic binding. 
Most importantly, we could not prove a correlation between immunoglobulin adsorption 
and microcapsule biocompatibility. That is, all the microcapsules (with a membrane) showed 
equivalent adsorption despite that only one of the four capsule types has shown adequate 
biocompatibility in vivo [11, 12]. This may be explained by the fact that we tested the adsorption 
of human Ig while the biocompatibility studies were performed on rodents. However, a more 
reasonable explanation is that the combination of IgG, IgM, and IgA adsorption does not 
determine the cellular response to the microcapsules. IgG is the most abundant of the 
immunoglobulins in plasma and serum [13], but it is also the most potent since its adsorption to 
surfaces makes the surface a target for phagocytosis by immune cells [14, 15]. Upon returning 
to Montréal, we attempted to continue the adsorption studies using more specific proteins, 
namely IgG, the complement factor C3, and albumin. However, preliminary experiments were 
not successful and experimental protocols were not optimized due to time constraints. That said, 
there has been some evidence of a correlation between total protein adsorption and cellular 
overgrowth on APA microcapsules [5, 6], but any other evidence has been sparse. 
So the question remains, can protein adsorption predict APA microcapsule 
biocompatibility ? We still don’t know for sure, but if the answer were ‘yes’ than this would be 
a very interesting option for screening microcapsules in vitro before having to use animals. The 
answer to this question risks being unanswered for a while yet, given the difficulty that others 
have had establishing clear correlations between protein adsorption and “ideal” biomaterials 
with highly specific, functionalized surfaces [16-18]. 
 
155 
8.2 So what properties govern alginate-polycation microcapsule 
biocompatibility ? 
8.2.1 All purified alginates are not equal 
The results of our study on the factors influencing alginate gel biocompatibility came to 
us as a bit of a surprise. Leading research groups have suggested that, as long as the alginate is 
purified, then it is biocompatible [11, 19, 20]. Therefore, we purified our alginates, and verified 
that they were pure. Yet, the alginate with higher guluronate (G) content produced gels that 
were not biocompatible. This told us that the conformational differences between the M and G 
residues played some role in determining biocompatibility, probably via their influence on the 
physical properties (stiffness, swellability) of the resulting gels. This viewpoint, however, has 
not been frequently mentioned, and so the results of this study, when they are published, will 
undoubtedly just add to the debate about what M/G composition of alginate is ideal for 
biocompatibility. 
Our results also indicated that the intrinsic viscosity (molar mass) of the alginate also 
plays a role in determining alginate gel biocompatibility. Perhaps this is the better explanation 
for why the HiG alginate gels were immunogenic. After all, at least one group of researchers 
also promotes the use of high viscosity alginate for ultimate performance [21-23]. However, the 
design of our study did not allow us to determine which of the two factors was the more 
important for biocompatibility : M/G content or molar mass. Resolving this problem would 
require access to alginates with highly controlled properties, which can be obtained (ideally) by 
extracting the alginate directly from the plant to control polydispersity and viscosity [24, 25] 
and then tailoring the M/G composition by epimerization [26-28]. While this would be 
interesting for future studies, we had opted to stick to two kinds of commercially available 
alginates that are commonly used in the cell encapsulation field. 
Finally, it must be noted that the biocompatible alginate is not necessarily the most 
suitable choice for cell encapsulation purposes, neither for biocompatibility nor for 
immunoprotection reasons. First of all, considering our results concerning microcapsule 
biocompatibility, the biocompatible alginate must also be able to interact with the polycation in 
an optimal manner in order to achieve biocompatibility of the microcapsule (with a membrane). 
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Furthermore, as we have seen, the biocompatible alginate produced a gel that was fragile. When 
we used this alginate to encapsulate islet transplants, a number of islets managed to move 
around within the gel, even escape the microcapsule or bead, and were rendered vulnerable to 
attack by the host immune system. Perhaps this problem could be overcome by using an alginate 
with a higher molecular weight or degree of polymerization [29, 30]. 
8.2.2 Can optimal biocompatibility be achieved when using a polycation? 
Our results suggested that the polycation is the ultimate problem for microcapsule 
biocompatibility. This supports many previous studies that came to the same conclusion [31-35]. 
For this reason, a couple of research groups have already decided to move forward using 
uncoated alginate gel beads for encapsulating transplanted islets [33, 36-38]. However, this does 
not necessarily mean that the biocompatibility of microcapsules with a polycationic membrane 
cannot be optimized. The Groningen group and the Perugia group both use alginate-polycation 
microcapsules successfully for islet encapsulation, and seem to have overcome most problems 
associated with biocompatibility [39-42]. This proves that it is possible to achieve optimal 
biocompatibility when using a polycationic membrane, but the question remains how. 
Our results indicated that the most important factor influencing biocompatibility is the 
ability for the polycation to diffuse into and bind to the alginate gel bead. It follows that both the 
alginate gel properties (including alginate M/G content and choice of crosslinking ion) and the 
polycation structure determine the stability and biocompatibility of the complete microcapsule. 
Previous studies have also investigated the interactions between alginate gel and polycation [43-
47], but most did not directly correlate their results with biocompatibility. Ideally, the polycation 
must be tightly complexed, so that no unbound (charged) part of the polymer is exposed to the 
tissues at the implantation site [48]. We showed that the combination of PLO and IntG alginate 
can achieve this effect to a certain extent, possibly due to the shorter lengths of the PLO side 
chains (in comparison with PLL) that can affect its conformational preferences in each solution 
and upon complexation [49-51], and the greater flexibility of MG blocks which are less 
involved in alginate gelation [28, 52, 53], a combination that may lead to better binding between 
the two polymers. However, further studies must be pursued in order to confirm such a 
hypothesis. 
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Historically, researchers have been adding an alginate coating to the microcapsules in 
order to enhance their biocompatibility. The idea is that the alginate ‘neutralizes’ the surface as 
it binds to any unbound portions of the polycation, and as we know, unbound PLL is 
immunogenic [54]. We and others have recently provided evidence that the alginate coating 
does not exist as a distinct outer layer, but rather diffuses into the alginate-polycation membrane 
[12, 40, 46, 48]. However, the research presented in this thesis is the first study to use 
physicochemical analyses in combination with in vivo studies to emphasize that this alginate 
coating is almost completely ineffective for enhancing microcapsule biocompatibility, at least 
for our capsule formulations. The general immunogenicity of complete APA microcapsules 
supports this notion, in contrast to a single study that has directly shown that their alginate 
coatings did have an effect in reducing microcapsule immunogenicity [31]. Perhaps with the use 
of an enzymatically tailored alginate, the coating could be more effective, as King et al 
suggested [26]. However, relying on the alginate coating to optimize microcapsule 
biocompatibility seems unwise, based on the results of this study. Besides, any defects in the 
membrane would likely result in exposure of unbound polycation, despite the alginate coating 
[39, 55]. 
In addition to inducing host cell adhesion, the polycation membrane proved to be 
problematic for microcapsule stability. This is quite ironic, since one of the main reasons that 
researchers use the membrane (besides to reduce permeability) is to increase the stability of the 
microcapsules, since alginate gels are soft an susceptible to biodegradation by chelating agents 
[53]. In our case, adding a membrane prevented gel swelling (as expected), but resulted in 
capsules that were poorly resistant to shear stresses or compressive forces that were induced in 
the in vivo environment. At least one other group [33] also observed that adding a membrane 
reduced the in vivo stability of their microcapsules. When we used complete microcapsules to 
transplant islets into immunocompetent mice, almost all of the samples degraded after several 
weeks. This is unfortunate because the fragility of the microcapsules interfered with our ability 
to judge whether these membranes could successfully immunoprotect islets despite their 
moderate immunogenicity. 
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8.2.3 The missing pieces of the puzzle 
While the relationships between the microcapsules chemistry, physicochemical 
characteristics, and in vivo biocompatibility have been clarified to a new level with this research, 
there are still a few physicochemical properties that were not characterized but could have added 
more pieces to the biocompatibility puzzle. 
Surface morphology 
As a general rule, smooth implant surfaces lead to better biocompatibility [14, 56]. 
Others have also started to prove this point, or at least emphasize the importance of smoothness, 
using atomic force microscopy (AFM) [57-59]. We attempted to measure this property (using 
AFM) on our own microcapsules, but we encountered numerous difficulties immobilizing the 
microcapsules in a liquid. Despite two years of trying, we never succeeded to keep the capsules 
still enough to generate reproducible results. We tried, without success, all of the fixation 
techniques that the other groups have tried, as well as a handful of others. Perhaps it was the 
smaller size (and thus smaller mass) of our microcapsules that made things problematic. 
Surface charge density 
Net surface charge of alginate-polycation microcapsules has been explored by two other 
research groups using zeta potential measurements [8-10]. This proved to be a good method to 
prove previous suspicions that polycation exposure leads to microcapsule immunogenicity due 
to the exposure of positive charges. Neither of these groups, however, tested the effect of the 
alginate coating for reducing this positive charge. 
Initially, we proposed to investigate local charge densities on the microcapsule surface, 
as opposed to the net charge of several microcapsules. This type of measure could highlight 
inhomogeneities in the alginate coating or polycation distribution, and therefore explain 
microcapsule immunogenicity even if the net charge is neutral. The proposed methodology was 
to immerse the microcapsules into solutions of different pH, thereby inducing changes in the 
ionization degree of the polyelectrolytes, and then measure the force between the AFM tip 
(which is charged in an ionic solution) and the microcapsule surface, thereby producing force 
maps that indicate the local distribution of the polycation and polyanion [60]. Such a study has 
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never been attempted before. However, as previously mentioned, we unfortunately never got 
past the sample fixation step.  
Wettability of the hydrated microcapsules 
Almost all microcapsules designed for cell transplantation are based on hydrogels, due to 
the pliability and hydrophilicity of these gels, which act to minimize protein and cell adhesion 
[3, 61]. In our research, we evaluated wettability of our samples by measuring the static contact 
angles of water droplets on dehydrated films that mimic the chemistry of our microcapsules. 
However, this is rather an evaluation of the sample’s capacity to rehydrate, and may not be 
representative of the hydrophilicity of the hydrated samples. To overcome this shortcoming, we 
started to measure the contact angle of air bubbles on hydrated films. Our preliminary results 
(not shown) showed that the air bubbles rolled off of all of the hydrated samples, independent of 
the composition of the film (type of alginate, with or without a polycation). Unfortunately, these 
studies were not pursued due to a lack of time. It would be interesting, however, to elaborate on 
this concept to show demonstrate any possible correlations between the hydrophilicity of the 
hydrated samples and their biocompatibility. 
 
8.3 Standardization of microcapsules for encapsulation 
No “winning formula” for achieving optimal microcapsule biocompatibility has been 
found, and no official standards have been written to this effect. This is a direct consequence of 
the many in-house protocols that have been developed for the fabrication of alginate-polycation 
microcapsules [62]. This situation has made it difficult to directly compare results between 
different study groups, thus hindering our progress towards the rational design of the optimal 
microcapsule. That said, this problem was addressed by researchers in the bioencapsulation field 
a few years back. As part of a COST865 funded project [63], a number of European research 
groups collaborated together in an effort to characterize and standardize the properties and 
characterization methods of microcapsules designed for bioencapsulation. The results of this 
collaborative effort have been recently published in a paper that ‘strongly advises’ the use of 
specific characterization techniques in future studies in order to improve reproducibility and 
help researchers understand variations in outcomes of biocapsules [64]. 
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8.4 Biocompatibility of the encapsulated islet system 
This research focused on the biocompatibility of empty microcapsules, since studies 
have shown evidence that an immune response to the microcapsules contributes to the death and 
dysfunction of the cells enclosed within [65-67]. It should be briefly mentioned, however, that 
once an islet is enclosed within the microcapsule, the system is changed. This should absolutely 
be kept in mind when considering the biocompatibility of the complete encapsulated islet 
system. Factors that should be considered include:  
Microcapsule stability :  Broken or damaged capsules expose the islets and render them 
vulnerable to recognition and attack by the host immune system. 
Membrane permeability :  Cytokines, nitric oxide, and other small molecules that can possibly 
penetrate the microcapsule membrane can enter the microcapsule and induce cell damage [65-
68]. Damaged or dying cells, as well as xenografts, may release chemical substances and shed 
antigens that can attract the host immune system [69-71]. 
Microcapsule size : Smaller capsules have been associated with bulging, i.e. protrusion of the 
islets due to inadequate encapsulation [72, 73]. Again, exposed islets can attract a response from 
the host immune system. 
Transplantation site : Some transplantation sites may be more suitable than others for 
accessibility reasons, proximity to the insulin-producing organs, or the partial pressure of 
oxygen (pO2), but these sites also differ in terms of the mechanical stress than can be induced on 
the microcapsules and the concentration of macrophages and other immune cells [74-79]. 
Animal model : Of course, the ultimate goal is to transplant into humans, but pre-clinical trials 
necessarily involve animal models. The sensitivity of the animal (i.e. the severity of its immune 
response to implants) is strain and species dependent [80-82], and conclusions about 
“biocompatibility” of the system should therefore be stated with caution. 
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CONCLUSIONS AND RECOMMENDATIONS 
 
Conclusions 
The biocompatibility of alginate-polycation microcapsules could not be optimized. They 
consistently showed immunogenicity, as characterized by host cell adhesion to the 
microcapsules in vivo, and supported by the adsorption of immunoglobulin in vitro. These 
foreign body reactions were clearly moderated by the presence of the polycation. Moreover, the 
alginate coating, intended to improve the biocompatibility of the microcapsules, had no 
significant effect on the physicochemical properties, nor on the biocompatibility of the samples. 
Although all microcapsule designs tested showed signs of being immunogenic, we showed that 
it may be possible to moderate the severity of response by simply choosing a combination of 
materials (alginate, crosslinking ion, polycation) that optimizes the penetration and binding of 
the polycation into the alginate gel. When tested with islets within, it was not the moderate 
immune response to empty microcapsules that was most problematic for graft survival, but the 
tendency of the microcapsules to degrade. 
In contrast, the alginate was proven to be perfectly biocompatible under specific 
conditions. In our case, this was an intermediate guluronate content, higher molecular mass and 
adequate purity level. The biocompatibility of these alginate gels, however, was dampened by 
their fragility, which will be a problem for cell immobilization purposes. Nevertheless, graft 
survival was improved with the use of alginate gel beads without a membrane. 
 
Recommendations  
In order to improve the biocompatibility of the alginate-polycation microcapsule, it is 
recommended to optimise the diffusion and the binding of the polycation to the alginate gel. In 
order to find the most suitable combination(s) of parameters to optimise polycation-alginate 
interactions (choice of materials, gelling dynamics, etc.), it is suggested to start with a thorough 
evaluation and screening process of different formulations using FTIR or similar techniques to 
monitor the intermolecular interactions. After getting through this initial step, it is recommended 
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to support this data by verifying the various other physicochemical properties that have been 
seen to correlate with biocompatibility, notably the membrane wettability (contact angle 
technique), surface charge (zeta potential), and surface morphology (atomic force microscopy or 
AFM). 
In contrast, it is not recommended to focus on improving the alginate coating technique 
as a strategy to improve microcapsule biocompatibility. Although it has been demonstrated that 
dilute alginate does indeed penetrate into the polycationic membrane and may even alter the 
surface morphology of the microcapsules, there has been little experimental evidence that this 
coating is effective for ‘neutralizing’ the surface of the device. Indeed, instead of trying to 
“cover” the problems associated with the polycation, it seems more wise to concentrate directly 
on the polycation so that there’s no problem to cover. 
It must be noted that even if the microcapsule biocompatibility is optimized, an immune 
response to the device is not necessarily, even unlikely, to be completely eliminated. Injury 
caused by the implantation surgery as well as physical imperfections of individual 
microcapsules are two scenarios that are essentially unavoidable yet likely to stimulate an 
inflammatory response. For this reason, incorporation of anti-inflammatory agents into the 
microcapsule system, which are effective short-term and work locally (vs. systematically), 
should be considered [1-3].  
Once biocompatibility of the microcapsule has been established, it is absolutely 
necessary to verify the effects of any modifications to the microcapsule design on its stability, 
permeability, and diffusion properties, since a biocompatible microcapsule is not very useful if 
it is incapable of immunoprotecting the transplanted cells enclosed within. 
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APPENDIX I 
SOLUTION FORMULAE 
 
Solution name Formula 
BaCl2, 10 mM (Mtl) 10 mM BaCl2, 16 mM HEPES, pH 7.4 
BaCl2, 10 mM (Gron) 10 mM BaCl2, 2 mM KCl, 135 mM NaCl, 10 mM 
HEPES, pH 7.4 
Ca2+-free KRH, 220 mOsm 90 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM 
MgSO4, 25 mM HEPES, pH 7.4 
Ca2+-free KRH, 310 mOsm 
 
135 mM NaCl, 4.7 mM KCl, 25 mM HEPES, 1.2 mM 
KH2PO4, and 1.2 mM MgSO4, pH 7.4 
CaCl2, 100 mM 100 mM CaCl2, 2 mM KCl, 10 mM HEPES , pH 7.4 
Ca Lactate, 100 mM 100 mM Ca Lactate 
KRH (Krebs-Ringer-Hepes), 
25 mM 
133 mM NaCl, 4.69 mM KCl, 1.18 mM KH2PO4, 1.18 
mM MgSO4, 25 mM HEPES, 2.52 mM CaCl2, pH 7.4 
Ringer’s solution 154 mM NaCl, 5.6 mM KCl, 1.7 mM CaCl2, 5 mM 
HEPES, pH 7.4 
Saline, 154 mM 154 mM NaCl, 12.5 mM HEPES, pH 7.4 
Spoelhepes 132 mM NaCl, 4.7 mM KCl, 1. mM MgCl2, 25 mM 
HEPES, 2.5 mM CaCl2  
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